

Author Index*

A

- AACHEN Trial Investigators (*see* Radke et al). 2006;152:761
Abenhaim L (*see* Walker et al). 2006;152:521-6
Aberg C (*see* Carlhed et al). 2006;152:1174-80
Abhayaratna WP, Marwick TH, Becker NG, Jeffery IM, McGill DA, Smith WT. Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. 2006;152:941-8
Abizaid AC (*see* Nunes et al). 2006;152:914
Abu-Ful A (*see* Amit et al). 2006;152:887
ACTIVATE Investigators (*see* Nicholls et al). 2006;152:67-74
Adams PX (*see* Mahaffey et al). 2006;152:291-6
Ades PA (*see* Williams et al). 2006;152:835-41
Adgey J (*see* Sinnavee et al). 2006;152:684
Afsharmanesh N, Horwitz TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. 2006;152:1076-82
Agarwal A (*see* Charytan et al). 2006;152:558-64
Agostino RD (*see* Cooper et al). 2006;152:59-66
Aguilar D, Fisher MR, O'Connor CM, Dunne MW, Muhlestein JB, Yao L, Gupta S, Benner RJ, Cook TD, Edwards D, Pfeffer MA, for the Investigators in the Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorder (WIZARD) study. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. 2006;152:298-304
Ahmed A, Perry GJ, Fleg JL, Love TE, Goff DC Jr, Kitzman DW. Outcomes in ambulatory chronic systolic and diastolic heart failure: A propensity score analysis. 2006;152:956-66
Ahn TH (*see* Han et al). 2006;152:887
Airoldi F (*see* Briguori et al). 2006;152:565-72
Aizawa Y (*see* Watanabe et al). 2006;152:731-5
Akasaka T (*see* Kume et al). 2006;152:755
Akbar Ali O, Bhindi R, McMahon AC, Briejer D, Krishnadas L, Lowe HC. Distal protection in cardiovascular medicine: Current status (Curriculum Cardiol.). 2006;152:207-16
Akers WS (*see* Steinhubl and Akers). 2006;152:200-3
Albert CM (*see* Koplan et al). 2006;152:714-9
Alderman MH (*see* Fang et al). 2006;152:1034-40
Al-Hajiri A (*see* Archbold et al). 2006;152:1090-4
Alings AM (*see* Van Gelder et al). 2006;152:420-6
Aljabbari S (*see* Thuesen et al). 2006;152:1139-44
Allaria L (*see* Boriani et al). 2006;152:527-36
Allemann S (*see* Stettler et al). 2006;152:27-38
Allen LaPointe NM, Kramer JM. Authors' reply (Letter reply). 2006;152:e45
Allison M (*see* Hsia et al). 2006;152:170-6
Alserius T, Hammar N, Nordqvist T, Ivert T. Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes. 2006;152:599-605
Altamura G (*see* Sanna et al). 2006;152:685
Alter P. Response to Letter to the Editor (Letter reply). 2006;152:e15
Ambrosioni E (*see* Borghi et al). 2006;152:470-7
Amin AA, Jones AM, Nugent K, Rumsfeld JS, Spertus JA. The prevalence of unrecognized depression in patients with acute coronary syndrome. 2006;152:928-34
Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Abu-Ful A, Weinstein JM, Wolak A, Ilia R, Zahger D. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. 2006;152:887
Ammash NM (*see* Gurevitz et al). 2006;152:155
Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. 2006;152:509-13
Amouyel P (*see* de Groote et al). 2006;152:736-41
Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation (Curriculum Cardiol.). 2006;152:217-22
Anderson FA Jr (*see* Emery et al). 2006;152:1015-21
Anderson GT (*see* Zhang et al). 2006;152:770-6
Anderson J (*see* Singh et al). 2006;152:974
Anderson JL (*see* May et al). 2006;152:997-1003
Anderson P (*see* Sleeper et al). 2006;152:427-33
Andreotti F, Coluzzi G, Cecchetti S, Lavorgna A, Marzo F, Crea F, Rumi C. Reduced CD34⁺, renal anemia, and adverse outcomes (Letter). 2006;152:e21
Angermann CE (*see* Störk et al). 2006;152:697-704
Ansell BJ, Fonarow GC, Maki KC, Dicklin MR, Bell M, Davidson MH, for the NEPTUNE II Steering Committee. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: Results of a national survey. 2006;152:976-81
Anstrom KJ (*see* Kramer et al). 2006;152:454-60
Antman EM (*see* Wiviott et al). 2006;152:627-35
Antonio Ravazzi P (*see* Gasparini et al). 2006;152:155
Antoniucci D (*see* Migliorini et al). 2006;152:903-8
Antoniucci D (*see* Parodi et al). 2006;152:1132-8
Anwaruddin S (*see* Peacock et al). 2006;152:253-62
Archbold RA, Balami D, Al-Hajiri A, Suliman A, Liew R, Cooper J, Ranjadayalan K, Knight CJ, Deane A, Timmis AD. Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients. 2006;152:1090-4
Archuleta L (*see* Roussanov et al). 2006;152:909-13
Armstrong KA (*see* Rakhit et al). 2006;152:363-70
Armstrong PW (*see* Goodman et al). 2006;152:277-84
Armstrong PW (*see* Mahaffey et al). 2006;152:291-6
Armstrong PW (*see* Sinnavee et al). 2006;152:684
Armstrong PW (*see* Welsh et al). 2006;152:1007-14
Armstrong PW, Granger CB. Reflections on early stopping of a clinical trial (Editorial). 2006;152:407-9
Arnett D (*see* Fox et al). 2006;152:749-55
Arnold JMO (*see* Janardhanan et al). 2006;152:246-52
Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. 2006;152:1083-9
Artis E (*see* Janardhanan et al). 2006;152:246-52

*July, pp. 1-196; August, pp. 197-406; September, pp. 407-606; October, pp. 607-806; November, pp. 807-1004; December, pp. 1005-1268.

- Arya A. Comparison of left ventricular and biventricular pacing in patients with heart failure (Letter). 2006;152:e55
- Asch FM, Shah S, Rattin C, Swaminathan S, Fuisz A, Lindsay J. Lack of sensitivity of the electrocardiogram for detection of old myocardial infarction: A cardiac magnetic resonance imaging study. 2006;152:742-8
- Asirvatham S (see Brown Fountain et al). 2006;152:e37-8
- ASSERT-3 and ASSERT-3 PLUS investigators (see Sinnavee et al). 2006;152:684
- ASSERT Investigators and Committees (see H. Hohnloser et al). 2006;152:442-7
- Atsma DE (see Beeres et al). 2006;152:684
- Aurigemma G (see Janardhanan et al). 2006;152:246-52
- Austin PC (see Guru et al). 2006;152:573-8
- AVID Investigators (see Brodsky et al). 2006;152:724-30
- Ávila LF (see Fernandes et al). 2006;152:1122-31
- Aylward PE (see White et al). 2006;152:1041-9
- Azzolini P (see Sanna et al). 2006;152:685

B

- Babapulle MN (see Brophy et al). 2006;152:263-9
- Babb JD (see Jollis et al). 2006;152:851-8
- Baccelli S (see Borghi et al). 2006;152:470-7
- Badesch D (see Walker et al). 2006;152:521-6
- Baesler C (see Brodsky et al). 2006;152:724-30
- Bair TL (see May et al). 2006;152:997-1003
- Balakrishnan SA (see Brush Jr et al). 2006;152:379-85
- Balam D (see Archbold et al). 2006;152:1090-4
- Balaravi B, Miller TD, Hodge DO, Gibbons RJ. The value of stress single photon emission computed tomography in patients without known coronary artery disease presenting with dyspnea. 2006;152:551-7
- Balasubramanyam A (see Bertoni et al). 2006;152:785-92
- Bales CW (see Huffman et al). 2006;152:793-800
- Ballman KV (see Witt et al). 2006;152:102-9
- Barbagelata A (see Goodman et al). 2006;152:277-84
- Barberena JE (see Green Conaway et al). 2006;152:1021-6
- Bardy GH (see Singh et al). 2006;152:974
- Bareiss P (see Ohlmann et al). 2006;152:1160-6
- Barnathan E (see Marmur et al). 2006;152:876-81
- Barolet A (see Dzavik et al). 2006;152:762-9
- Barr A (see Goodman et al). 2006;152:277-84
- Barsan WG (see Nallamothu et al). 2006;152:613-8
- Barsness G (see Elesber et al). 2006;152:469
- Barst RJ (see Walker et al). 2006;152:521-6
- Bartling A (see Schulze et al). 2006;152:493
- Bartunek J (see Van Laethem et al). 2006;152:297
- Barvik S (see Melberg et al). 2006;152:888-95
- Bates ER (see Jeger et al). 2006;152:686-92
- Bates ER (see Nallamothu et al). 2006;152:613-8
- Battler A (see Iakobishvili et al). 2006;152:285-90
- Bauters C (see de Groot et al). 2006;152:736-41
- Bax J (see Schuijff and Bax). 2006;152:29
- Bax JJ (see Beeres et al). 2006;152:684
- BEAUTIFUL Steering Committee (see Fox et al). 2006;152:860-6
- Becker NG (see Abhayaratna et al). 2006;152:941-8
- Beeres SL, Bax JJ, Dibbets-Schneider P, Stokkel MP, Fibbe WE, van der Wall EE, Schalij MJ, Atsma DE. Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: Twelve-month follow-up results. 2006;152:684
- BELIEVE Investigators (see Gasparini et al). 2006;152:155
- BELIEVE investigators (see Gasparini, on behalf of the BELIEVE investigators). 2006;152:e57

- Bell M (see Ansell et al). 2006;152:976-81
- Beller E (see Rakhit et al). 2006;152:363-70
- Belli G (see Zavalloni et al). 2006;152:908
- Bellocci F (see Sanna et al). 2006;152:685
- Belló-Klein A (see Nunes et al). 2006;152:914
- Belmans A (see Mertens et al). 2006;152:125
- Benjamin DK Jr (see Menon et al). 2006;152:394-9
- Benner RJ (see Aguilar et al). 2006;152:298-304
- Beranger N (see Ohlmann et al). 2006;152:1160-6
- Berdan LG (see White et al). 2006;152:1041-9
- Berezny KY (see Menon et al). 2006;152:394-9
- Berger PB (see Jollis et al). 2006;152:851-8
- Berglind S (see Strandberg et al). 2006;152:585-92
- Bernard D (see Van de Veire et al). 2006;152:297
- Bertenthal D (see Ruo et al). 2006;152:921
- Bertoni AG, Bonds DE, Steffes S, Jackson E, Crago L, Balasubramanyam A, Chen H, Goff DC Jr. Quality of cholesterol screening and management with respect to the National Cholesterol Education's Third Adult Treatment Panel (ATPIII) guideline in primary care practices in North Carolina. 2006;152:785-92
- Beyond 12 hours Reperfusion Alternative Evaluation (BRAVE-2) Trial Investigators (see Parodi et al). 2006;152:1132-8
- Beyth R (see Deswal et al). 2006;152:348-54
- Bhargava R (see Kavvas et al). 2006;152:118-25
- Bhatt DL (see Chen and Bhatt). 2006;152:e53
- Bhatt DL (see Patel et al). 2006;152:641-7
- Bhatti S (see Hakeem and Bhatti). 2006;152:e47
- Bhimraj A (see Ellerbeck et al). 2006;152:579-84
- Bhindi R (see Akbar Ali et al). 2006;152:207-16
- Biemond BJ (see Hirsch et al). 2006;152:434-41
- Biffi M (see Boriani et al). 2006;152:527-36
- Biondi-Zoccali G (see Briguori et al). 2006;152:565-72
- Birkmeier K (see Staudt et al). 2006;152:712
- Birnbaum Y (see Goodman et al). 2006;152:277-84
- Bittl JA (see Exaire et al). 2006;152:157-63
- Bittl JA (see Rajagopal et al). 2006;152:149-54
- Bittner V (see Jaffe et al). 2006;152:126-35
- Bittner V (see Ruo et al). 2006;152:921
- Blazek G (see Stöllberger et al). 2006;152:e61
- Bleumink GS (see Kardys et al). 2006;152:514-20
- Blomkalns AL, O'Connell EM, Eady CE, Lindsell CJ, Gibler WB. Evaluation of dyslipidemia in the emergency department: Impact of cholesterol testing on subsequent therapy. 2006;152:1181-5
- Blotta MHS (see Fernandes et al). 2006;152:1122-31
- Blumberg N (see Rogers et al). 2006;152:1027-33
- Blumenthal JA (see Jaffe et al). 2006;152:126-35
- Blumenthal RS (see Lakoski et al). 2006;152:593-8
- Blumenthal RS (see Orakzai et al). 2006;152:819-27
- Bocchiaro M (see Boriani et al). 2006;152:527-36
- Bocchiaro M (see Gasparini et al). 2006;152:155
- Bocks W (see Scharl and Bocks). 2006;152:414-6
- Boden WE (see Diercks et al). 2006;152:140-8
- Bogaerts K (see Sinnavee et al). 2006;152:684
- Böger RH (see Schulze et al). 2006;152:493
- Boivin V (see Störk et al). 2006;152:697-704
- Bojara W (see Lindstaedt et al). 2006;152:156
- Bojestig M (see Carlhed et al). 2006;152:1174-80
- Bolognesi JA (see Cannon et al). 2006;152:237-45
- Bolwell B (see Ellis et al). 2006;152:1050
- Bonapace S, Rossi A, Cicora M, Golia G, Zanolli L, Franceschini L, Conti L, Marino P, Zardini P, Vassanelli C. Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy. 2006;152:93

- Bonarjee V (see Melberg et al). 2006;152:888-95
Bonds DE (see Bertoni et al). 2006;152:785-92
Bonzel T (see Zahn et al). 2006;152:1145-51
Booth J (see Zhang et al). 2006;152:1152-9
Borges-Neto S (see Whellan et al). 2006;152:340-7
Borghi C, Bacchelli S, Esposti DD, Ambrosioni E, on behalf of the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction. 2006;152:470-7
Boriani G, Gasparini M, Lunati M, Santini M, Landolina M, Vincenti A, Curnis A, Bocchiardo M, Padeletti L, Biffi M, Allaria L, Denaro A, on behalf of the InSync ICD Italian Registry Investigators. Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death. 2006;152:527-36
Bosker HA (see Van Gelder et al). 2006;152:420-6
Boston AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, Jacques PF, McKenney J, for the FAVORIT Investigators. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial (Trial Design). 2006;152:448-53
Botker HE (see Kelbæk et al). 2006;152:882-6
Botker HE (see Thuesen et al). 2006;152:1139-44
Boudoulas KD, Montague CR, Goldschmidt-Clermont PJ, Cooke GE. Estradiol increases platelet aggregation in $\text{PI}^{\text{A1/A1}}$ individuals. 2006;152:136-9
Bourassa MG (see de Denus et al). 2006;152:705-12
Bourge RC (see Walker et al). 2006;152:521-6
Braunwald E (see Gibson et al). 2006;152:668-75
Braunwald E (see Gibson et al). 2006;152:756-61
Braunwald E (see Morrow et al). 2006;152:400-6
Braunwald E (see Wiviott et al). 2006;152:627-35
Brener SJ, Ivanc TB, Poliszcuk R, Chen M, Tuzcu EM, Hu T, Frid DJ, Nissen SE. Antihypertensive therapy and regression of coronary artery disease: Insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. 2006;152:1058-62
Brezina KJ (see Ellis et al). 2006;152:1050
Brieger D (see Akbar Ali et al). 2006;152:207-16
Briguori C, Airoldi F, Chieffo A, Montorfano M, Carlino M, Massimo Sangiorgi G, Morici N, Michev I, Iakovou I, Biondi-Zoccali G, Colombo A. Elective versus provisional intraaortic balloon pumping in unprotected left main stenting. 2006;152:565-72
Brindis RG (see Patel et al). 2006;152:641-7
Brindis RG (see Rao et al). 2006;152:321-6
Brinkworth GD, Noakes M, Buckley JD, Clifton PM. Weight loss improves heart rate recovery in overweight and obese men with features of the metabolic syndrome. 2006;152:693
Brito FS Jr (see Nunes et al). 2006;152:914
Brodsky MA, McAnulty J, Zipes DP, Baessler C, Hallstrom AP, for the AVID Investigators. A history of heart failure predicts arrhythmia treatment efficacy: Data from the Antiarrhythmics versus Implantable Defibrillators (AVID) Study. 2006;152:724-30
Brogan GX (see Mehta et al). 2006;152:648-60
Brophy JM, Babapulle MN, Costa V, Rinfrat S. A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. 2006;152:263-9
Brosh D (see Iakobishvili et al). 2006;152:285-90
Brough J (see Brush Jr et al). 2006;152:379-85
Brown Fountain R, Holmes DR, Chandrasekaran K, Packer D, Asirvatham S, Van Tassel R, Turi Z. Response to letter to the editor by Dr Claudia Stöllberger (Letter reply). 2006;152:e37-8
Brown RD Jr (see Witt et al). 2006;152:102-9
Brozic A (see Lear et al). 2006;152:333-9
Bruce CJ (see Gurevitz et al). 2006;152:155
Brunckhorst C (see Burkhoff et al). 2006;152:469
Brush JE Jr, Balakrishnan SA, Brough J, Hartman C, Hines G, Liverman DP, Parker JP, Rich J, Tindall N. Implementation of a continuous quality improvement program for percutaneous coronary intervention and cardiac surgery at a large community hospital. 2006;152:379-85
Buckley JD (see Brinkworth et al). 2006;152:693
Budoff MJ (see Orakzai et al). 2006;152:819-27
Bui S (see Dzavik et al). 2006;152:762-9
Buonomi P (see Migliorini et al). 2006;152:903-8
Burg MM (see Sieckmann et al). 2006;152:922-7
Burkhoff D, Cohen H, Brunckhorst C, O'Neill WW, for the TandemHeart Investigators Group. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. 2006;152:469
Burks EJ. Controlling the independent variables in the clinical study of prayer: The devil is in the details (Letter). 2006;152:e41-2
Butler R (see Yang et al). 2006;152:983-90
Butman SM (see Exaire et al). 2006;152:157-63
Büttner H-J (see Radke et al). 2006;152:761
Bybee KA (see Elesber et al). 2006;152:469
- C**
- Cafri C (see Amit et al). 2006;152:887
Cagide A (see Krauss et al). 2006;152:1004
Caixeta A (see Nunes et al). 2006;152:914
Calabro A (see Palazzuoli et al). 2006;152:1095
Califf RM (see Goodman et al). 2006;152:277-84
Califf RM (see Janardhanan et al). 2006;152:183-9
Califf RM (see Menon et al). 2006;152:394-9
Califf RM (see Reed et al). 2006;152:500-8
Califf RM (see Whellan et al). 2006;152:340-7
Califf RM (see White et al). 2006;152:1041-9
Califf RM, for the Workshop Participants. Evaluation of diagnostic imaging technologies and therapeutic devices: Better information for better decisions: Proceedings of a multidisciplinary workshop (Meetings). 2006;152:50-8
Calvin JE (see Jaffe et al). 2006;152:126-35
Cameron VA (see Collins et al). 2006;152:312-20
Camp NJ (see Horne et al). 2006;152:305-11
Campagna SM (see Palazzuoli et al). 2006;152:1095
Canadian ACS Registry Investigators (see Yan et al). 2006;152: 270-6
Canadian Acute Coronary Syndrome Registry Investigators (see Yan et al). 2006;152:676-83
Canham RM (see Kamath et al). 2006;152:355-61
Cannon CP, Curtis SP, Bolognesi JA, Laine L, for the MEDAL Steering Committee. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis (Trial Design). 2006;152:237-45
Cannon-Albright LA (see Horne et al). 2006;152:305-11
Capobianco S (see Palazzuoli et al). 2006;152:1095
Capucci A (see H. Hohnloser et al). 2006;152:442-7
Capuno M (see Roussanov et al). 2006;152:909-13

- Carlhed R, Bojestig M, Wallentin L, Lindström G, Peterson A, Åberg C, Lindahl B, for the QUICC study group. Improved adherence to Swedish national guidelines for acute myocardial infarction: The Quality Improvement in Coronary Care (QUICC) study. 2006;152:1174-80
- Carlier SG (see Jensen et al). 2006;152:327-32
- Carlino M (see Briguori et al). 2006;152:565-72
- Carlioz R (see Perrier et al). 2006;152:e23
- Carlquist JF (see May et al). 2006;152:997-1003
- Carpenter MA (see Boston et al). 2006;152:448-53
- Carr JJ (see Ellison et al). 2006;152:177-82
- Carrabba N (see Migliorini et al). 2006;152:903-8
- Caron RC, Hart AM, Naumann R. Letter to the Editor (Letter). 2006;152:e63
- Casey DE (see Hennekens et al). 2006;152:e59
- Catalano G (see Zavalloni et al). 2006;152:908
- Catellier DJ (see Jaffe et al). 2006;152:126-35
- Caussin C (see Perrier et al). 2006;152:e23
- Cavusoglu E (see Marmur et al). 2006;152:876-81
- Cecchetti S (see Andreotti et al). 2006;152:e21
- Chacko M (see Ellis et al). 2006;152:1050
- Chan KH, Ionescu A. Letter to the Editor (Letter). 2006;152:e51
- Chandrasekaran K (see Brown Fountain et al). 2006;152:e37-8
- Chandrasekaran K (see Fountain et al). 2006;152:720-3
- Chang R-KR, Rodriguez S, Lee M, Klitzner TS. Risk factors for deaths occurring within 30 days and 1 year after hospital discharge for cardiac surgery among pediatric patients. 2006;152:386-93
- Channick R (see Walker et al). 2006;152:521-6
- Chapa D (see Friedmann et al). 2006;152:940
- Chaparro S (see Flaker et al). 2006;152:967-73
- Chaplin WF (see Rieckmann et al). 2006;152:922-7
- Charde JP (see Kramer et al). 2006;152:454-60
- Charlier F (see Mertens et al). 2006;152:125
- CHARM Investigators (see Ducharme et al). 2006;152:86-92
- Charytan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. 2006;152:558-64
- Chaudhry M (see Shannon and Chaudhry). 2006;152:842-50
- Chen AY (see Mehta et al). 2006;152:648-60
- Chen AY (see Patel et al). 2006;152:641-7
- Chen H (see Bertoni et al). 2006;152:785-92
- Chen M (see Brener et al). 2006;152:1058-62
- Chen MS, Bhatt DL. Response to Letter to the Editor (Letter reply). 2006;152:e53
- Chen X (see Nilsson et al). 2006;152:537
- Cherng W-J (see Wang et al). 2006;152:1050
- Chew DP (see White et al). 2006;152:1041-9
- Chibout S-D (see Donahue et al). 2006;152:478-85
- Chieffo A (see Briguori et al). 2006;152:565-72
- Chiswell K (see White et al). 2006;152:1041-9
- Choi IS (see Han et al). 2006;152:887
- Chopra SS (see Watanabe et al). 2006;152:731-5
- Chow C-M (see Yan et al). 2006;152:270-6
- Chow C-M (see Yan et al). 2006;152:676-83
- Chowdhury UK, Venkataiyan JK, Patel CD, Seth S, Yadav R, Singh R, Subramanian GK, Malik V, Venugopal P. Serial radionuclide angiographic assessment of left ventricular ejection fraction and regional wall motion after mitral valve replacement in patients with rheumatic disease. 2006;152:1200-6
- Christenson RH (see Peacock et al). 2006;152:253-62
- Christenson RH (see Taylor et al). 2006;152:1070-5
- Chung T, Sindone A, Foo F, Dwyer A, Paoloni R, Janu MR, Wong H, Hall J, Freedman SB. Influence of history of heart failure on diagnostic performance and utility of B-type natriuretic peptide testing for acute dyspnea in the emergency department. 2006;152:949-55
- Chung W-J (see Han et al). 2006;152:887
- Churchill T (see Nicholls et al). 2006;152:67-74
- Cicoira M (see Bonapace et al). 2006;152:93
- Clark AL (see Thackray et al). 2006;152:713
- Clark BJ (see Sleeper et al). 2006;152:427-33
- Clarke JL (see May et al). 2006;152:997-1003
- Claussell N (see Nunes et al). 2006;152:914
- Cleland JG (see Thackray et al). 2006;152:713
- Clifton PM (see Brinkworth et al). 2006;152:693
- Cocilho OR (see Fernandes et al). 2006;152:1122-31
- Cohen DJ (see Cooper et al). 2006;152:59-66
- Cohen DH (see Gibson et al). 2006;152:756-61
- Cohen DJ (see Rajagopal et al). 2006;152:149-54
- Cohen DJ (see Reynolds et al). 2006;152:1096-102
- Cohen H (see Burkhoff et al). 2006;152:469
- Cohen M (see White et al). 2006;152:1041-9
- Cohen MG, Roe MT, Mulgund J, Peterson ED, Sonel AF, Menon V, Smith SC Jr, Saucedo JF, Lytle BL, Pollack CV Jr, Garza L, Gibler WB, Ohman EM. Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: Results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE). 2006;152:110-7
- Cohen-Solal A (see Ducharme et al). 2006;152:86-92
- Cohn JN. What is the role of angiotensin-receptor blockade in cardiovascular protection? (Trial Design). 2006;152:859
- Colan SD (see Sleeper et al). 2006;152:427-33
- Collins RP, Palmer BR, Pilbow AP, Frampton CM, Troughton RW, Yandle TG, Skelton L, Richards AM, Cameron VA. Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients. 2006;152:312-20
- Collins-Nakai RL (see King et al). 2006;152:1186-92
- Collinson PO (see Peacock et al). 2006;152:253-62
- Colombo A (see Briguori et al). 2006;152:565-72
- Coluzzi G (see Andreotti et al). 2006;152:e21
- Connolly SJ (see Flaker et al). 2006;152:967-73
- Connolly SJ (see Hohnloser et al). 2006;152:442-7
- Constantine G (see Walker et al). 2006;152:521-6
- Conte L (see Bonapace et al). 2006;152:93
- Conti A (see Parodi et al). 2006;152:1132-8
- Cook TD (see Aguilar et al). 2006;152:298-304
- Cooke GE (see Boudoulas et al). 2006;152:136-9
- Cooper CJ, Murphy TP, Matsumoto A, Steffes M, Cohen DJ, Jaff M, Kuntz R, Jamerson K, Reid D, Rosenfield K, Rundback J, Agostino RD, Henrich W, Dworkin L. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: Rationale and design of the CORAL trial (Trial Design). 2006;152:59-66
- Cooper J (see Archbold et al). 2006;152:1090-4
- Copenhagen K (see Iversen et al). 2006;152:85
- Copenhagen Ø (see Iversen et al). 2006;152:85
- Copenhagen S (see Iversen et al). 2006;152:85
- Cornel JH (see Van Gelder et al). 2006;152:420-6
- Costa V (see Brophy et al). 2006;152:263-9
- Cowper PA, DeLong ER, Hannan EL, Muhlbauer LH, Lytle BL, Jones RH, Holman WL, Pokorny JJ, Stafford JA, Mark DB, Peterson ED. Trends in postoperative length of stay after bypass surgery. 2006;152:1193-9
- Crago L (see Bertoni et al). 2006;152:785-92

- Crea F (see Andreotti et al). 2006;152:e21
Crijns HJ (see Van Gelder et al). 2006;152:420-6
Criqui M (see Lakoski et al). 2006;152:593-8
Criqui MH (see Hsia et al). 2006;152:170-6
Criss D (see Foo et al). 2006;152:290
Croft JB (see Fang et al). 2006;152:1034-40
Crowe T (see Nicholls et al). 2006;152:67-74
Crowe T (see Sipahi et al). 2006;152:544-50
CRUSADE Investigators (see Mehta et al). 2006;152:648-60
Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB. Comparative lipid-lowering effects of policosanol and atorvastatin: A randomized, parallel, double-blind, placebo-controlled trial. 2006;152:982
Cubeddu RJ (see Cubeddu et al). 2006;152:982
Cuculi F (see Kunz et al). 2006;152:190-5
Cui J, Randell E, Renouf J, Sun G, Green R, Han F-Y, Xie Y-G. Thrombospondin-4 1186G>C (A387P) is a sex-dependent risk factor for myocardial infarction: A large replication study with increased sample size from the same population. 2006;152:543
Cull CA (see Stettler et al). 2006;152:27-38
Curnis A (see Borhani et al). 2006;152:527-36
Currie G (see King et al). 2006;152:1186-92
Curtis JP (see Rathore et al). 2006;152:371-8
Curtis SP (see Cannon et al). 2006;152:237-45
Cushman M (see Lakoski et al). 2006;152:593-8
- D**
- da Silva LFF (see Nunes et al). 2006;152:914
Dabbous OH (see Emery et al). 2006;152:1015-21
D'Agostino RB Jr (see Lakoski et al). 2006;152:593-8
Daimon M (see Fukuda et al). 2006;152:1207-13
Daley WL (see Janardhanan et al). 2006;152:246-52
Dallongeville J (see de Groote et al). 2006;152:736-41
Dalsgaard M (see Iversen et al). 2006;152:85
Dambrink J-H (see De Luca et al). 2006;152:915-20
Dangas G (see Jensen et al). 2006;152:327-32
Danicek V (see Iakobishvili et al). 2006;152:285-90
Daniel W (see Radke et al). 2006;152:761
Daniel WG (see Schulze et al). 2006;152:493
DAPA Investigators (see Ottenvanger et al). 2006;152:636-40
Das P, Ziada K, Steinhubl SR, Moliterno DJ, Hamdalla H, Jozic J, Mukherjee D. Heparin-induced thrombocytopenia and cardiovascular diseases (Curriculum Cardiol.). 2006;152:19-26
Davidson KW (see Rieckmann et al). 2006;152:922-7
Davidson MH (see Ansell et al). 2006;152:976-81
Davies JE (see Ng et al). 2006;152:94-101
De Backer G (see Van Laethem et al). 2006;152:297
de Boer M-J (see De Luca et al). 2006;152:915-20
de Boer M-J (see Ottenvanger et al). 2006;152:636-40
De Buyzere M (see Van de Veire et al). 2006;152:297
De Buyzere M (see Van de Veire et al). 2006;152:486-92
de Denus S, Tardif JC, White M, Bourassa MG, Racine N, Levesque S, Ducharme A. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: A retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. 2006;152:705-12
De Feyter P (see Valgimigli et al). 2006;152:896-902
de Groote P, Lamblin N, Helbecque N, Mouquet F, Hermant X, Amouyel P, Dallongeville J, Bauters C. The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: A study in 686 consecutive patients. 2006;152:736-41
de Jaegere P (see Valgimigli et al). 2006;152:896-902

- de Lemos JA (see Kamath et al). 2006;152:355-61
De Luca G, Suryapranata H, van't Hof AW, Ottenvanger JP, Hoornje JC, Dambrink J-H, Gosselink AM, de Boer M-J. Comparison between stenting and balloon angioplasty in patients undergoing primary angioplasty of small coronary vessels. 2006;152:915-20
de Rekeneire N (see Ding et al). 2006;152:1108-14
de Roos A (see Grotenhuis et al). 2006;152:975
De Sutter J (see Van de Veire et al). 2006;152:297
De Sutter J (see Van de Veire et al). 2006;152:486-92
De Winter O (see Van de Veire et al). 2006;152:297
De Winter O (see Van de Veire et al). 2006;152:486-92
Deaner A (see Archbold et al). 2006;152:1090-4
Deckers JW (see Kardys et al). 2006;152:514-20
Deitchman D (see Menon et al). 2006;152:394-9
DeLong ER (see Cowper et al). 2006;152:1193-9
Denaro A (see Borhani et al). 2006;152:527-36
Desmet W (see Mertens et al). 2006;152:125
Desmet WJ (see Rajagopal et al). 2006;152:149-54
Deswal A, Petersen NJ, Urbauer DL, Wright SM, Beyth R. Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. 2006;152:348-54
Diamantouros P (see Leong-Sit et al). 2006;152:1103-7
Diaz R (see Reed et al). 2006;152:500-8
Dibbets-Schneider P (see Beeres et al). 2006;152:684
Dicklin MR (see Ansell et al). 2006;152:976-81
Dickstein K (see Estensen et al). 2006;152:927
Diem P (see Stettler et al). 2006;152:27-38
Diercks DB (see Mehta et al). 2006;152:648-60
Diercks DB, Roe MT, Mulgund J, Pollack CV Jr, Kirk JD, Gibler WB, Ohman EM, Smith SC Jr, Boden WE, Peterson ED. The obesity paradox in non-ST-segment elevation acute coronary syndromes: Results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative. 2006;152:140-8
Ding J, Nicklas BJ, Fallon MD, de Rekeneire N, Kritchevsky SB, Pahor M, Rodondi N, Li R, Zmuda JM, Harris TB. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. 2006;152:1108-14
Djoussé L (see Ellison et al). 2006;152:177-82
Doevendans PA (see Hirsch et al). 2006;152:434-41
Dohi K (see Yamanaka et al). 2006;152:966
Donahue MP, Rose K, Hochstrasser D, Vonderscher J, Grass P, Chibout S-D, Nelson CL, Sinnaeve P, Goldschmidt-Clermont PJ, Granger CB. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. 2006;152:478-85
Dong C (see Kunz et al). 2006;152:190-5
Doornbos J (see Grotenhuis et al). 2006;152:975
Dörr M (see Staudt et al). 2006;152:712
Douglas JS Jr (see Zhang et al). 2006;152:770-6
Dovellini EV (see Migliorini et al). 2006;152:903-8
Drazner MH (see Kamath et al). 2006;152:355-61
Drexler H (see Radke et al). 2006;152:761
Ducharme A (see de Denus et al). 2006;152:705-12
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S, on behalf of the CHARM Investigators. Prevention of atrial fibrillation in patients with

- symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 2006;152:86-92
- Dullum MK (see Hernandez et al). 2006;152:494-9
- Dunne MW (see Aguilar et al). 2006;152:298-304
- Duscha BD (see Huffman et al). 2006;152:793-800
- Dušek L (see Meluzin et al). 2006;152:975
- Dworkin L (see Cooper et al). 2006;152:59-66
- Dwyer A (see Chung et al). 2006;152:949-55
- Dzavik V, Kharbanda R, Ivanov J, Ing DJ, Bui S, Mackie K, Ramsamujh R, Barolet A, Schwartz L, Seidelin PH. Predictors of long-term outcome after crush stenting of coronary bifurcation lesions: Importance of the bifurcation angle. 2006;152:762-9
- Dzavik V. Drug-eluting stents in total coronary occlusions: Another piece of the puzzle solved? (Editorial). 2006;152:807-9

E

- Eady CE (see Blomkalns et al). 2006;152:1181-5
- Eagle KA (see Emery et al). 2006;152:1015-21
- Eagle KA (see Petrina et al). 2006;152:11-8
- Ebrahimi R (see Exaire et al). 2006;152:157-63
- Eckstein M (see Rokos et al). 2006;152:661-7
- Edmundowicz D (see Orakzai et al). 2006;152:819-27
- Edwards D (see Aguilar et al). 2006;152:298-304
- Egger M (see Stettler et al). 2006;152:27-38
- El Behliti R (see Ohlmann et al). 2006;152:1160-6
- Elesber A, Lerman A, Bybee KA, Murphy JG, Barsness G, Singh M, Rihal CS, Prasad A. Myocardial perfusion in apical ballooning syndrome: Correlate of myocardial injury. 2006;152:469
- Ellerbeck EF, Bhimaraj A, Hall S. Impact of organizational infrastructure on β -blocker and aspirin therapy for acute myocardial infarction. 2006;152:579-84
- Ellis SG, Penn MS, Bolwell B, Garcia M, Chacko M, Wang T, Brezina KJ, McConnell G, Topol EJ. Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial. 2006;152:1050
- Ellis W (see Whellan et al). 2006;152:340-7
- Ellison RC, Zhang Y, Hopkins PN, Knox S, Djoussé L, Carr JJ. Is alcohol consumption associated with calcified atherosclerotic plaque in the coronary arteries and aorta? 2006;152:177-82
- Emery M, López-Sendón J, Steg PG, Anderson FA Jr, Dabbous OH, Scheubel A, Eagle KA, for the GRACE Investigators. Patterns of use and potential impact of early β -blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: The Global Registry of Acute Coronary Events. 2006;152:1015-21
- Engstrom T (see Kelbæk et al). 2006;152:882-6
- Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Trial Investigators (see Jaffe et al). 2006;152:126-35
- Enomoto T (see Kinoshita et al). 2006;152:692
- Enriquez JR (see Green Conaway et al). 2006;152:1021-6
- Epstein LM (see Koplan et al). 2006;152:714-9
- Escolar E (see Kim et al). 2006;152:693
- Eshaghian S (see Fonarow et al). 2006;152:e7
- Esplugas E (see Mertens et al). 2006;152:125
- Esposti DD (see Borghi et al). 2006;152:470-7
- Essebag V (see Reynolds et al). 2006;152:1096-102
- Estacio G (see Roussanov et al). 2006;152:909-13
- Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, Dickstein K, Omland T. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. 2006;152:927
- Everett BM (see Foo et al). 2006;152:290

Everson-Rose SA, Lewis TT, Karavolos K, Matthews KA, Sutton-Tyrrell K, Powell LH. Cynical hostility and carotid atherosclerosis in African American and white women: The Study of Women's Health Across the Nation (SWAN) Heart Study. 2006;152:982

Exaire JE, Butman SM, Ebrahimi R, Kleiman NS, Harrington RA, Schweiger MJ, Bittl JA, Wolski K, Topol EJ, Lincoff AM, for the REPLACE-2 Investigators. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. 2006;152:157-63

F

- Fain E (see H. Hohnloser et al). 2006;152:442-7
- Falconi M (see Krauss et al). 2006;152:1004
- Fallin MD (see Ding et al). 2006;152:1108-14
- Faludi R, Toth L. Letter to the Editor (Letter). 2006;152:e13
- Fan M, Kähönen M, Rontu R, Lehtinen R, Viik J, Niemi M, Nieminen T, Niemelä K, Pörsti I, Kööbi T, Turjanmaa V, Lehtimäki T. The *p22pbx C242T* gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study. 2006;152:538-42
- Fan Y-T (see Mank-Seymour et al). 2006;152:1115-21
- Fang J, Mensah GA, Alderman MH, Croft JB. Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States. 2006;152:1034-40
- Faris P (see King et al). 2006;152:1186-92
- Faure A (see Ohlmann et al). 2006;152:1160-6
- FAVORIT Investigators (see Bostom et al). 2006;152:448-53
- Fedele F (see Sanna et al). 2006;152:685
- Feit F (see Rajagopal et al). 2006;152:149-54
- Felix SB (see Staudt et al). 2006;152:712
- Ferguson JJ III (see White et al). 2006;152:1041-9
- Ferguson TB (see Hernandez et al). 2006;152:494-9
- Ferguson TB Jr. Reporting for provider performance: Should we punish the bad, or try to make them all good? (Editorial). 2006;152:410-3
- Fernandes JL, Serrano CV JR, Blotta MHS, Coelho OR, Nicolau JC, Ávila LF, Rochitte CE, Filho JRP. Regression of coronary artery outward remodeling in patients with non-ST-segment acute coronary syndromes: A longitudinal study using noninvasive magnetic resonance imaging. 2006;152:1122-31
- Ferrari R (see Fox et al). 2006;152:860-6
- Fetterolf D (see Kramer et al). 2006;152:454-60
- Fibbe WE (see Beeres et al). 2006;152:684
- Figuera J (see Mertens et al). 2006;152:125
- Figulla HR (see Radke et al). 2006;152:761
- Filho JRP (see Fernandes et al). 2006;152:1122-31
- Filipliak KJ (see Grabowski and Filipiak). 2006;152:e11
- Filloon TG (see Mahaffey et al). 2006;152:291-6
- Finn PV (see Janardhanan et al). 2006;152:183-9
- Finsterer J (see Stöllberger et al). 2006;152:e35
- Finsterer J (see Stöllberger et al). 2006;152:e61
- Fischell TA. "Bolus-only" glycoprotein IIb/IIIa inhibitor use for elective percutaneous coronary intervention: Maybe less is more? (Editorial). 2006;152:812-4
- Fischer D (see Radke et al). 2006;152:761
- Fish P (see Gibson et al). 2006;152:668-75
- Fisher MR (see Aguilar et al). 2006;152:298-304
- Fitchett DH (see Yan et al). 2006;152:270-6

- Fitchett DH (see Yan et al). 2006;152:676-83
- Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horow J, Halperin JL, the SPORTIF Investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. 2006; 152:967-73
- Fleg JL (see Ahmed et al). 2006;152:956-66
- Fleg JL (see Russell et al). 2006;152:867-75
- Fonarow GC (see Afsarmanesh et al). 2006;152:1076-82
- Fonarow GC (see Ansell et al). 2006;152:976-81
- Fonarow GC (see Heidenreich and Fonarow). 2006;152:935-9
- Fonarow GC, Horwitz TB, Eshaghian S. Reply (Letter reply). 2006;152:e7
- Foo F (see Chung et al). 2006;152:949-55
- Foo SY, Everett BM, Yeh RW, Criss D, Laposata M, Van Cott EM, Jang I-K. Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. 2006;152:290
- Foody JM (see Rathore et al). 2006;152:371-8
- Ford I (see Fox et al). 2006;152:860-6
- Foster JK (see Zhang et al). 2006;152:770-6
- Fountain R, Holmes DR Jr, Hodgson PK, Chandrasekaran K, Van Tassel R, Sick P. Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation. 2006;152:720-3
- Fox ER, Han H, Taylor HA, Walls UC, Samdarshi T, Skelton TN, Pan J, Arnett D. The prognostic value of the mitral diastolic filling velocity ratio for all-cause mortality and cardiovascular morbidity in African Americans: the atherosclerotic Risks in Communities (ARIC) study. 2006;152:749-55
- Fox K, Ferrari R, Tendera M, Steg PG, Ford I, on behalf of the BEAUTIFUL Steering Committee. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvaluATion of the I_f inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) Study (Trial Design). 2006;152:860-6
- Frampton CM (see Collins et al). 2006;152:312-20
- Franceschini L (see Bonapace et al). 2006;152:93
- Freedland KE (see Jaffe et al). 2006;152:126-35
- Freedman SB (see Chung et al). 2006;152:949-55
- Fremes SE (see Guru et al). 2006;152:573-8
- French WJ (see Rokos et al). 2006;152:661-7
- Frid DJ (see Brener et al). 2006;152:1058-62
- Friedman PA (see Gurevitz et al). 2006;152:155
- Friedmann E, Thomas SA, Liu F, Morton PG, Chapa D, Gottlieb SS, on behalf of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality. 2006;152:940
- Fritz MK (see Lindstaedt et al). 2006;152:156
- Frohlich JJ (see Lear et al). 2006;152:333-9
- Frost A (see Walker et al). 2006;152:521-6
- Fu Y (see Goodman et al). 2006;152:277-84
- Fuchs S (see Amit et al). 2006;152:887
- Fuisz A (see Asch et al). 2006;152:742-8
- Fujii K (see Jensen et al). 2006;152:327-32
- Fujimoto N (see Yamanaka et al). 2006;152:966
- Fukuda S, Gillinov AM, Song J-M, Daimon M, Kongsaerepong V, Thomas JD, Shioya T. Echocardiographic insights into atrial and ventricular mechanisms of functional tricuspid regurgitation. 2006;152:1207-13
- Funabiki-Yamanaka K (see Yamanaka et al). 2006;152:966
- Furberg CD. The COX-2 inhibitors—An update (Editorial). 2006;152:197-9
- G**
- Gaine S (see Walker et al). 2006;152:521-6
- Galloway WJ (see Russell et al). 2006;152:867-75
- Garcia M (see Ellis et al). 2006;152:1050
- Garcia-Garcia HM (see Valgimigli et al). 2006;152:896-902
- Garza L (see Cohen et al). 2006;152:110-7
- Gasparini GL (see Zavalloni et al). 2006;152:908
- Gasparini M (see Boriani et al). 2006;152:527-36
- Gasparini M, Bocchiardo M, Lunati M, Antonio Ravazzi P, Santini M, Zardini M, Signorelli S, Passardi M, Klerys C, on behalf of the BELIEVE Investigators. Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: The Bi vs Left Ventricular Pacing: An International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study. 2006;152:155
- Gasparini M, on behalf of the BELIEVE investigators. Reply to Letter to the Editor (Letter reply). 2006;152:e57
- Genuini I (see Sanna et al). 2006;152:685
- George A (see Hauptman et al). 2006;152:1095
- Georgescu AA (see Yan et al). 2006;152:270-6
- Gerber Y, Weston SA, Killian JM, Jacobsen SJ, Roger VL. Sex and classic risk factors after myocardial infarction: a community study. 2006;152:461-8
- Gerin W (see Rieckmann et al). 2006;152:922-7
- Gerlach RF, Tanus-Santos JE. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure (Letter). 2006;152:e9
- German Cypher Stent Registry (see Zahn et al). 2006;152:1145-51
- Germing A (see Lindstaedt et al). 2006;152:156
- Gersh BJ (see Gurevitz et al). 2006;152:155
- Gersh BJ (see Holmes Jr and Gersh). 2006;152:e49
- Gersony WM (see Williams et al). 2006;152:1004
- Geva T (see Sleeper et al). 2006;152:427-33
- Ghali JK. There is still hope for multifaceted intervention in heart failure (Letter). 2006;152:e43
- Ghali WA (see Guru et al). 2006;152:573-8
- Ghosh JM (see Thackray et al). 2006;152:713
- Ghostine S (see Perrier et al). 2006;152:e23
- Giannotti G (see Palazzuoli et al). 2006;152:1095
- Gibbons RJ (see Balaravi et al). 2006;152:551-7
- Gibler WB (see Blomkalns et al). 2006;152:1181-5
- Gibler WB (see Cohen et al). 2006;152:110-7
- Gibler WB (see Diercks et al). 2006;152:140-8
- Gibler WB (see Mehta et al). 2006;152:648-60
- Gibler WB (see Patel et al). 2006;152:641-7
- Gibson CM (see Patel et al). 2006;152:641-7
- Gibson CM (see Wiviott et al). 2006;152:627-35
- Gibson CM, Kirtane AJ, Morrow DA, Palabrica TM, Murphy SA, Stone PH, Scirica BM, Jennings JK, Herrmann HC, Cohen DJ, McCabe CH, Braunwald E, for the TIMI Study Group. Association between Thrombolysis In Myocardial Infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: Observations from the Randomized Trial to Evaluate the Relative PROTECTION against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic Agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30). 2006;152:756-61

- Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, Kaziha S, Rokos I, Shamma NW, Palabrica TM, Fish P, McCabe CH, Braunwald E, for the TIMI Study Group. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. 2006; 152:668-75
- Gillebert TC (see Van de Veire et al). 2006;152:297
- Gillen AM (see Fukuda et al). 2006;152:1207-13
- Gir M (see Van de Veire et al). 2006;152:486-92
- Glowe D (see Mehta et al). 2006;152:801-6
- Goethals M (see Van Laethem et al). 2006;152:297
- Goff DC Jr (see Bertoni et al). 2006;152:785-92
- Goff DC Jr (see Ahmed et al). 2006;152:956-66
- Gold MR (see Hohnloser et al). 2006;152:442-7
- Gold MR, Hoffmann E, for the SAFARI Investigators. Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: The Study of Atrial Fibrillation Reduction (SAFARI) (Trial Design). 2006;152:231-6
- Goldman S (see Flaker et al). 2006;152:967-73
- Goldschmidt-Clermont PJ (see Boudoulas et al). 2006;152:136-9
- Goldschmidt-Clermont PJ (see Donahue et al). 2006;152:478-85
- Goldschmidt-Clermont PJ (see Kunz et al). 2006;152:190-5
- Golia G (see Bonapace et al). 2006;152:93
- Gonin R (see Walker et al). 2006;152:521-6
- Goodacre SW (see Peacock et al). 2006;152:253-62
- Goodman SG (see Petrina et al). 2006;152:11-8
- Goodman SG (see Yan et al). 2006;152:270-6
- Goodman SG (see Yan et al). 2006;152:676-83
- Goodman SG, Fu Y, Langer A, Barr A, Tan M, Wagner GS, Barbagelata A, Sgarbossa EB, Birnbaum Y, Granger CB, Calif RM, Van de Werf F, Topol EJ, Armstrong PW, for the GUSTO-IIb Investigators. The prognostic value of the admission and pre-discharge electrocardiogram in acute coronary syndromes: The GUSTO-IIb ECG Core Laboratory experience. 2006;152:277-84
- Goormastic M (see Nicholls et al). 2006;152:67-74
- Gosselink AM (see De Luca et al). 2006;152:915-20
- Gottlieb SS (see Friedmann et al). 2006;152:940
- Gottlieb SS (see Taylor et al). 2006;152:1070-5
- Goudeva L (see Schulze et al). 2006;152:493
- Grabowski M, Filipiak KJ. What information can an invasive cardiologist obtain from brain natriuretic peptide? (Letter). 2006;152:e11
- GRACE Investigators (see Emery et al). 2006;152:1015-21
- Granger CB (see Armstrong and Granger). 2006;152:407-9
- Granger CB (see Donahue et al). 2006;152:478-85
- Granger CB (see Ducharme et al). 2006;152:86-92
- Granger CB (see Goodman et al). 2006;152:277-84
- Granger CB (see Jollis et al). 2006;152:851-8
- Granger CB (see Mahaffey et al). 2006;152:291-6
- Granger CB (see Rokos et al). 2006;152:661-7
- Granger CB (see Sinnave et al). 2006;152:684
- Grass P (see Donahue et al). 2006;152:478-85
- Gray NA Jr, Selzman CH. Current status of the total artificial heart (Curriculum Cardiol.). 2006;152:4-10
- Green Conaway DL, Enriquez JR, Barberena JE, Jones PG, O'Keefe JH Jr, Spertus JA. Assessment of and physician response to glycemic control in diabetic patients presenting with an acute coronary syndrome. 2006;152:1021-6
- Green R (see Cui et al). 2006;152:543
- Gregg D (see Kunz et al). 2006;152:190-5
- Grebe R (see Iversen et al). 2006;152:85
- Grimm RA (see Srichai et al). 2006;152:75-84
- Groch L (see Meluzin et al). 2006;152:975
- Grotenhuis HB, Westerberg JJ, Doornbos J, Kroft IJ, Schoof PH, Hazekamp MG, Vliegen HW, Ottenkamp J, de Roos A. Aortic root dysfunction and its effect on left ventricular function in Ross procedure patients assessed with magnetic resonance imaging. 2006;152:975
- Gruber M (see Flaker et al). 2006;152:967-73
- Gula LJ (see Leong-Sit et al). 2006;152:1103-7
- Gupta S (see Aguilar et al). 2006;152:298-304
- Gurevitz OT, Varadachari CJ, Ammash NM, Malouf JF, Rosales AG, Herges RM, Bruce CJ, Somers VK, Hammill SC, Gersh BJ, Friedman PA. The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion. 2006;152:155
- Gurm HS (see Rajagopal et al). 2006;152:149-54
- Guru V, Fremes SE, Naylor CD, Austin PC, Shreve FM, Ghali WA, Tu JV, in collaboration with the Cardiac Care Network (CCN) of Ontario. Public versus private institutional performance reporting: What is mandatory for quality improvement? 2006;152:573-8
- GUSTO-IIb Investigators (see Goodman et al). 2006;152:277-84

H

- Haas D (see Rieckmann et al). 2006;152:922-7
- Hakeem A, Bhatti S. Letter to the Editor (Letter). 2006;152:e47
- Halinen MO (see Flaker et al). 2006;152:967-73
- Hall J (see Chung et al). 2006;152:949-55
- Hall S (see Ellerbeck et al). 2006;152:579-84
- Hallstrom AP (see Brodsky et al). 2006;152:724-30
- Halperin JL (see Flaker et al). 2006;152:967-73
- Hamdalla H (see Das et al). 2006;152:19-26
- Hamm CW (see Zahn et al). 2006;152:1145-51
- Hamm LF (see Williams et al). 2006;152:835-41
- Hammar N (see Alserius et al). 2006;152:599-605
- Hammerstingl C, Lickfett L, Jeong K-M, Troatz C, Wedekind J-A, Tiemann K, Lüderitz B, Lewalter T. Persistence of iatrogenic atrial septal defect after pulmonary vein isolation—an underestimated risk? 2006;152:362
- Hammill B (see Kramer et al). 2006;152:454-60
- Hammill SC (see Gurevitz et al). 2006;152:155
- Han F-Y (see Cui et al). 2006;152:543
- Han H (see Fox et al). 2006;152:749-55
- Han SH, Ahn TH, Kang WC, Oh KJ, Chung W-J, Shin M-S, Koh KK, Choi IS, Shin EK. The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: Randomized controlled prospective study. 2006;152:887
- Hanefeld C (see Schulze et al). 2006;152:493
- Hannan EL (see Cowper et al). 2006;152:1193-9
- Hanrath P (see Radke et al). 2006;152:761
- Harrington RA (see Exaire et al). 2006;152:157-63
- Harrington RA (see Mehta et al). 2006;152:801-6
- Harrington RA (see Patel et al). 2006;152:641-7
- Harrington RA (see White et al). 2006;152:1041-9
- Harris TB (see Ding et al). 2006;152:1108-14
- Hart AM (see Carron et al). 2006;152:e63
- Hartman C (see Brush Jr et al). 2006;152:379-85
- Hasdai D (see Iakobishvili et al). 2006;152:285-90
- Hassan Q (see Yan et al). 2006;152:270-6
- Hasselblad V (see Mahaffey et al). 2006;152:291-6
- Hatano Y (see Kinoshita et al). 2006;152:692
- Hauptman PJ, Mikolajczak P, George A, Mohr CJ, Hoover R, Swindle J, Schnitzler MA. Chronic inotropic therapy in end-stage heart failure. 2006;152:1095

- Hauser TH, Yeon SB, Kissinger KV, Josephson ME, Manning WJ. Variation in pulmonary vein size during the cardiac cycle: Implications for non-electrocardiogram-gated imaging. 2006;152:974
- Havranek EP (see Rathore et al). 2006;152:371-8
- Hazan L (see Menon et al). 2006;152:394-9
- Hazeckamp MG (see Grotenhuis et al). 2006;152:975
- Healey J (see Hohnloser et al). 2006;152:442-7
- HEBE investigators (see Hirsch et al). 2006;152:434-41
- Heckbert SR (see Hsia et al). 2006;152:170-6
- Hee TT (see Anand et al). 2006;152:217-22
- Heidenreich PA, Fonarow GC. Are registry hospitals different? A comparison of patients admitted to hospitals of a commercial heart failure registry with those from national and community cohorts. 2006;152:935-9
- Heimowitz T (see Cubeddu et al). 2006;152:982
- Hein L (see Störk et al). 2006;152:697-704
- Helbecque N (see de Groot et al). 2006;152:736-41
- Hellenbrand WE (see Williams et al). 2006;152:1004
- Hellkamp AS (see Singh et al). 2006;152:974
- Helqvist S (see Kelbæk et al). 2006;152:882-6
- Helqvist S (see Thuesen et al). 2006;152:1139-44
- Henderson JA (see Russell et al). 2006;152:867-75
- Hennekens AR (see Hennekens et al). 2006;152:e59
- Hennekens CH, Hennekens AR, Hollar D, Casey DE. Response to Letter to the Editor by Dr Mackin (Letter reply). 2006;152:e59
- Henrich W (see Cooper et al). 2006;152:59-66
- Henriques JP (see Ottenvanger et al). 2006;152:636-40
- Henry TD (see Rokos et al). 2006;152:661-7
- Herges RM (see Gurevitz et al). 2006;152:155
- Hermant X (see de Groot et al). 2006;152:736-41
- Hernandez AF, Velazquez EJ, Dullum MK, O'Brien SM, Ferguson TB, Peterson ED. Contemporary performance of surgical ventricular restoration procedures: Data from the Society of Thoracic Surgeons' National Cardiac Database. 2006;152:494-9
- Herrington DM (see Hsia et al). 2006;152:170-6
- Herrington DM (see Lakoski et al). 2006;152:593-8
- Herrmann HC (see Gibson et al). 2006;152:756-61
- Higgins JA (see Higgins et al). 2006;152:619-26
- Higgins JP, Williams G, Nagel JS, Higgins JA. Left bundle-branch block artifact on single photon emission computed tomography with technetium Tc 99m (Tc-99m) agents: Mechanisms and a method to decrease false-positive interpretations (Curriculum Cardiol.). 2006;152:619-26
- Hilden J (see Nilsson et al). 2006;152:537
- Hill J (see Roussanov et al). 2006;152:909-13
- Hines G (see Brush Jr et al). 2006;152:379-85
- Hiroyama A (see Oyabu et al). 2006;152:1167-73
- Hirsch A, Nijveldt R, van der Vleuten PA, Biemond BJ, Doevedans PA, van Rossum AC, Tijssen JG, Zijlstra F, Pieck JJ, on behalf of the HEBE investigators. Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: Rationale and design of the HEBE trial—A prospective, multicenter, randomized trial (Trial Design). 2006;152:434-41
- Hlatky MA (see Ruo et al). 2006;152:921
- Hlinomaz O (see Meluzin et al). 2006;152:975
- Hobbins P. A step towards more ethical prayer studies (Letter). 2006;152:e33
- Hochman JS (see Jeger et al). 2006;152:686-92
- Hochstrasser D (see Donahue et al). 2006;152:478-85
- Hodge DO (see Balaravi et al). 2006;152:551-7
- Hodgson PK (see Fountain et al). 2006;152:720-3
- Hoekstra JW (see Mehta et al). 2006;152:648-60
- Hoffmann BS (see Kramer et al). 2006;152:454-60
- Hoffmann E (see Gold et al). 2006;152:231-6
- Hoffmann R (see Radke et al). 2006;152:761
- Hofman A (see Kardys et al). 2006;152:514-20
- Hogg R (see Menon et al). 2006;152:394-9
- Hognestad A (see Estensen et al). 2006;152:927
- Hohnloser SH, Capucci A, Fain E, Gold MR, van Gelder IC, Healey J, Israel CW, Lau CP, Morillo C, Connolly SJ, on behalf of the ASSERT Investigators and Committees. ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT) (Trial Design). 2006;152:442-7
- Holland-Letz T (see Lindstaedt et al). 2006;152:156
- Hollar D (see Hennekens et al). 2006;152:e59
- Holman RR (see Stettler et al). 2006;152:27-38
- Holman WL (see Cowper et al). 2006;152:1193-9
- Holmes DR (see Brown Fountain et al). 2006;152:e37-8
- Holmes DR Jr, Gersh BJ. RE: Rescue percutaneous coronary intervention after failed fibrinolytic therapy: Have expectations been met? (Letter reply). 2006;152:e49
- Holmes DR Jr (see Fountain et al). 2006;152:720-3
- Honeycutt E (see Mehta et al). 2006;152:801-6
- Hoornje JJC (see De Luca et al). 2006;152:915-20
- Hoover R (see Hauptman et al). 2006;152:1095
- Hopkins PN (see Ellison et al). 2006;152:177-82
- Horf R (see Störk et al). 2006;152:697-704
- Hornáček I (see Meluzin et al). 2006;152:975
- Hornberger LK (see Pitkänen et al). 2006;152:163
- Horne BD (see May et al). 2006;152:997-1003
- Horne BD, Camp NJ, Muhlestein JB, Cannon-Albright LA. Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database. 2006;152:305-11
- Horrow J (see Flaker et al). 2006;152:967-73
- Horwitz TB (see Afsharmanesh et al). 2006;152:1076-82
- Horwitz TB (see Fonarow et al). 2006;152:e7
- Houmard JA (see Huffman et al). 2006;152:793-800
- Howard BV (see Russell et al). 2006;152:867-75
- Howard J (see Russell et al). 2006;152:867-75
- Hróbjartsson A (see Iversen et al). 2006;152:85
- Hsia J, Criqui MH, Herrington DM, Manson JE, Wu L, Heckbert SR, Allison M, McGrae McDermott M, Robinson J, Masaki K, for the Women's Health Initiative Research Group. Conjugated equine estrogens and peripheral arterial disease risk: The Women's Health Initiative. 2006;152:170-6
- Hsieh I-C (see Wang et al). 2006;152:1050
- Hsu DT (see Sleeper et al). 2006;152:427-33
- Hu T (see Brener et al). 2006;152:1058-62
- Hu T (see Rajagopal et al). 2006;152:149-54
- Huang Y (see Sinnaeve et al). 2006;152:684
- Huffman KM, Samsa GP, Slentz CA, Duscha BD, Johnson JL, Bales CW, Tanner CJ, Houmard JA, Kraus WE. Response of high-sensitivity C-reactive protein to exercise training in an at-risk population. 2006;152:793-800
- Hummel A (see Staudt et al). 2006;152:712
- Hung A (see Wang et al). 2006;152:1050
- Hunsicker LG (see Bostom et al). 2006;152:448-53
- Iakobishvili Z, Danicek V, Porter A, Imbar S, Brosh D, Battler A, Hasdai D. Antecedent left ventricular mass and infarct size in ST-elevation myocardial infarction. 2006;152:285-90
- Jakovou I (see Briguori et al). 2006;152:565-72
- Ignaszewski A (see Lear et al). 2006;152:333-9

- Ikeda H (see Kinoshita et al). 2006;152:692
- Ilia R (see Amit et al). 2006;152:887
- Imbar S (see Iakobishvili et al). 2006;152:285-90
- in collaboration with the Cardiac Care Network (CCN) of Ontario (see Guru et al). 2006;152:573-8
- Ing DJ (see Dzavik et al). 2006;152:762-9
- InSync ICD Italian Registry Investigators (see Boriani et al). 2006;152:527-36
- Investigators in the Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorder (WIZARD) study (see Aguilar et al). 2006;152:298-304
- Ionescu A (see Chan et al). 2006;152:e51
- Iovine F (see Palazzuoli et al). 2006;152:1095
- Iranami H (see Kinoshita et al). 2006;152:692
- Ireland CC (see Ruot et al). 2006;152:921
- Isbel NM (see Rakshit et al). 2006;152:363-70
- Israel CW (see H. Hohnloser et al). 2006;152:442-7
- Ito M (see Yamanaka et al). 2006;152:966
- Ivanc TB (see Brenner et al). 2006;152:1058-62
- Ivanov J (see Dzavik et al). 2006;152:762-9
- Iversen K, Sogaard Teisner A, Dalsgaard M, Greibe R, Timm HB, Skovgaard LT, Hrøbjartsson A, Copenhagen Ø, Copenhagen S, Copenhagen K. Effect of teaching and type of stethoscope on cardiac auscultatory performance. 2006;152:85
- Ivert T (see Alserius et al). 2006;152:599-605
- J**
- Jaber WA (see Amos et al). 2006;152:509-13
- Jackson E (see Bertoni et al). 2006;152:785-92
- Jacobsen SJ (see Gerber et al). 2006;152:461-8
- Jacobsen SJ (see Witt et al). 2006;152:102-9
- Jacques PF (see Bostom et al). 2006;152:448-53
- Jacqgi E (see Pitkänen et al). 2006;152:163
- Jaff M (see Cooper et al). 2006;152:59-66
- Jaffe AS (see Kavak et al). 2006;152:118-25
- Jaffe AS, Krumholz HM, Catellier DJ, Freedland KE, Bittner V, Blumenthal JA, Calvin JE, Norman J, Sequeira R, O'Connor C, Rich MW, Sheps D, Wu C, for the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Trial Investigators. Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study. 2006;152:126-35
- Jahns R (see Störk et al). 2006;152:697-704
- Jamerson K (see Cooper et al). 2006;152:59-66
- Janardhanan R, Daley WL, Naqvi TZ, Mulvagh SL, Aurigemma G, Zile M, Arnold JMO, Artis E, Purkayastha D, Thomas JD, Solomon SD, for the VALIIDD Investigators. Rationale and design: The VALsartan In Diastolic Dysfunction (VALIIDD) Trial: Evolving the management of diastolic dysfunction in hypertension (Trial Design). 2006;152:246-52
- Janardhanan R, Kenchaiah S, Velazquez Ej, Park Y, McMurray JJ, Weaver WD, Finn PV, White HD, Marin-Neto JA, O'Connor C, Pfeffer MA, Calif RM, Solomon SD, for the VALIANT Investigators. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. 2006;152:183-9
- Jang I-K (see Foo et al). 2006;152:290
- Janousek S (see Meluzin et al). 2006;152:975
- Janu MR (see Chung et al). 2006;152:949-55
- Januzzi JL (see Peacock et al). 2006;152:253-62
- Jaquequin L (see Ohlmann et al). 2006;152:1160-6
- Jarmukli NF (see Roussanov et al). 2006;152:909-13
- Jeffery IM (see Abhayaratna et al). 2006;152:941-8
- Jeger RV, Tseng C-H, Hochman JS, Bates ER. Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—a report from the SHould we revascularize Occluded Coronaries for cardiogenic shock? (SHOCK) trial and registry. 2006;152:686-92
- Jennings LK (see Gibson et al). 2006;152:756-61
- Jensen GV (see Kelbæk et al). 2006;152:882-6
- Jensen GV (see Thuesen et al). 2006;152:1139-44
- Jensen LO, Mintz GS, Carlier SG, Fujii K, Moussa I, Dangas G, Mehran R, Stone GW, Leon MB, Moses JW. Intravascular ultrasound assessment of fibrous cap remnants after coronary plaque rupture. 2006;152:327-32
- Jeong K-M (see Hammerstingl et al). 2006;152:362
- Jernberg T (see Johnston et al). 2006;152:1051-7
- Jesse RL (see Peacock et al). 2006;152:253-62
- Johnson JL (see Huffman et al). 2006;152:793-800
- Johnston N, Jernberg T, Lagerqvist B, Wallentin L. Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease. 2006;152:1051-7
- Jollis JG (see Whellan et al). 2006;152:340-7
- Jollis JG, Mehta RH, Roettig ML, Berger PB, Babb JD, Granger CB. Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): Study design (Trial Design). 2006;152:851-8
- Jolobe O. A perspective on antiarrhythmic drug therapy (Letter). 2006;152:e17
- Jones AM (see Amin et al). 2006;152:928-34
- Jones PG (see Green Conaway et al). 2006;152:1021-6
- Jones RH (see Cowper et al). 2006;152:1193-9
- Jordaens IJ (see Ottenvanger et al). 2006;152:636-40
- Jorge M (see Taylor et al). 2006;152:1070-5
- Jorgensen E (see Kelbæk et al). 2006;152:882-6
- Jorgensen E (see Thuesen et al). 2006;152:1139-44
- Josephson ME (see Hauser et al). 2006;152:974
- Jozic J (see Das et al). 2006;152:19-26
- Jüni P (see Stettler et al). 2006;152:27-38
- Junor C (see Srichai et al). 2006;152:75-84
- Jurkovic CT (see Zhang et al). 2006;152:770-6
- K**
- Kähönen M (see Fan et al). 2006;152:538-42
- Kaiser PA (see Kamath et al). 2006;152:355-61
- Kala P (see Meluzin et al). 2006;152:975
- Kamath SA, Meo Neto JdP, Canham RM, Uddin F, Toto KH, Nelson LL, Kaiser PA, de Lemos JA, Drazner MH. Low voltage on the electrocardiogram is a marker of disease severity and a risk factor for adverse outcomes in patients with heart failure due to systolic dysfunction. 2006;152:355-61
- Kaminek M (see Meluzin et al). 2006;152:975
- Kamp O (see Van Gelder et al). 2006;152:420-6
- Kang WC (see Han et al). 2006;152:887
- Kapadia S (see Sipahi et al). 2006;152:544-50
- Karasil P (see Singh et al). 2006;152:974
- Karavolos K (see Everson-Rose et al). 2006;152:982
- Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BHC, Witteman JC. C-reactive protein and risk of heart failure. The Rotterdam Study. 2006;152:514-20
- Karwowska-Prokopczuk E (see Morrow et al). 2006;152:400-6
- Kaski JC (see Peacock et al). 2006;152:253-62
- Kastrati A (see Parodi et al). 2006;152:1132-8
- Kavak PA, MacRae AR, Lustig V, Bhargava R, Vandersluis R, Palomaki GE, Yerme M-J, Jaffe AS. The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin

- assays on the frequency of acute myocardial infarction. 2006;152:118-25
- Kawamoto T (see Kume et al). 2006;152:755
- Kay JD (see Menon et al). 2006;152:394-9
- Kaye GC (see Thackray et al). 2006;152:713
- Kazzabi S (see Gibson et al). 2006;152:668-75
- Keast S (see Walker et al). 2006;152:521-6
- Kelbæk H (see Thuesen et al). 2006;152:1139-44
- Kelbæk H, Helqvist S, Thuesen L, Klovgaard L, Jorgensen E, Saunamäki K, Krusell LR, Botker HE, Engstrom T, Jensen GV, for the SCANDSTENT investigators. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: Subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) Trial. 2006;152:882-6
- Kelm M (see Zahn et al). 2006;152:1145-51
- Kempf J (see Yood et al). 2006;152:777-84
- Kenchaiah S (see Janardhanan et al). 2006;152:183-9
- Kent KM (see Kim et al). 2006;152:693
- Keteyian SJ (see Williams et al). 2006;152:835-41
- Kharbanda R (see Dzavik et al). 2006;152:762-9
- Kiess M (see Lear et al). 2006;152:333-9
- Kilaru R (see Menon et al). 2006;152:394-9
- Killian JM (see Gerber et al). 2006;152:461-8
- Kim C (see Rogers et al). 2006;152:1027-33
- Kim S-W, Mintz GS, Escolar E, Ohmann P, Pregowski J, Tyczynski P, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R, Weissman NJ. The impact of cardiovascular risk factors on subclinical left main coronary artery disease: An intravascular ultrasound study. 2006;152:693
- Kindermann W (see Scharrer and Kindermann). 2006;152:e3
- King NM, Tsuyuki R, Faris P, Currie G, Maitland A, Collins-Nakai RL. A randomized controlled trial of women's early use of a novel undergarment following sternotomy: The Women's Recovery from Sternotomy Trial (WREST). 2006;152:1186-92
- Kinoshita H, Shibano A, Sakoda T, Ikeda H, Iranami H, Hatano Y, Enomoto T. Uvulopalatopharyngoplasty decreases levels of C-reactive protein in patients with obstructive sleep apnea syndrome. 2006;152:692
- Kirk JD (see Diercks et al). 2006;152:140-8
- Kirtane AJ (see Gibson et al). 2006;152:668-75
- Kirtane AJ (see Gibson et al). 2006;152:756-61
- Kissinger KV (see Hauser et al). 2006;152:974
- Kitamura T (see Yamanaka et al). 2006;152:966
- Kitzman DW (see Ahmed et al). 2006;152:956-66
- Kjekshus J (see Estensen et al). 2006;152:927
- Klabusay M (see Meluzin et al). 2006;152:975
- Kleiman NS (see Exaire et al). 2006;152:157-63
- Kleiman NS (see Patel et al). 2006;152:641-7
- Kleiman NS (see Rajagopal et al). 2006;152:149-54
- Kleiman NS (see White et al). 2006;152:1041-9
- Klein GJ (see Leong-Sit et al). 2006;152:1103-7
- Klein LW (see Rao et al). 2006;152:321-6
- Klein LW. Acute coronary syndromes in young patients with angiographically normal coronary arteries (Editorial). 2006;152:607-10
- Klersy C (see Gasparini et al). 2006;152:155
- Klitzner TS (see Chang et al). 2006;152:386-93
- Klovgaard L (see Kelbæk et al). 2006;152:882-6
- Klovgaard L (see Thuesen et al). 2006;152:1139-44
- Klues HG (see Radke et al). 2006;152:761
- Knetsch AM (see Kardys et al). 2006;152:514-20
- Knight CJ (see Archbold et al). 2006;152:1090-4
- Knox S (see Ellison et al). 2006;152:177-82
- Kober L (see Nilsson et al). 2006;152:537
- Kober L (see Reed et al). 2006;152:500-8
- Kodama K (see Oyabu et al). 2006;152:1167-73
- Koenig WJ (see Rokos et al). 2006;152:661-7
- Koh KK (see Han et al). 2006;152:887
- Kolek MJ (see May et al). 2006;152:997-1003
- Kolm P (see Zhang et al). 2006;152:1152-9
- Kolm P (see Zhang et al). 2006;152:770-6
- Kongsarepong V (see Fukuda et al). 2006;152:1207-13
- Kontos MC (see Peacock et al). 2006;152:253-62
- Körbi T (see Fan et al). 2006;152:538-42
- Koplan BA, Epstein LM, Albert CM, Stevenson WG. Survival in octogenarians receiving implantable defibrillators. 2006;152:714-9
- Korelitz JJ (see Walker et al). 2006;152:521-6
- Kooišek Z (see Meluzin et al). 2006;152:975
- Krähenbühl S (see Stettler et al). 2006;152:27-38
- Krahn AD (see Leong-Sit et al). 2006;152:1103-7
- Kramer JM (see Allen LaPointe and Kramer). 2006;152:e45
- Kramer JM, Hammill B, Anstrom KJ, Fetterolf D, Snyder R, Charde JP, Hoffman BS, LaPointe NA, Peterson E. National evaluation of adherence to β -blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. 2006;152:454-60
- Krauss WE (see Huffman et al). 2006;152:793-800
- Krauss J, Pizarro R, Oberti PF, Falconi M, Cagide A. Prognostic implication of valvular lesion and left ventricular size in asymptomatic patients with chronic organic mitral regurgitation and normal left ventricular performance. 2006;152:1004
- Krieg T (see Staudt et al). 2006;152:712
- Kritchevsky SB (see Ding et al). 2006;152:1108-14
- Kritharides L (see Akbar Ali et al). 2006;152:207-16
- Kroft IJ (see Grotenhuis et al). 2006;152:975
- Krone RJ (see Rao et al). 2006;152:321-6
- Kronish IM (see Rieckmann et al). 2006;152:922-7
- Krumholz HM (see Jaffe et al). 2006;152:126-35
- Krumholz HM (see Rathore et al). 2006;152:371-8
- Krusell LR (see Kelbæk et al). 2006;152:882-6
- Krusell LR (see Thuesen et al). 2006;152:1139-44
- Kucera GP (see Yood et al). 2006;152:777-84
- Kuiper KK-J (see Melberg et al). 2006;152:888-95
- Kume T, Akasaka T, Kawamoto T, Okura H, Watanabe N, Toyota E, Neishi Y, Sukmawan R, Sadahira Y, Yoshida K. Measurement of the thickness of the fibrous cap by optical coherence tomography. 2006;152:755
- Kuntz R (see Cooper et al). 2006;152:59-66
- Kuntz RE (see Charytan et al). 2006;152:558-64
- Kunz GA, Liang G, Cuculi F, Gregg D, Vata KC, Shaw LK, Goldschmidt-Clermont PJ, Dong C, Taylor DA, Peterson ED. Circulating endothelial progenitor cells predict coronary artery disease severity. 2006;152:190-5
- Kuo L-T (see Wang et al). 2006;152:1050
- Kurashina Y (see Watanabe et al). 2006;152:731-5
- Kurita T (see Yamanaka et al). 2006;152:966
- Kusek JW (see Bostom et al). 2006;152:448-53
- Kusus M (see Schulze et al). 2006;152:493
- Lachaine J, Rinfret S, Merikle EP, Tarride J-E. Persistence and adherence to cholesterol lowering agents: Evidence from Régie de l'Assurance Maladie du Québec data. 2006;152:164-9
- LaFontaine TP (see Williams et al). 2006;152:835-41
- Lagerqvist B (see Johnston et al). 2006;152:1051-7
- Lahoz C (see Mostaza-Prieto et al). 2006;152:1063-9
- Lai K (see Yan et al). 2006;152:676-83

- Laine I (*see* Cannon et al). 2006;152:237-45
- Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB Jr, Herrington DM. Gender and C-reactive protein: Data from the Multiethnic Study of Atherosclerosis (MESA) cohort. 2006;152:593-8
- Lamas GA (*see* Cubeddu et al). 2006;152:982
- Lamblin N (*see* de Groot et al). 2006;152:736-41
- Landolina M (*see* Borani et al). 2006;152:527-36
- Langa KM (*see* Rogers et al). 2006;152:1027-33
- Langer A (*see* Goodman et al). 2006;152:277-84
- Langer A (*see* Yan et al). 2006;152:270-6
- Langer A (*see* Yan et al). 2006;152:676-83
- Langleben D (*see* Walker et al). 2006;152:521-6
- Langlois M (*see* Van de Veire et al). 2006;152:297
- LaPointe NA (*see* Kramer et al). 2006;152:454-60
- Laposata M (*see* Foo et al). 2006;152:290
- Larsen A (*see* Melberg et al). 2006;152:888-95
- Larson DM (*see* Rokos et al). 2006;152:661-7
- Lassen JF (*see* Thuesen et al). 2006;152:1139-44
- Lau CP (*see* H. Hohnloser et al). 2006;152:442-7
- Lauzon C (*see* Yan et al). 2006;152:676-83
- Lavelle T (*see* Reynolds et al). 2006;152:1096-102
- Lavorgna A (*see* Andreotti et al). 2006;152:e21
- Lear SA, Spinelli JJ, Linden W, Brozic A, Kiess M, Frohlich JJ, Ignaszewski A. The Extensive Lifestyle Management Intervention (ELMI) after cardiac rehabilitation: A 4-year randomized controlled trial. 2006;152:333-9
- Lee ET (*see* Russell et al). 2006;152:867-75
- Lee KL (*see* Singh et al). 2006;152:974
- Lee M (*see* Chang et al). 2006;152:386-93
- Lefevre G (*see* Peacock et al). 2006;152:253-62
- Lehtimäki T (*see* Fan et al). 2006;152:538-42
- Lehtinen R (*see* Fan et al). 2006;152:538-42
- Leiter L (*see* Yan et al). 2006;152:676-83
- Lekston A (*see* Wojnicz et al). 2006;152:713
- Lenzen H (*see* Schulze et al). 2006;152:493
- Leon MB (*see* Jensen et al). 2006;152:327-32
- Leong-Sit P, Gula LJ, Diamantourous P, Krahm AD, Skanes AC, Yee R, Klein GJ. Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation. 2006;152:1103-7
- Lerman A (*see* Elesber et al). 2006;152:469
- Levenson B (*see* Zahn et al). 2006;152:1145-51
- Levesque S (*see* de Denu et al). 2006;152:705-12
- Levey AS (*see* Bostom et al). 2006;152:448-53
- Levy JH (*see* Mahaffey et al). 2006;152:291-6
- Lewalter T (*see* Hammerstingl et al). 2006;152:362
- Lewis TT (*see* Everson-Rose et al). 2006;152:982
- Li JS (*see* Menon et al). 2006;152:394-9
- Li R (*see* Ding et al). 2006;152:1108-14
- Liang G (*see* Kunz et al). 2006;152:190-5
- Lickfett L (*see* Hammerstingl et al). 2006;152:362
- Lieber ML (*see* Srichai et al). 2006;152:75-84
- Liew R (*see* Archbold et al). 2006;152:1090-4
- Lilly SM. A "STEP" in the right direction (Letter). 2006;152:e31
- Lincoff AM (*see* Exaire et al). 2006;152:157-63
- Lincoff AM (*see* Rajagopal et al). 2006;152:149-54
- Lindahl B (*see* Carlhed et al). 2006;152:1174-80
- Linden W (*see* Lear et al). 2006;152:333-9
- Lindsay J (*see* Asch et al). 2006;152:742-8
- Lindsell CJ (*see* Blomkalns et al). 2006;152:1181-5
- Lindstaedt M, Yazar A, Germing A, Fritz MK, Holland-Letz T, Mügge A, Bojara W. Clinical outcome in patients with intermediate or equivocal left main coronary artery disease after deferral of surgical revascularization on the basis of fractional flow reserve measurements. 2006;152:156
- Lindström G (*see* Carlhed et al). 2006;152:1174-80
- Lins J (*see* Gibson et al). 2006;152:668-75
- Liu F (*see* Friedmann et al). 2006;152:940
- Liverman DP (*see* Brush Jr et al). 2006;152:379-85
- Lobianco F (*see* Sanna et al). 2006;152:685
- Lohse MJ (*see* Störk et al). 2006;152:697-704
- Loke IW (*see* Ng et al). 2006;152:94-101
- Lokhnygina Y (*see* White et al). 2006;152:1041-9
- López I (*see* Mostaza-Prieto et al). 2006;152:1063-9
- López-Sendón J (*see* Emery et al). 2006;152:1015-21
- Love TE (*see* Ahmed et al). 2006;152:956-66
- Lowrie HC (*see* Akbar Ali et al). 2006;152:207-16
- Luchansky J (*see* Yan et al). 2006;152:270-6
- Lüderitz B (*see* Hammerstingl et al). 2006;152:362
- Lunati M (*see* Borani et al). 2006;152:527-36
- Lunati M (*see* Gasparini et al). 2006;152:155
- Lustig V (*see* Kavak et al). 2006;152:118-25
- Lytle BL (*see* Cohen et al). 2006;152:110-7
- Lytle BL (*see* Cowper et al). 2006;152:1193-9
- Lytle BL (*see* Mehta et al). 2006;152:648-60

M

- Maas R (*see* Schulze et al). 2006;152:493
- Mackie K (*see* Dzavik et al). 2006;152:762-9
- MacRae AR (*see* Kavak et al). 2006;152:118-25
- Maes A (*see* Mertens et al). 2006;152:125
- Maggioni AP (*see* Ducharme et al). 2006;152:86-92
- Maggioni AP (*see* Reed et al). 2006;152:500-8
- Mahaffey KW (*see* White et al). 2006;152:1041-9
- Mahaffey KW, Van de Werf F, Sherman SK, Granger CB, Verrier ED, Filloon TG, Todaro TG, Adams PX, Levy JH, Hasselblad V, Armstrong PW. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview. 2006;152:291-6
- Mahoney EM (*see* Zhang et al). 2006;152:1152-9
- Mahony L (*see* Sleeper et al). 2006;152:427-33
- Maisch B (*see* Schulze et al). 2006;152:493
- Maitland A (*see* King et al). 2006;152:1186-92
- Maki KC (*see* Ansell et al). 2006;152:976-81
- Makiyama Y (*see* Watanabe et al). 2006;152:731-5
- Malagutti P (*see* Valgimigli et al). 2006;152:896-902
- Malik V (*see* Chowdhury et al). 2006;152:1200-6
- Malouf JF (*see* Gurevitz et al). 2006;152:155
- Manen O (*see* Perrier et al). 2006;152:e23
- Mank-Seymour AR, Richmond JL, Wood LS, Reynolds JM, Fan YT, Warnes GR, Milos PM, Thompson JF. Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes. 2006;152:1115-21
- Manning WJ (*see* Hauser et al). 2006;152:974
- Manson JE (*see* Hsia et al). 2006;152:170-6
- Mantilla T (*see* Mostaza-Prieto et al). 2006;152:1063-9
- Mareev V (*see* Reed et al). 2006;152:500-8
- Marin-Neto JA (*see* Janardhanan et al). 2006;152:183-9
- Marino P (*see* Bonapace et al). 2006;152:93
- Mark DB (*see* Cowper et al). 2006;152:1193-9
- Mark DB (*see* Singh et al). 2006;152:974
- Marmur JD, Mitre CA, Barnathan E, Cavusoglu E. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial. 2006;152:876-81
- Martín-Jadrake L (*see* Mostaza-Prieto et al). 2006;152:1063-9

- Marwick TH (see Abhayaratna et al). 2006;152:941-8
- Marwick TH (see Rakhit et al). 2006;152:363-70
- Marzo F (see Andreotti et al). 2006;152:e21
- Masaki K (see Hsia et al). 2006;152:170-6
- Masoudi FA (see Rathore et al). 2006;152:371-8
- Massimo Sangiorgi G (see Briguori et al). 2006;152:565-72
- Matsui K (see Watanabe et al). 2006;152:731-5
- Matsumoto A (see Cooper et al). 2006;152:59-66
- Matt Dorn J. Intercessory prayer (Letter). 2006;152:e25
- Matthews KA (see Everson-Rose et al). 2006;152:982
- Mauri L (see Charytan et al). 2006;152:558-64
- May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, Clarke JL, Kolek MJ, Bair TL, Pearson RR, Sudhir K, Carlquist JF. Lipoprotein-associated phospholipase A₂ independently predicts the angiographic diagnosis of coronary artery disease and coronary death. 2006;152:997-1003
- Mayer B (see Schunkert and Mayer). 2006;152:204-6
- Mayer J (see Meluzín et al). 2006;152:975
- Mazzotti NG (see Nunes et al). 2006;152:914
- McAnulty J (see Brodsky et al). 2006;152:724-30
- McCabe CH (see Gibson et al). 2006;152:668-75
- McCabe CH (see Gibson et al). 2006;152:756-61
- McCabe CH (see Morrow et al). 2006;152:400-6
- McCabe CH (see Wiviott et al). 2006;152:627-35
- McCarthy BD (see Yood et al). 2006;152:777-84
- McConnell G (see Ellis et al). 2006;152:1050
- McCrindle BW (see Sleeper et al). 2006;152:427-33
- McCullough PA. Failure of β-blockers in the reduction of perioperative events: Where did we go wrong? (Editorial). 2006;152:815-8
- McGill DA (see Abhayaratna et al). 2006;152:941-8
- McGoon M (see Walker et al). 2006;152:521-6
- McGrae McDermott M (see Hsia et al). 2006;152:170-6
- McGuire DK (see Yan et al). 2006;152:676-83
- McKenney J (see Boston et al). 2006;152:448-53
- McLachlan C, Mossop P. Are elevations of N-terminal probrain natriuretic peptide in endurance athletes after prolonged strenuous exercise due to systemic inflammatory cytokines? (Letter). 2006;152:e1
- McLaughlin V (see Walker et al). 2006;152:521-6
- McMahon AC (see Akbar Ali et al). 2006;152:207-16
- McMurray JJ (see Ducharme et al). 2006;152:86-92
- McMurray JJ (see Janardhanan et al). 2006;152:183-9
- McMurray JJ (see Reed et al). 2006;152:500-8
- MEDAL Steering Committee (see Cannon et al). 2006;152:237-45
- Mehilli J (see Parodi et al). 2006;152:1132-8
- Mehrani R (see Jensen et al). 2006;152:327-32
- Mehta RH (see Jollis et al). 2006;152:851-8
- Mehta RH, Honeycutt E, Shaw LK, Glower D, Harrington RA, Sketch MH Jr. Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts. 2006;152:801-6
- Mehta RH, Newby LK, Patel Y, Hoekstra JW, Miller CD, Chen AY, Lytle BL, Diercks DB, Summers RL, Brogan GX, Peacock WF, Pollack CV Jr, Roe MT, Peterson ED, Ohman EM, Gibler WB, for the CRUSADE Investigators. The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes. 2006;152:648-60
- Melberg T, Nilsen DW, Larsen A, Barvik S, Bonarjee V, Kuiper KK-J, Nordrehauge JE. Nonemergent coronary angioplasty without on-site surgical backup: A randomized study evaluating outcomes in low-risk patients. 2006;152:888-95
- Meluzín J, Mayer J, Groch L, Janoušek S, Hornáček I, Hlinomaz O, Kala P, Panovský R, Prášek J, Kaminek M, Staníček J, Klábusay M, Kořistek Z, Navrátil M, Dušek L, Vinklářková J. Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: The effect of the dose of transplanted cells on myocardial function. 2006;152:975
- Menon S, Berezný KY, Kilaru R, Benjamin DK Jr, Kay JD, Hazan L, Portman R, Hogg R, Deitchman D, Calif RM, Li JS. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. 2006;152:394-9
- Menon V (see Cohen et al). 2006;152:110-7
- Menon V (see Gibson et al). 2006;152:668-75
- Mensah GA (see Fang et al). 2006;152:1034-40
- Meo Neto JDP (see Kamath et al). 2006;152:355-61
- Merikle EP (see Lachaine et al). 2006;152:164-9
- MERLIN-TIMI 36 Investigators (see Morrow et al). 2006;152:400-6
- Mertens P, Maes A, Nyuts J, Belmans A, Desmet W, Esplugas E, Charlier F, Figueras J, Sambuceti G, Schwaiger M, Mortelmans L, Van de Werf F, for the PSALM investigators. Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial. 2006;152:125
- Meverden RA (see Witt et al). 2006;152:102-9
- Michelson EL (see Ducharme et al). 2006;152:86-92
- Michev I (see Briguori et al). 2006;152:565-72
- Michotey M-O (see Ohlmann et al). 2006;152:1160-6
- Micò M (see Sanna et al). 2006;152:685
- Migliorini A, Moschi G, Valenti R, Parodi G, Dovellini EV, Carrabba N, Buonamici P, Antonucci D. Routine percutaneous coronary intervention in elderly patients with cardiogenic shock complicating acute myocardial infarction. 2006;152:903-8
- Mikolajczak P (see Hauptman et al). 2006;152:1095
- Miller CD (see Mehta et al). 2006;152:648-60
- Miller TD (see Balaravi et al). 2006;152:551-7
- Milos PM (see Mank-Seymour et al). 2006;152:1115-21
- Miner SE (see Pitkänen et al). 2006;152:163
- Mintz GS (see Jensen et al). 2006;152:327-32
- Mintz GS (see Kim et al). 2006;152:693
- Mitre CA (see Marmur et al). 2006;152:876-81
- Mohiuddin SM (see Anand et al). 2006;152:217-22
- Mohr CJ (see Hauptman et al). 2006;152:1095
- Moliterno DJ (see Das et al). 2006;152:19-26
- Molnar J (see Arora et al). 2006;152:1083-9
- Monassier J-P (see Ohlmann et al). 2006;152:1160-6
- Mondal T (see Pitkänen et al). 2006;152:163
- Montague CR (see Boudoulas et al). 2006;152:136-9
- Montalescot G (see Wiviott et al). 2006;152:627-35
- Monteiro B (see Mostaza-Prieto et al). 2006;152:1063-9
- Montorfano M (see Briguori et al). 2006;152:565-72
- Mooss AN (see Anand et al). 2006;152:217-22
- Morel O (see Ohlmann et al). 2006;152:1160-6
- Morenghi E (see Vallboni et al). 2006;152:908
- Morici N (see Briguori et al). 2006;152:565-72
- Morillo C (see Hohnloser et al). 2006;152:442-7
- Morris DL (see Peacock et al). 2006;152:253-62
- Morrow DA (see Gibson et al). 2006;152:756-61
- Morrow DA, Scirica BM, Karwatowska-Prokocicka E, Skene A, McCabe CH, Braunwald E, for the MERLIN-TIMI 36 Investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. 2006;152:400-6
- Mortelmans L (see Mertens et al). 2006;152:125

- Morton PG (see Friedmann et al). 2006;152:940
 Moschi G (see Migliorini et al). 2006;152:903-8
 Moses JW (see Jensen et al). 2006;152:327-32
 Mossop P (see McLachlan and Mossop). 2006;152:e1
 Mostaza-Prieto JM, Martín-Jadraque L, López I, Tranche S, Lahoz C, Taboada M, Mantilla T, Soler B, Monteiro B, Sanchez-Zamorano MA. Evidence-based cardiovascular therapies and achievement of therapeutic goals in diabetic patients with coronary heart disease attended in primary care. 2006;152:1063-9
 Mottironi P (see Sanna et al). 2006;152:685
 Motz W (see Radke et al). 2006;152:761
 Mouquet F (see de Groot et al). 2006;152:736-41
 Moussa I (see Jensen et al). 2006;152:327-32
 Mügge A (see Lindstaedt et al). 2006;152:156
 Mügge A (see Radke et al). 2006;152:761
 Mügge A (see Schulze et al). 2006;152:493
 Muhlbauer LH (see Cowper et al). 2006;152:1193-9
 Muhlestein JB (see Aguilar et al). 2006;152:298-304
 Muhlestein JB (see Horne et al). 2006;152:305-11
 Muhlestein JB (see May et al). 2006;152:997-1003
 Mukherjee D (see Das et al). 2006;152:19-26
 Mulgund J (see Cohen et al). 2006;152:110-7
 Mulgund J (see Diercks et al). 2006;152:140-8
 Mulvagh SL (see Janardhanan et al). 2006;152:246-52
 Murali S (see Walker et al). 2006;152:521-6
 Murin J (see Reed et al). 2006;152:500-8
 Murphy JG (see Elesber et al). 2006;152:469
 Murphy SA (see Gibson et al). 2006;152:668-75
 Murphy SA (see Gibson et al). 2006;152:756-61
 Murphy TP (see Cooper et al). 2006;152:59-66
 Murrah NV (see Zhang et al). 2006;152:770-6
 Mutrie D (see Peacock et al). 2006;152:253-62
 Muzzarelli S, Pfisterer M, for the TIME Investigators. Anemia as independent predictor of major events in elderly patients with chronic angina. 2006;152:991-6

N

- Nagel JS (see Higgins et al). 2006;152:619-26
 Nakano T (see Yamanaka et al). 2006;152:966
 Nallamothu BK (see Rogers et al). 2006;152:1027-33
 Nallamothu BK, Taheri PA, Barsan WG, Bates ER. Broken bodies, broken hearts? Limitations of the trauma system as a model for regionalizing care for ST-Elevation Myocardial Infarction in the United States (Curriculum Cardiol.). 2006;152:613-8
 Naqvi TZ (see Janardhanan et al). 2006;152:246-52
 Nasir K (see Orakzai et al). 2006;152:819-27
 Naumann R (see Carron et al). 2006;152:e63
 Navratiil M (see Meluzin et al). 2006;152:975
 Naylor CD (see Guru et al). 2006;152:573-8
 Ndrepapa G (see Parodi et al). 2006;152:1132-8
 Neishi Y (see Kume et al). 2006;152:755
 Nelson CL (see Donahue et al). 2006;152:478-85
 Nelson LL (see Kamath et al). 2006;152:355-61
 NEPTUNE II Steering Committee (see Ansell et al). 2006;152: 976-81
 Nessel CC (see White et al). 2006;152:1041-9
 Newby LK (see Mehta et al). 2006;152:648-60
 Newby LK (see Patel et al). 2006;152:641-7
 Ng L (see Estensen et al). 2006;152:927
 Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. 2006;152:94-101
 Nicholls SJ (see Sipahi et al). 2006;152:544-50

- Nicholls SJ, Sipahi I, Schoenhagen P, Wisniewski L, Churchill T, Crowe T, Goormastic M, Wolski K, Tuzcu EM, Nissen SE, for the ACTIVATE Investigators. Intravascular ultrasound assessment of novel antiatherosclerotic therapies: Rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study (Trial Design). 2006;152:67-74

- Nicklas BJ (see Ding et al). 2006;152:1108-14
 Nicolau JC (see Fernandes et al). 2006;152:1122-31
 Nield LE (see Pitkänen et al). 2006;152:163
 Niemelä K (see Fan et al). 2006;152:538-42
 Niemi M (see Fan et al). 2006;152:538-42
 Nieminen MS (see Strandberg et al). 2006;152:585-92
 Nieminen T (see Fan et al). 2006;152:538-42
 Nienaber CA (see Zahn et al). 2006;152:1145-51
 Nijveldt R (see Hirsch et al). 2006;152:434-41
 Nikitin NP (see Thackray et al). 2006;152:713
 Nilssen DW (see Melberg et al). 2006;152:888-95
 Nilsson B, Chen X, Pehrson S, Kober L, Hilden J, Svendsen JH. Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: A randomized trial of the ostial versus the extraostial ablation strategy. 2006;152:537
 Nissen SE (see Brener et al). 2006;152:1058-62
 Nissen SE (see Nicholls et al). 2006;152:67-74
 Nissen SE (see Sipahi et al). 2006;152:544-50
 Noakes M (see Brinkworth et al). 2006;152:693
 Nobori T (see Yamanaka et al). 2006;152:966
 Nordqvist T (see Alserius et al). 2006;152:599-605
 Nordrehaug JE (see Melberg et al). 2006;152:888-95
 Norman J (see Jaffe et al). 2006;152:126-35
 Nowak J (see Wojnicz et al). 2006;152:713
 Nowakowska-Kozielewska E (see Wojnicz et al). 2006;152:713
 Nugara F (see Zhang et al). 2006;152:1152-9
 Nugent K (see Amin et al). 2006;152:928-34
 Nunes GL, Abizaid AC, Theodoro MP, Brito FS Jr, Caixeta A, da Silva LFF, Mazzotti NG, Belló-Klein A, Clausell N. Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: A randomized study. 2006;152:914

- Nuti R (see Palazzuoli et al). 2006;152:1095
 Nuysts J (see Mertens et al). 2006;152:125

O

- Oberti PF (see Krauss et al). 2006;152:1004
 O'Brien SM (see Hernandez et al). 2006;152:494-9
 O'Connell EM (see Blomkäns et al). 2006;152:1181-5
 O'Connor C (see Jaffe et al). 2006;152:126-35
 O'Connor C (see Janardhanan et al). 2006;152:183-9
 O'Connor CM (see Aguilar et al). 2006;152:298-304
 O'Connor CM (see Whellan et al). 2006;152:340-7
 Ogasawara N (see Oyabu et al). 2006;152:1167-73
 Oh KJ (see Han et al). 2006;152:887
 Ohlmann P (see Kim et al). 2006;152:693
 Ohlmann P, Jaquemin L, Morel O, El Behlighi R, Faure A, Michotey M-O, Beranger N, Roul G, Schneider F, Bareiss P, Monassier JP. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. 2006;152:1160-6
 Ohman EM (see Cohen et al). 2006;152:110-7
 Ohman EM (see Diercks et al). 2006;152:140-8
 Ohman EM (see Mehta et al). 2006;152:648-60
 Ohman EM (see Patel et al). 2006;152:641-7
 Okada K (see Oyabu et al). 2006;152:1167-73
 O'Keefe JH Jr (see Green Conaway et al). 2006;152:1021-6

- Okura H (see Kume et al). 2006;152:755
Okura Y (see Watanabe et al). 2006;152:731-5
Oliveria S (see Yood et al). 2006;152:777-84
Olofsson B (see Ducharme et al). 2006;152:86-92
Olsson L (see Ducharme et al). 2006;152:86-92
Omland T (see Estensen et al). 2006;152:927
O'Neill WW (see Burkhoff et al). 2006;152:469
Onishi K (see Yamanaka et al). 2006;152:966
Orakzai RH (see Orakzai et al). 2006;152:819-27
Orakzai SH, Orakzai RH, Nasir K, Santos RD, Edmundowicz D, Budoff MJ, Blumenthal RS. Subclinical coronary atherosclerosis: Racial profiling is necessary! (Curriculum Cardiol.). 2006;152:819-27
Ortlepp JR (see Radke et al). 2006;152:761
Osterziel KJ (see Schulze et al). 2006;152:493
Ottenkamp J (see Grotenhuis et al). 2006;152:975
Ottervanger JP (see De Luca et al). 2006;152:915-20
Ottervanger JP, Ramdat Misier AR, Zijlstra F, Schalij MJ, Wever E, Jordaeus IJ, Henriques JP, de Boer MJ, Robbe HW, Wellens HJ, for the DAPA Investigators. Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: Rationale and design of the Defibrillator After Primary Angioplasty (DAPA) Trial (Trial Design). 2006;152:636-40
Oudiz RJ (see Walker et al). 2006;152:521-6
Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama K. Angioscopic evaluation of neointima coverage: Sirolimus drug-eluting stent versus bare metal stent. 2006;152:1167-73

P

- Packer D (see Brown Fountain et al). 2006;152:e37-8
Padeletti L (see Boriani et al). 2006;152:527-36
Pagnotta P (see Zavalloni et al). 2006;152:908
Pahor M (see Ding et al). 2006;152:1108-14
Palabrica TM (see Gibson et al). 2006;152:668-75
Palabrica TM (see Gibson et al). 2006;152:756-61
Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A, Campagna SM, Nuti R. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. 2006;152:1095
Palmer BR (see Collins et al). 2006;152:312-20
Palomaki GE (see Kavak et al). 2006;152:118-25
Paltiel O (see Amit et al). 2006;152:887
Pan J (see Fox et al). 2006;152:749-55
Panovský R (see Meluzín et al). 2006;152:975
Paoloni R (see Chung et al). 2006;152:949-55
Park Y (see Janardhanan et al). 2006;152:183-9
Parker JP (see Brush Jr et al). 2006;152:379-85
Parker KM (see Zhang et al). 2006;152:770-6
Parlow J (see Yang et al). 2006;152:983-90
Parodi G (see Migliorini et al). 2006;152:903-8
Parodi G, Ndrepepa G, Kastrati A, Conti A, Mehilli J, Scaglià R, Schwaiger M, Antonucci D, Schöning A, for the Beyond 12 hours Reperfusion Alternative Evaluation (BRAVE-2) Trial Investigators. Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms. 2006;152:1132-8
Passardi M (see Gasparini et al). 2006;152:155
Patel CD (see Chowdhury et al). 2006;152:1200-6
Patel MR, Chen AY, Peterson ED, Newby LK, Pollack CV Jr, Brindis RG, Gibson CM, Kleiman NS, Saucedo JF, Bhatt DL, Gibler WB, Ohman EM, Harrington RA, Roe MT. Prevalence, predictors, and

- outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: Results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. 2006;152:641-7
Patel Y (see Mehta et al). 2006;152:648-60
Pathik K (see Ng et al). 2006;152:94-101
Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, Januzzi JL, Jesse RL, Kaski JC, Kontos MC, Lefevre G, Mutrie D, Sinha MK, Utzwiller-Geiger D, Pollack CV. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. 2006;152:253-62
Peacock WF (see Mehta et al). 2006;152:648-60
Pearce GL (see Sprecher and Pearce). 2006;152:694-6
Pearson RR (see May et al). 2006;152:997-1003
Pediatric Heart Network Investigators (see Sleeper et al). 2006;152:427-33
Pehrson S (see Nilsson et al). 2006;152:537
Penn MS (see Ellis et al). 2006;152:1050
Perna F (see Sanna et al). 2006;152:685
Perrier E, Manen O, Ghostine S, Caussin C, Plotton C, Carlioz R. Multislice computed tomography to rule out coronary artery disease in patients with acquired left bundle-branch block and low cardiac risk (Letter). 2006;152:e23
Perry GJ (see Ahmed et al). 2006;152:956-66
Petersen JL (see White et al). 2006;152:1041-9
Petersen NJ (see Deswal et al). 2006;152:348-54
Peterson A (see Carlhed et al). 2006;152:1174-80
Peterson E (see Kramer et al). 2006;152:454-60
Peterson ED (see Cohen et al). 2006;152:110-7
Peterson ED (see Cowper et al). 2006;152:1193-9
Peterson ED (see Diercks et al). 2006;152:140-8
Peterson ED (see Hernandez et al). 2006;152:494-9
Peterson ED (see Kunz et al). 2006;152:190-5
Peterson ED (see Mehta et al). 2006;152:648-60
Peterson ED (see Patel et al). 2006;152:641-7
Peterson ED (see Rao et al). 2006;152:321-6
Peterson ED, Roe MT. Continued improvements in quality improvement research (Editorial). 2006;152:1005-6
Petrina M, Goodman SG, Eagle KA. The 12-lead electrocardiogram as a predictive tool of mortality after acute myocardial infarction: Current status in an era of revascularization and reperfusion (Curriculum Cardiol.). 2006;152:11-8
Pfeffer MA (see Aguilar et al). 2006;152:298-304
Pfeffer MA (see Boston et al). 2006;152:448-53
Pfeffer MA (see Ducharme et al). 2006;152:86-92
Pfeffer MA (see Janardhanan et al). 2006;152:183-9
Pfisterer M (see Mazzarelli et al). 2006;152:991-6
Philipp J (see Van de Veire et al). 2006;152:297
Pichard AD (see Kim et al). 2006;152:693
Pickering T (see Raina et al). 2006;152:39-49
Piek JJ (see Hirsch et al). 2006;152:434-41
Pieper KS (see White et al). 2006;152:1041-9
Pilbrow AP (see Collins et al). 2006;152:312-20
Pistolese M (see Sanna et al). 2006;152:685
Pitkänen KH (see Strandberg et al). 2006;152:585-92
Pitkänen OM, Hornberger LK, Miner SE, Mondal T, Smallhorn JF, Jaeggi E, Nield LE. Borderline left ventricles in prenatally diagnosed atrioventricular septal defect or double outlet right ventricle: Echocardiographic predictors of biventricular repair. 2006;152:163
Pizarro R (see Krauss et al). 2006;152:1004

- Plotton C (see Perrier et al). 2006;152:e23
POISE Trial Investigators. Rationale, design, and organization of the *PeriOperative ISchemic Evaluation (POISE) Trial: A randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery (Trial Design)*. 2006;152:223-30
- Pokorny JJ (see Cowper et al). 2006;152:1193-9
 Poliszcuk R (see Brener et al). 2006;152:1058-62
 Pollack CV (see Peacock et al). 2006;152:253-62
 Pollack CV Jr (see Cohen et al). 2006;152:110-7
 Pollack CV Jr (see Mehta et al). 2006;152:648-60
 Pollack CV Jr (see Diercks et al). 2006;152:140-8
 Pollack CV Jr (see Patel et al). 2006;152:641-7
 Poloni L (see Wojnicz et al). 2006;152:713
 Poolaw B (see Russell et al). 2006;152:867-75
 Poole J (see Singh et al). 2006;152:974
 Pörsti I (see Fan et al). 2006;152:538-42
 Porter A (see Iakobishvili et al). 2006;152:285-90
 Portman R (see Menon et al). 2006;152:394-9
 Powell LH (see Everson-Rose et al). 2006;152:982
 Prasad A (see Elesber et al). 2006;152:469
 Prášek J (see Meluzín et al). 2006;152:975
 Pregowski J (see Kim et al). 2006;152:693
 Presbitero P (see Zavalloni et al). 2006;152:908
PSALM investigators (see Mertens et al). 2006;152:125
 Puglisi A (see Sanna et al). 2006;152:685
 Purkayastha D (see Janardhanan et al). 2006;152:246-52
 Puu M (see Ducharme et al). 2006;152:86-92

Q

- QUICC study group** (see Carlhed et al). 2006;152:1174-80

R

- Racine N (see de Denus et al). 2006;152:705-12
 Radke PW, Figulla HR, Drexler H, Klues HG, Mügge A, Silber S, Daniel W, Schmeisser A, Reifart N, Motz W, Büttner H-J, Fischer D, Ortlepp JR, Schaefers K, Hoffmann R, Hanrath P, for the AACHEN Trial Investigators. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilextil on intimal hyperplasia after coronary stent implantation. 2006;152:761
 Raina A, Pickering T, Shimbo D. Statin use in heart failure: A cause for concern? (*Curriculum Cardiol.*). 2006;152:39-49
 Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. 2006;152:149-54
 Rakhit DJ, Armstrong KA, Beller E, Isbel NM, Marwick TH. Risk stratification of patients with chronic kidney disease: Results of screening strategies incorporating clinical risk scoring and dobutamine stress echocardiography. 2006;152:363-70
 Ramdat Misier AR (see Ottervanger et al). 2006;152:636-40
 Ramsamujh R (see Dzavik et al). 2006;152:762-9
 Ranchor AV (see Van Gelder et al). 2006;152:420-6
 Randell E (see Cui et al). 2006;152:543
 Ranjadyalan K (see Archbold et al). 2006;152:1090-4
 Rao K (see Taylor et al). 2006;152:1070-5
 Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Krone RJ, Peterson ED. Patterns and outcomes of drug-eluting coronary stent use in clinical practice. 2006;152:321-6
 Rathore SS, Masoudi FA, Wang Y, Curtis JP, Foody JM, Havranek EP, Krumholz HM. Socioeconomic status, treatment, and outcomes

among elderly patients hospitalized with heart failure: Findings from the National Heart Failure Project. 2006;152:371-8

- Ratner RE (see Russell et al). 2006;152:867-75
 Rattin C (see Asch et al). 2006;152:742-8
 Raymer K (see Yang et al). 2006;152:983-90
 Reed SD, McMurray JJ, Velazquez EJ, Schulman KA, Califf RM, Kober L, Maggioni AP, Van de Werf F, White HD, Diaz R, Mareev V, Murin J, for the VALIANT Committees and Investigators. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial infarction (VALIANT) trial. 2006;152:500-8
 Reid D (see Cooper et al). 2006;152:59-66
 Reifart N (see Radke et al). 2006;152:761
 Renlund DG (see May et al). 2006;152:997-1003
 Renouf J (see Cui et al). 2006;152:543
 REPLACE-2 Investigators (see Exaire et al). 2006;152:157-63
 Restrepo B (see Cubeddu et al). 2006;152:982
 Reynolds JM (see Mank-Seymour et al). 2006;152:1115-21
 Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: The Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. 2006;152:1096-102
 Rich J (see Brush Jr et al). 2006;152:379-85
 Rich MW (see Jaffe et al). 2006;152:126-35
 Rich S (see Walker et al). 2006;152:521-6
 Richards AM (see Collins et al). 2006;152:312-20
 Richardt G (see Zahn et al). 2006;152:1145-51
 Richmond JL (see Mank-Seymour et al). 2006;152:1115-21
 Rieckmann N, Kronish IM, Haas D, Gerin W, Chaplin WF, Burg MM, Vorcheimer D, Davidson KW. Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. 2006;152:922-7
 Rienstra M (see Van Gelder et al). 2006;152:420-6
 Riesmeyer J (see Viviot et al). 2006;152:627-35
 Rihal CS (see Elesber et al). 2006;152:469
 Rinfré S (see Brophy et al). 2006;152:263-9
 Rinfré S (see Lachaine et al). 2006;152:164-9
 Robbie HW (see Ottervanger et al). 2006;152:636-40
 Robbins IM (see Walker et al). 2006;152:521-6
 Roberts R (see Yang et al). 2006;152:983-90
 Robinson J (see Hsia et al). 2006;152:170-6
 Rochitte CE (see Fernandes et al). 2006;152:1122-31
 Rodondi N (see Ding et al). 2006;152:1108-14
 Rodriguez Granillo GA (see Valgimigli et al). 2006;152:896-902
 Rodriguez LL (see Srichai et al). 2006;152:75-84
 Rodriguez S (see Chang et al). 2006;152:386-93
 Roe MT (see Cohen et al). 2006;152:110-7
 Roe MT (see Diercks et al). 2006;152:140-8
 Roe MT (see Mehta et al). 2006;152:648-60
 Roe MT (see Patel et al). 2006;152:641-7
 Roe MT (see Peterson and Roe). 2006;152:1005-6
 Roe MT (see Rokos et al). 2006;152:661-7
 Roettig ML (see Jollis et al). 2006;152:851-8
 Roger VL (see Gerber et al). 2006;152:461-8
 Roger VL (see Witt et al). 2006;152:102-9
 Rogers MA, Blumberg N, Saint SK, Kim C, Nallamothu BK, Lang KM. Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery. 2006;152:1027-33
 Rohrbeck S (see Gibson et al). 2006;152:668-75
 Roitman JL (see Williams et al). 2006;152:835-41
 Rokos I (see Gibson et al). 2006;152:668-75

- Rokos IC, Larson DM, Henry TD, Koenig WJ, Eckstein M, French WJ, Granger CB, Roe MT. Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks. 2006;152:661-7
- Roman MJ (see Russell et al.). 2006;152:867-75
- Rontu R (see Fan et al.). 2006;152:538-42
- Rosales AG (see Gurevitz et al.). 2006;152:155
- Roscio G (see Sanna et al.). 2006;152:685
- Rose K (see Donahue et al.). 2006;152:478-85
- Rosenfeld K (see Cooper et al.). 2006;152:59-66
- Rossi A (see Bonapace et al.). 2006;152:93
- Rossi ML (see Zavalloni et al.). 2006;152:908
- Roth SJ (see Sleeper et al.). 2006;152:427-33
- Roul G (see Ohlmann et al.). 2006;152:1160-6
- Rouleau JL (see Ducharme et al.). 2006;152:86-92
- Roussanov O, Estacio G, Capuno M, Archuleta L, Hill J, Jarmukli NF. Nonemergent percutaneous coronary interventions in a veterans affairs medical center without onsite cardiac surgery. 2006;152:909-13
- Rubin LJ (see Walker et al.). 2006;152:521-6
- Rumi C (see Andreotti et al.). 2006;152:e21
- Rumsfeld JS (see Amin et al.). 2006;152:928-34
- Rundback J (see Cooper et al.). 2006;152:59-66
- Rundek T (see Lakoski et al.). 2006;152:593-8
- Ruo B, Bertenthal D, Sen S, Bittner V, Ireland CC, Hlatky MA. Self-rated health among women with coronary disease: Depression is as important as recent cardiovascular events. 2006;152:921
- Ruppert J (see Staudt et al.). 2006;152:712
- Russell M, Fleg JL, Galloway WJ, Henderson JA, Howard J, Lee ET, Poolaw B, Ratner RE, Roman MJ, Silverman A, Stylianou M, Weir MR, Wilson C, Yeh F, Zhu J, Howard BV. Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS) (Trial Design). 2006;152:867-75
- Russell SD (see Amos et al.). 2006;152:509-13
- Ruzzolini M (see Sanna et al.). 2006;152:685

S

- Sabin G (see Zahn et al.). 2006;152:1145-51
- Sadahira Y (see Kume et al.). 2006;152:755
- Safar ME, Smulyan H. The blood pressure measurement—revisited (Editorial). 2006;152:417-9
- SAFARI Investigators (see Gold et al.). 2006;152:231-6
- Saint SK (see Rogers et al.). 2006;152:1027-33
- Sakoda T (see Kinoshita et al.). 2006;152:692
- Sambuceti G (see Mertens et al.). 2006;152:125
- Samdarshi T (see Fox et al.). 2006;152:749-55
- Samsa GP (see Huffman et al.). 2006;152:793-800
- Sanchez-Zamorano MA (see Mostaza-Prieto et al.). 2006;152:1063-9
- Sanna T, Fedele F, Genuini I, Puglisi A, Azzolini P, Altamura G, Lobianco F, Ruzzolini M, Perna F, Micò M, Roscio G, Mottironi P, Saraceni C, Pistolese M, Bellocchi F. Home defibrillation: A feasibility study in myocardial infarction survivors at intermediate risk of sudden death. 2006;152:685
- Santini M (see Borian et al.). 2006;152:527-36
- Santini M (see Gasparini et al.). 2006;152:155
- Santos RD (see Orakzai et al.). 2006;152:819-27
- Saraceni C (see Sanna et al.). 2006;152:685
- Satler LF (see Kim et al.). 2006;152:693
- Saucedo JF (see Cohen et al.). 2006;152:110-7
- Saucedo JF (see Patel et al.). 2006;152:641-7
- Saul JP (see Sleeper et al.). 2006;152:427-33
- Saunamäki K (see Kelbæk et al.). 2006;152:882-6
- Saunamäki K (see Thuesen et al.). 2006;152:1139-44

- SCANDSTENT investigators (see Kelbæk et al.). 2006;152:882-6
- SCANDSTENT Investigators Copenhagen, Skejby, and Roskilde, Denmark and Leiden, the Netherlands. (see Thuesen et al.). 2006;152:1139-44
- Scatturin M (see Zavalloni et al.). 2006;152:908
- SCD-HeFT Investigators (see Singh et al.). 2006;152:974
- Schaefers K (see Radke et al.). 2006;152:761
- Schalij MJ (see Beeres et al.). 2006;152:684
- Schalij MJ (see Ottervanger et al.). 2006;152:636-40
- Scharhag JW, Kindermann W. Brain natriuretic peptide (BNP) and exercise-induced immune reactions: Reply to the letter-to-the-editor of McLachlan and Mossop (Letter reply). 2006;152:e3
- Schartl M, Bocks W. How to assess coronary artery remodeling by intravascular ultrasound (Editorial). 2006;152:414-6
- Scheuble A (see Emery et al.). 2006;152:1015-21
- Schmeisser A (see Radke et al.). 2006;152:761
- Schmidt-Lucke C (see Schulze et al.). 2006;152:493
- Schneider B (see Stöllberger et al.). 2006;152:e35
- Schneider F (see Ohlmann et al.). 2006;152:1160-6
- Schneider S (see Zahn et al.). 2006;152:1145-51
- Schnitzler MA (see Hauptman et al.). 2006;152:1095
- Schoenhagen P (see Nicholls et al.). 2006;152:67-74
- Schoenhagen P (see Sipahi et al.). 2006;152:544-50
- Schömig A (see Parodi et al.). 2006;152:1132-8
- Schoof PH (see Grotenhuis et al.). 2006;152:975
- Schuijff J, Bax J. Response to letter to the Editor (Letter reply). 2006;152:e29
- Schulman KA (see Reed et al.). 2006;152:500-8
- Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, Ströder D, Simon BC, Mügge A, Daniel WG, Tillmanns H, Maisch B, Streichert T, Böger RH. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: Results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. 2006;152:493
- Schunkert H, Mayer B. In transition: From family history into the post-genomic era (Editorial). 2006;152:204-6
- Schwaiger M (see Mertens et al.). 2006;152:125
- Schwaiger M (see Parodi et al.). 2006;152:1132-8
- Schwartz L (see Dzavik et al.). 2006;152:762-9
- Schwedhelm E (see Schulze et al.). 2006;152:493
- Schweiger MJ (see Exaire et al.). 2006;152:157-63
- Sciagà R (see Parodi et al.). 2006;152:1132-8
- Scirica B (see Charytan et al.). 2006;152:558-64
- Scirica BM (see Gibson et al.). 2006;152:756-61
- Scirica BM (see Morrow et al.). 2006;152:400-6
- Seidelin PH (see Dzavik et al.). 2006;152:762-9
- Selzman CH (see Gray Jr and Selzman). 2006;152:4-10
- Sen S (see Ruo et al.). 2006;152:921
- Senaratne M (see Welsh et al.). 2006;152:1007-14
- Senges J (see Zahn et al.). 2006;152:1145-51
- Sequeira R (see Jaffe et al.). 2006;152:126-35
- Serrano CV Jr (see Fernandes et al.). 2006;152:1122-31
- Serruy PW (see Valgimigli et al.). 2006;152:896-902
- Servoss S (see Charytan et al.). 2006;152:558-64
- Seth S (see Chowdhury et al.). 2006;152:1200-6
- Sgarbossa EB (see Goodman et al.). 2006;152:277-84
- Shah S (see Asch et al.). 2006;152:742-8
- Shamas NW (see Gibson et al.). 2006;152:668-75
- Shannon R, Chaudhry M. Effect of α_1 -adrenergic receptors in cardiac pathophysiology (Progress Cardiol.). 2006;152:842-50
- Shaw LK (see Kunz et al.). 2006;152:190-5
- Shaw LK (see Mehta et al.). 2006;152:801-6

- Shaw LK (see Whellan et al). 2006;152:340-7
- Shaw RE (see Rao et al). 2006;152:321-6
- Sheps D (see Jaffe et al). 2006;152:126-35
- Sherman SK (see Mahaffey et al). 2006;152:291-6
- Shibano A (see Kinoshita et al). 2006;152:692
- Shimbo D (see Raina et al). 2006;152:39-49
- Shin EK (see Han et al). 2006;152:887
- Shin M-S (see Han et al). 2006;152:887
- Shiota T (see Fukuda et al). 2006;152:1207-13
- Shrime FM (see Guru et al). 2006;152:573-8
- Sick P (see Fountain et al). 2006;152:720-3
- Signorelli S (see Gasparini et al). 2006;152:155
- Silber S (see Radke et al). 2006;152:761
- Silverberg D (see Palazzioli et al). 2006;152:1095
- Silverman A (see Russell et al). 2006;152:867-75
- Simon BC (see Schulze et al). 2006;152:493
- Sindone A (see Chung et al). 2006;152:949-55
- Singh M (see Elesber et al). 2006;152:469
- Singh M. The predicament of offering elective percutaneous coronary intervention at sites without on-site cardiac surgery (Editorial). 2006;152:810-1
- Singh R (see Chowdhury et al). 2006;152:1200-6
- Singh SN, Poole J, Anderson J, Hellkamp AS, Karasik P, Mark DB, Lee KL, Bardy GH, for the SCD-HeFT Investigators. Role of amiodarone or implantable cardioverter-defibrillator in patients with atrial fibrillation and heart failure. 2006;152:974
- Sinha MK (see Peacock et al). 2006;152:253-62
- Sinnaeve P (see Donahue et al). 2006;152:478-85
- Sinnaeve PR, Huang Y, Bogaerts K, Vahanian A, Adgey J, Armstrong PW, Wallentin L, Van de Werf FJ, Granger CB, on behalf of the ASSENT-3 and ASSENT-3 PLUS investigators. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. 2006;152:684
- Sipahi I (see Nicholls et al). 2006;152:67-74
- Sipahi I, Tuzcu EM, Schoenhagen P, Nicholls SJ, Crowe T, Kapadia S, Nissen SE. Static and serial assessments of coronary arterial remodeling are discordant: An intravascular ultrasound analysis from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. 2006;152:544-50
- Skanes AC (see Leong-Sit et al). 2006;152:1103-7
- Skelton L (see Collins et al). 2006;152:312-20
- Skelton TN (see Fox et al). 2006;152:749-55
- Skene A (see Morrow et al). 2006;152:400-6
- Sketch MH Jr (see Mehta et al). 2006;152:801-6
- Skolnick AH. Letter to the editor by Dr. Adam H. Skolnick (Letter). 2006;152:e39
- Skovgaard LT (see Iversen et al). 2006;152:85
- Sleeper LA, Anderson P, T. Hsu D, Mahony L, McCrindle BW, Roth SJ, Saul JP, Williams RV, Geva T, Colan SD, Clark BJ, for the Pediatric Heart Network Investigators. Design of a large cross-sectional study to facilitate future clinical trials in children with the Fontan palliation (Trial Design). 2006;152:427-33
- Slentz CA (see Huffman et al). 2006;152:793-800
- Smallhorn JF (see Pitkänen et al). 2006;152:163
- Smedira NG (see Srichai et al). 2006;152:75-84
- Smith SC Jr (see Cohen et al). 2006;152:110-7
- Smith SC Jr (see Diercks et al). 2006;152:140-8
- Smith WT (see Abbayaratna et al). 2006;152:941-8
- Smulyan H (see Safar et al). 2006;152:417-9
- Snieder H (see Thayer et al). 2006;152:e27
- Snyder R (see Kramer et al). 2006;152:454-60
- Sogaard Teisner A (see Iversen et al). 2006;152:85
- Soler B (see Mostaza-Prieto et al). 2006;152:1063-9
- Solomon SD (see Janardhanan et al). 2006;152:183-9
- Solomon SD (see Janardhanan et al). 2006;152:246-52
- Somers VK (see Gurevitz et al). 2006;152:155
- Sonen AF (see Cohen et al). 2006;152:110-7
- Song JM (see Fukuda et al). 2006;152:1207-13
- Spertus JA (see Amin et al). 2006;152:928-34
- Spertus JA (see Green Conaway et al). 2006;152:1021-6
- Spertus JA (see Zhang et al). 2006;152:1152-9
- Spinelli JJ (see Lear et al). 2006;152:333-9
- SPORTIF Investigators (see Flaker et al). 2006;152:967-73
- Sprecher DL, Pearce GL. Skin cholesterol adds to Framingham risk assessment. 2006;152:694-6
- Squire I (see Estensen et al). 2006;152:927
- Squire IB (see Ng et al). 2006;152:94-101
- Squires RW (see Williams et al). 2006;152:835-41
- Srichai MB, Junor C, Rodriguez LL, Stillman AE, Grimm RA, Lieber ML, Weaver JA, Smedira NG, White RD. Clinical, imaging, and pathological characteristics of left ventricular thrombus: A comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. 2006;152:75-84
- Stables RH (see Zhang et al). 2006;152:1152-9
- Stafford JA (see Cowper et al). 2006;152:1193-9
- Stang P (see Yood et al). 2006;152:777-84
- Staniček J (see Meluzin et al). 2006;152:975
- Staudt A, Hummel A, Ruppert J, Dörr M, Trimpert C, Birkenmeier K, Krieg T, Staudt Y, Felix SB. Immunoabsorption in dilated cardiomyopathy: 6-month results from a randomized study. 2006;152:712
- Staudt Y (see Staudt et al). 2006;152:712
- Steffes M (see Cooper et al). 2006;152:59-66
- Steffes S (see Bertoni et al). 2006;152:785-92
- Steg PG (see Emery et al). 2006;152:1015-21
- Steg PG (see Fox et al). 2006;152:860-6
- Steinhubl SR (see Das et al). 2006;152:19-26
- Steinhubl SR, Akers WS. Clopidogrel-statin interaction: A mountain or a mole hill? (Editorial). 2006;152:200-3
- Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials (Curriculum Cardiol.). 2006;152:27-38
- Stevenson WG (see Koplan et al). 2006;152:714-9
- Stillman AE (see Srichai et al). 2006;152:75-84
- Stokkel MP (see Beeres et al). 2006;152:684
- Stöllberger C, Finsterer J, Blazek G. Cardiology and neurologic family screening in noncompaction (Letter). 2006;152:e61
- Stöllberger C, Schneider B, Finsterer J. WATCHMAN: An effective protection against stroke? (Letter). 2006;152:e35
- Stone GW (see Jensen et al). 2006;152:327-32
- Stone PH (see Gibson et al). 2006;152:756-61
- Störk S, Boivin V, Hof R, Hein L, Lohse MJ, Angermann CE, Jahns R. Stimulating autoantibodies directed against the cardiac β_1 -adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. 2006;152:697-704
- Strandberg TE, Pitkala KH, Berglund S, Nieminen MS, Tilvis RS. Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: The Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: A randomized, controlled trial. 2006;152:585-92
- Streichert T (see Schulze et al). 2006;152:493
- Stricker BHC (see Kardys et al). 2006;152:514-20
- Strödter D (see Schulze et al). 2006;152:493

- Strom BL (see Walker et al). 2006;152:521-6
Stylianou M (see Russell et al). 2006;152:867-75
Subramanian GK (see Chowdhury et al). 2006;152:1200-6
Suddath WO (see Kim et al). 2006;152:693
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators (see Friedmann et al). 2006;152:940
Sudhir K (see May et al). 2006;152:997-1003
Sukmawan R (see Kume et al). 2006;152:755
Suliman A (see Archbold et al). 2006;152:1090-4
Summers RL (see Mehta et al). 2006;152:648-60
Sun G (see Cui et al). 2006;152:543
Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study (see Borghi et al). 2006;152:470-7
Suryapranata H (see De Luca et al). 2006;152:915-20
Sutton-Tyrrell K (see Everson-Rose et al). 2006;152:982
Suzuki H (see Watanabe et al). 2006;152:731-5
Svendsen JH (see Nilsson et al). 2006;152:537
Swaminathan S (see Asch et al). 2006;152:742-8
Swedberg K (see Ducharme et al). 2006;152:86-92
Swindle J (see Hauptman et al). 2006;152:1095
Syversen U (see Estensen et al). 2006;152:927
Szyszka-Jurkiewicz B (see Wojnicz et al). 2006;152:713

T

- Taboada M (see Mostaza-Prieto et al). 2006;152:1063-9
Taheri PA (see Nallamothu et al). 2006;152:613-8
Tan M (see Goodman et al). 2006;152:277-84
Tan M (see Yan et al). 2006;152:270-6
Tan M (see Yan et al). 2006;152:676-83
Tanabe M (see Yamanaka et al). 2006;152:966
Tanabe N (see Watanabe et al). 2006;152:731-5
TandemHeart Investigators Group (see Burkhoff et al). 2006;152:469
Tang WW. Biomarker screening for cardiac dysfunction: The more the merrier? (Editorial). 2006;152:1-3
Tanigawa T (see Yamanaka et al). 2006;152:966
Tanner CJ (see Huffman et al). 2006;152:793-800
Tanus-Santos JE (see Gerlach and Tanus-Santos). 2006;152:e9
Tapson V (see Walker et al). 2006;152:521-6
Tardif JC (see de Demos et al). 2006;152:705-12
Tarride JE (see Lachaine et al). 2006;152:164-9
Tayek JA. A1c and mortality: An unexpected relationship in patients with advanced heart failure (Letter). 2006;152:e5
Taylor DA (see Kunz et al). 2006;152:190-5
Taylor HA (see Fox et al). 2006;152:749-55
Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS. B-Type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. 2006;152:1070-5
Tebbe U (see Zahn et al). 2006;152:1145-51
Tendera M (see Fox et al). 2006;152:860-6
Ten Vergert EM (see Van Gelder et al). 2006;152:420-6
Thackray SD, Ghosh JM, Wright GA, Witte KK, Nikitin NP, Kaye GC, Clark AL, Tweddell A, Cleland JG. The effect of altering heart rate on ventricular function in patients with heart failure treated with β -blockers. 2006;152:713
Thayer JF, Wang X, Snieder H. Ethnic differences in heart rate variability: Does ultralow-frequency heart rate variability really measure autonomic tone? (Letter). 2006;152:e27
Theodoro MP (see Nunes et al). 2006;152:914
Thomas JD (see Fukuda et al). 2006;152:1207-13
Thomas JD (see Janardhanan et al). 2006;152:246-52
Thomas SA (see Friedmann et al). 2006;152:940
Thompson JF (see Mank-Seymour et al). 2006;152:1115-21

- Thuesen L (see Kelbæk et al). 2006;152:882-6
Thuesen L, Kelbæk H, Klovgaard L, Helqvist S, Jorgensen E, Aljabbari S, Krusell LR, Jensen GV, Botker HE, Saunamäki K, Lassen JF, van Weert A, for the SCANDSTENT Investigators Copenhagen, Skejby, and Roskilde, Denmark and Leiden, the Netherlands.. Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: Subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). 2006;152:1139-44

- Tiemann K (see Hammerstingl et al). 2006;152:362
Tijssen JG (see Hirsch et al). 2006;152:434-41
Tijssen JG (see Van Gelder et al). 2006;152:420-6
Tillmanns H (see Schulze et al). 2006;152:493
Tilvis RS (see Strandberg et al). 2006;152:585-92
TIME Investigators (see Mazzarelli et al). 2006;152:991-6
TIMI Study Group (see Gibson et al). 2006;152:668-75
TIMI Study Group (see Gibson et al). 2006;152:756-61
Timm HB (see Iversen et al). 2006;152:85
Timmis AD (see Archbold et al). 2006;152:1090-4
Tindall N (see Brush Jr et al). 2006;152:379-85
Ting M-K (see Wang et al). 2006;152:1050
Todaro TG (see Mahaffey et al). 2006;152:291-6
Topol EJ (see Ellis et al). 2006;152:1050
Topol EJ (see Exaire et al). 2006;152:157-63
Topol EJ (see Goodman et al). 2006;152:277-84
Topol EJ (see Rajagopal et al). 2006;152:149-54
Tosi G (see Zavalloni et al). 2006;152:908
Toth L (see Faludi and Toth). 2006;152:e13
Toth KH (see Kamath et al). 2006;152:355-61
Toyota E (see Kume et al). 2006;152:755
Tranche S (see Mostaza-Prieto et al). 2006;152:1063-9
Travers A (see Welsh et al). 2006;152:1007-14
Trimpert C (see Staudt et al). 2006;152:712
TRITON-TIMI 38 Investigators (see Wiviott et al). 2006;152:627-35
Troatz C (see Hammerstingl et al). 2006;152:362
Troughton RW (see Collins et al). 2006;152:312-20
Trzeciak P (see Wojnicz et al). 2006;152:713
Tseng C-H (see Jeger et al). 2006;152:686-92
Tsuchida K (see Valgimigli et al). 2006;152:896-902
Tsuyuki R (see King et al). 2006;152:1186-92
Tu JV (see Guru et al). 2006;152:573-8
Tuininga YS (see Van Gelder et al). 2006;152:420-6
Turi Z (see Brown Fountain et al). 2006;152:e37-8
Turjammaa V (see Fan et al). 2006;152:538-42
Tuttle RH (see Whellan et al). 2006;152:340-7
Tuzcu EM (see Brener et al). 2006;152:1058-62
Tuzcu EM (see Nicholls et al). 2006;152:67-74
Tuzcu EM (see Sipahi et al). 2006;152:544-50
Tweddell A (see Thackray et al). 2006;152:713
Tyczynski P (see Kim et al). 2006;152:693

U

- Uddin F (see Kamath et al). 2006;152:355-61
Ueda Y (see Oyabu et al). 2006;152:1167-73
Uettwiller-Geiger D (see Peacock et al). 2006;152:253-62
Urbauer DL (see Deswal et al). 2006;152:348-54

V

- Vahanian A (see Flaker et al). 2006;152:967-73
Vahanian A (see Sinnnaeve et al). 2006;152:684
Valenti R (see Migliorini et al). 2006;152:903-8
Valgimigli M, Malagutti P, Rodriguez Granillo GA, Tsuchida K, Garcia-Garcia HM, van Mieghem CA, Van der Giessen WJ, De Feyter P, de Jaegere P, Van Domburg RT, Serruys PW. Single-

- vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries. 2006;152:896-902
- VALIANT Committees and Investigators (see Reed et al). 2006;152:500-8
- VALIANT Investigators (see Janardhanan et al). 2006;152:183-9
- VALIDD Investigators (see Janardhanan et al). 2006;152:246-52
- Van Cott EM (see Foo et al). 2006;152:290
- Van De Veire N (see Van Laethem et al). 2006;152:297
- Van de Veire NR, De Winter O, Gir M, De Buyzere M, Van De Wiele C, De Sutter J. Fasting blood glucose levels are related to exercise capacity in patients with coronary artery disease. 2006;152:486-92
- Van de Veire NR, De Winter O, Philippe J, De Buyzere M, Bernard D, Langlois M, Gillebert TC, De Sutter J. Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: The role of inflammation on top of tissue Doppler-derived systolic and diastolic function. 2006;152:297
- Van de Werf F (see Goodman et al). 2006;152:277-84
- Van de Werf F (see Mahaffey et al). 2006;152:291-6
- Van de Werf F (see Mertens et al). 2006;152:125
- Van de Werf F (see Reed et al). 2006;152:500-8
- Van de Werf FJ (see Sinnavee et al). 2006;152:684
- Van De Wiele C (see Van de Veire et al). 2006;152:486-92
- Van Den Berg MP (see Van Gelder et al). 2006;152:420-6
- Van der Giesen WJ (see Valgimigli et al). 2006;152:896-902
- van der Vleuten PA (see Hirsch et al). 2006;152:434-41
- van der Wall EE (see Beeres et al). 2006;152:684
- Van Domburg RT (see Valgimigli et al). 2006;152:896-902
- van Gelder IC (see H. Hohnloser et al). 2006;152:442-7
- Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Bosker HA, Cornel JH, Kamp O, Veeger NJ, Volbeda M, Rienstra M, Ranchor AV, Ten Vergert EM, Van Den Berg MP. Rate Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II (Trial Design). 2006;152:420-6
- Van Laethem C, Van De Veire N, De Sutter J, Bartunek J, De Backer G, Goethals M, Vanderheyden M. Prospective evaluation of the oxygen uptake efficiency slope as a submaximal predictor of peak oxygen uptake in aged patients with ischemic heart disease. 2006;152:297
- van Mieghem CA (see Valgimigli et al). 2006;152:896-902
- van Rossum AC (see Hirsch et al). 2006;152:434-41
- Van Tassel R (see Brown Fountain et al). 2006;152:e37-8
- Van Tassel R (see Fountain et al). 2006;152:720-3
- Van Veldhuisen DJ (see Van Gelder et al). 2006;152:420-6
- van Weert A (see Thuesen et al). 2006;152:1139-44
- Vanderheyden M (see Van Laethem et al). 2006;152:297
- Vandersluis R (see Kavak et al). 2006;152:118-25
- van't Hof AW (see De Luca et al). 2006;152:915-20
- Varadachari CJ (see Gurevitz et al). 2006;152:155
- Vassanelli C (see Bonapace et al). 2006;152:93
- Vata KC (see Kunz et al). 2006;152:190-5
- Veeger NJ (see Van Gelder et al). 2006;152:420-6
- Velazquez EJ (see Hernandez et al). 2006;152:494-9
- Velazquez EJ (see Janardhanan et al). 2006;152:183-9
- Velazquez EJ (see Reed et al). 2006;152:500-8
- Velazquez EJ (see Whellan et al). 2006;152:340-7
- Venkataiyan JK (see Chowdhury et al). 2006;152:1200-6
- Venkatesh PK (see Arora et al). 2006;152:1083-9
- Venugopal P (see Chowdhury et al). 2006;152:1200-6
- Verma S (see Wang et al). 2006;152:1050
- Verrier ED (see Mahaffey et al). 2006;152:291-6
- Viik J (see Fan et al). 2006;152:538-42
- Vincenti A (see Borhani et al). 2006;152:527-36
- Vinklarková J (see Meluzín et al). 2006;152:975
- Vliegen HW (see Grotenhuis et al). 2006;152:975
- Volbeda M (see Van Gelder et al). 2006;152:420-6
- Vonderscher J (see Donahue et al). 2006;152:478-85
- Vorchheimer D (see Rieckmann et al). 2006;152:922-7
- W**
- Wagner GS (see Goodman et al). 2006;152:277-84
- Wagner GS. Potential for improving sensitivity for detection of old myocardial infarction using the Q wave equivalent criteria in the Selvester QRS scoring system (Editorial). 2006;152:611-2
- Waksman R (see Kim et al). 2006;152:693
- Waldo AL. Response to Letter to the Editor (Letter reply). 2006;152:c19
- Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenham L, Constantine G. Temporal trends and drug exposures in pulmonary hypertension: An American experience. 2006;152:521-6
- Wallentin L (see Carlhed et al). 2006;152:1174-80
- Wallentin L (see Johnston et al). 2006;152:1051-7
- Wallentin L (see Sinnavee et al). 2006;152:684
- Walls UC (see Fox et al). 2006;152:749-55
- Wang C-H, Ting M-K, Verma S, Kuo L-T, Yang N-I, Hsieh I-C, Wang S-Y, Hung A, Chering W-J. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. 2006;152:1050
- Wang S-Y (see Wang et al). 2006;152:1050
- Wang T (see Ellis et al). 2006;152:1050
- Wang X (see Thayer et al). 2006;152:e27
- Wang Y (see Rathore et al). 2006;152:371-8
- Warmke JW (see Wiviott et al). 2006;152:627-35
- Warnes GR (see Mank-Seymour et al). 2006;152:1115-21
- Watanabe H, Tanabe N, Makiyama Y, Chopra SS, Okura Y, Suzuki H, Matsui K, Watanabe T, Kurashina Y, Aizawa Y. ST-segment abnormalities and premature complexes are predictors of new-onset atrial fibrillation: The Niigata Preventive Medicine Study. 2006;152:731-5
- Watanabe N (see Kume et al). 2006;152:755
- Watanabe T (see Watanabe et al). 2006;152:731-5
- Weaver JA (see Srichai et al). 2006;152:75-84
- Weaver WD (see Janardhanan et al). 2006;152:183-9
- Wedekind J-A (see Hammerstingl et al). 2006;152:362
- Weerakkody G (see Wiviott et al). 2006;152:627-35
- Weinberg GB (see Cubeddu et al). 2006;152:982
- Weinstein JM (see Amit et al). 2006;152:887
- Weintraub WS (see Rao et al). 2006;152:321-6
- Weintraub WS (see Zhang et al). 2006;152:1152-9
- Weintraub WS (see Zhang et al). 2006;152:770-6
- Weir MR (see Russell et al). 2006;152:867-75
- Weissman NJ (see Kim et al). 2006;152:693
- Wellens HJ (see Ottenvanger et al). 2006;152:636-40
- Wells K (see Yood et al). 2006;152:777-84
- Welsh RC, Travers A, Senaratne M, Williams R, Armstrong PW. Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center. 2006;152:1007-14
- Westenberg JJ (see Grotenhuis et al). 2006;152:975

- Weston SA (see Gerber et al). 2006;152:461-8
Weston SA (see Witt et al). 2006;152:102-9
Wever E (see Ottenvanger et al). 2006;152:636-40
Whellan DJ, Tuttle RH, Velazquez EJ, Shaw LK, Jollis JG, Ellis W, O'Connor CM, Califf RM, Borges-Neto S. Predicting significant coronary artery disease in patients with left ventricular dysfunction. 2006;152:340-7
White HD (see Janardhanan et al). 2006;152:183-9
White HD (see Reed et al). 2006;152:500-8
White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ III, Califf RM. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 2006;152:1041-9
White M (see de Denus et al). 2006;152:705-12
White RD (see Srichai et al). 2006;152:75-84
Wilczek K (see Wojnicz et al). 2006;152:713
Williams G (see Higgins et al). 2006;152:619-26
Williams IA, Gersony WM, Hellenbrand WE. Anomalous right coronary artery arising from the pulmonary artery: A report of 7 cases and a review of the literature. 2006;152:1004
Williams MA, Ades PA, Hamm LF, Keteyian SJ, LaFontaine TP, Roitman JL, Squires RW. Clinical evidence for a health benefit from cardiac rehabilitation: An update (Curriculum Cardiol.). 2006;152:835-41
Williams R (see Welsh et al). 2006;152:1007-14
Williams RV (see Sleeper et al). 2006;152:427-33
Wilson C (see Russell et al). 2006;152:867-75
Winters KJ (see Wiviott et al). 2006;152:627-35
Wisniewski L (see Nicholls et al). 2006;152:67-74
Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA, Roger VL. Ischemic stroke after heart failure: A community-based study. 2006;152:102-9
Witte KK (see Thackray et al). 2006;152:713
Witterman JC (see Kardys et al). 2006;152:514-20
Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E, for the TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) (Trial Design). 2006;152:627-35
Wodniecki J (see Wojnicz et al). 2006;152:713
Wojnicz R, Nowak J, Szygula-Jurkiewicz B, Wilczek K, Lekston A, Trzeciak P, Nowakowska E, Zembala M, Wodniecki J, Polonski L. Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: One-year follow-up results of the randomized trial. 2006;152:713
Wolak A (see Amit et al). 2006;152:887
Wolpert RL (see May et al). 2006;152:997-1003
Wolski K (see Exaire et al). 2006;152:157-63
Wolski K (see Nicholls et al). 2006;152:67-74
Women's Health Initiative Research Group (see Hsia et al). 2006;152:170-6
Wong H (see Chung et al). 2006;152:949-55
Wood LS (see Mank-Seymour et al). 2006;152:1115-21
Workshop Participants (see Califf, for the Workshop Participants). 2006;152:50-8

- Wright GA (see Thackray et al). 2006;152:713
Wright SM (see Deswal et al). 2006;152:348-54
Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: The role of biologic variation in the interpretation of results (Curriculum Cardiol.). 2006;152:828-34
Wu C (see Jaffe et al). 2006;152:126-35
Wu L (see Hsia et al). 2006;152:170-6

X

- Xie Y-G (see Cui et al). 2006;152:543

Y

- Yadav R (see Chowdhury et al). 2006;152:1200-6
Yamanaka T, Onishi K, Tanabe M, Dohi K, Funabiki-Yamanaka K, Fujimoto N, Kurita T, Tanigawa T, Kitamura T, Ito M, Nobori T, Nakano T. Force- and relaxation-frequency relations in patients with diastolic heart failure. 2006;152:966
Yan AT (see Yan et al). 2006;152:676-83
Yan AT, Yan RT, Tan M, Chow C-M, Fitchett DH, Georgescu AA, Hassan Q, Luchansky J, Langer A, Goodman SG, for the Canadian ACS Registry Investigators. ST-segment depression in non-ST elevation acute coronary syndromes: Quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. 2006;152:270-6
Yan RT (see Yan et al). 2006;152:270-6
Yan RT, Yan AT, Tan M, McGuire DK, Leiter L, Fitchett DH, Lauzon C, Lai K, Chow C-M, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. 2006;152:676-83
Yandle TG (see Collins et al). 2006;152:312-20
Yang H, Raymer K, Butler R, Parlow J, Roberts R. The effects of perioperative β -blockade: Results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. 2006;152:983-90
Yang N-I (see Wang et al). 2006;152:1050
Yao L (see Aguilar et al). 2006;152:298-304
Yaroslavtsev S (see Amit et al). 2006;152:887
Yazar A (see Lindstaedt et al). 2006;152:156
Yee R (see Leong-Sit et al). 2006;152:1103-7
Yeh F (see Russell et al). 2006;152:867-75
Yeh RW (see Foo et al). 2006;152:290
Yeon SB (see Hauser et al). 2006;152:974
Yerna MJ (see Kavak et al). 2006;152:1118-25
Yood MU, McCarthy BD, Kempf J, Kucera GP, Wells K, Oliveria S, Stang P. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. 2006;152:777-84
Yoshida K (see Kume et al). 2006;152:755
Young JB (see Ducharme et al). 2006;152:86-92
Yusuf S (see Ducharme et al). 2006;152:86-92

Z

- Zahger D (see Amit et al). 2006;152:887
Zahn R, Hamm CW, Schneider S, Zeymer U, Richard G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, Senges J, for the German Cypher Stent Registry. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry. 2006;152:1145-51

- Zanolla L (*see* Bonapace et al). 2006;152:93
- Zardini M (*see* Gasparini et al). 2006;152:155
- Zardini P (*see* Bonapace et al). 2006;152:93
- Zavalloni D, Belli G, Rossi ML, Scatturin M, Morenghi E, Catalano G, Tosi G, Gasparini GL, Pagnotta P, Presbitero P. Comparison between drug-eluting stents and beta-radiation for the treatment of diffuse in-stent restenosis: Clinical and angiographic outcomes. 2006;152:908
- Zembala M (*see* Wojnicz et al). 2006;152:713
- Zeymer U (*see* Zahn et al). 2006;152:1145-51
- Zhang Y (*see* Ellison et al). 2006;152:177-82
- Zhang Z, Foster JK, Kolm P, Jurkowitz CT, Parker KM, Murrah NV, Anderson GT, Douglas JS Jr, Weintraub WS. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: Results from the Cilostazol for RESTenosis (CREST) trial. 2006;152:770-6
- Zhang Z, Mahoney EM, Spertus JA, Booth J, Nugara F, Kolm P, Stables RH, Weintraub WS. The impact of age on outcomes after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: One-year results from the Stent or Surgery (SoS) trial. 2006;152:1152-9
- Zhu J (*see* Russell et al). 2006;152:867-75
- Ziada K (*see* Das et al). 2006;152:19-26
- Zijlstra F (*see* Hirsch et al). 2006;152:434-41
- Zijlstra F (*see* Ottenvanger et al). 2006;152:636-40
- Zile M (*see* Janardhanan et al). 2006;152:246-52
- Zimetbaum P (*see* Reynolds et al). 2006;152:1096-102
- Zipes DP (*see* Brodsky et al). 2006;152:724-30
- Zmuda JM (*see* Ding et al). 2006;152:1108-14

Subject Index*

A

Abciximab

Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS (Sinnave et al). 2006;152:684.e1-684.e9
Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial (Marmor et al). 2006;152:876-81

ACE inhibitors; see Angiotensin-converting enzyme inhibitors

Acetyl-CoA C-Acetyltransferase

Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA: Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study (Nicholls et al). 2006;152:67-74
(Trial design)

Acute coronary syndromes; see Angina, unstable; Myocardial infarction; Myocardial ischemia

Adrenergic beta-antagonists

The effect of altering heart rate on ventricular function in patients with heart failure treated with β -blockers (Thackray et al). 2006;152:713.e9-713.e13
The effects of perioperative β -blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial (Yang et al). 2006;152:983-90
Failure of β -blockers in the reduction of perioperative events: where did we go wrong? (McCullough). 2006;152:815-18
(Editorial)
Geographic variation in the treatment of acute myocardial infarction in the Valsartan In Acute myocardial infarction (VALIANT) trial (Reed et al). 2006;152:500-8
Impact of organizational infrastructure on β -blocker and aspirin therapy for acute myocardial infarction (Ellerbeck et al). 2006;152:579-84

Improved outcomes in peripartum cardiomyopathy with contemporary (Amos et al). 2006;152:509-13
National evaluation of adherence to β -blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance (Kramer et al). 2006;152:454.e1-454.e8
Patterns of use and potential impact of early β -blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events (Emery et al). 2006;152:1015-21

There is still hope for multifaceted intervention in heart failure (Ghali) (Letter); (LaPointe and Kramer) (Reply). 2006;152:e43, e45

Age factors

The impact of age on outcomes after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: one-year results from the Stent or Surgery (SoS) trial (Zhang et al). 2006;152:1152-9

Age factors (continued)

Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study (Reynolds et al). 2006;152:1096-102

Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative (Patel et al). 2006;152:641-7

Aged

Anemia as independent predictor of major events in elderly patients with chronic angina (Mazzarelli and Pfisterer). 2006;152:991-6

Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: the role of inflammation on top of tissue Doppler-derived systolic and diastolic function (Van de Veire et al). 2006;152:297.e1-297.e7

Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: the Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: a randomized, controlled trial (Strandberg et al). 2006;152:585-92

Prospective evaluation of the oxygen uptake efficiency slope as a submaximal predictor of peak oxygen uptake in aged patients with ischemic heart disease (Van Laethem et al).

2006;152:297.e9-297.e15

Routine percutaneous coronary intervention in elderly patients with cardiogenic shock complicating acute myocardial infarction (Migliorini et al). 2006;152:903-8

Socioeconomic status, treatment, and outcomes among elderly patients hospitalized with heart failure: findings from the National Heart Failure Project (Rathore et al). 2006;152:371-8
Survival in octogenarians receiving implantable defibrillators (Koplan et al). 2006;152:714-19

Albumins

Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department (Peacock et al). 2006;152:253-62

Alcohol drinking

Is alcohol consumption associated with calcified atherosclerotic plaque in the coronary arteries and aorta? (Ellison et al). 2006;152:177-82

Alpha-1 adrenergic receptors; see Receptors, adrenergic, alpha-1

Ambulatory care

Racial variations in quality of care and outcomes in an ambulatory heart failure cohort (Deswal et al). 2006;152:348-54

Amiodarone

Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation (Leong-Sit et al). 2006;152:1103-7

Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure (Singh et al). 2006;152:974.e7-974.e11

Amlodipine

Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials (Brener et al). 2006;152:1058-62

*July, pp. 1-196; August, pp. 197-406; September, pp. 407-606; October, pp. 607-806; November, pp. 807-1004; December, pp. 1005-1268.

AMP deaminase

- Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients (Collins et al). 2006;152:312-20
- The impact of the *AMPD1* gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: a study in 686 consecutive patients (Groote et al). 2006;152:736-41

Anemia

- Anemia as independent predictor of major events in elderly patients with chronic angina (Muzzarelli and Pfisterer). 2006;152:991-6
- Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia (Palazzuoli et al). 2006;152:1095.e9-1095.e15
- Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients (Archbold et al). 2006;152:1090-4
- Reduced CD34⁺, renal anemia, and adverse outcomes (Andreotti et al). 2006;152:e21 (Letter)

Angina, unstable

- Assessment of and physician response to glycemic control in diabetic patients presenting with an acute coronary syndrome (Conaway et al). 2006;152:1021-6
- Letter to the editor (Chan and Ionescu) (Letter); (Chen and Bhatt) (Reply). 2006;152:e51, e53

Angina pectoris

- Nonemergent coronary angioplasty without on-site surgical backup: a randomized study evaluating outcomes in low-risk patients (Melberg et al). 2006;152:888-95
- Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results (Beceres et al). 2006;152:684.e11-684.e16
- What information can an invasive cardiologist obtain from brain natriuretic peptide? (Grabowski and Filipiak). 2006;152:e11 (Letter)

Angiography

- Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent (Oyabu et al). 2006;152:1167-73
- Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials (Brener et al). 2006;152:1058-62
- The favorable clinical and angiographic outcomes of high-dose dexamethasone-eluting stent: randomized controlled prospective study (Han et al). 2006;152:887.e1-887.e7
- Lipoprotein-associated phospholipase A₂ independently predicts the angiographic diagnosis of coronary artery disease and coronary death (May et al). 2006;152:997-1003
- The *p22pbx* C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study (Fan et al). 2006;152:538-42
- Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries (Valgimigli et al). 2006;152:896-902

Angiography (continued)

- The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients (Charytan et al). 2006;152:558-64
- Variation in pulmonary vein size during the cardiac cycle: implications for non-electrocardiogram-gated imaging (Hauser et al). 2006;152:974.e1-974.e6
- What information can an invasive cardiologist obtain from brain natriuretic peptide? (Grabowski and Filipiak). 2006;152:e11 (Letter)

Angioplasty

- Comparison between stenting and balloon angioplasty in patients undergoing primary angioplasty of small coronary vessels (De Luca et al). 2006;152:915-20
- Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial—A prospective, multicenter, randomized trial (Hirsch et al). 2006;152:434-41 (Trial design)
- Letter to the editor (Hakeem and Bhatti) (Letter); (Holmes Jr and Gersh) (Reply). 2006;152:e47, e49
- Nonemergent coronary angioplasty without on-site surgical backup: a randomized study evaluating outcomes in low-risk patients (Melberg et al). 2006;152:888-95
- Nonemergent percutaneous coronary interventions in a veterans affairs medical center without onsite cardiac surgery (Roussanov et al). 2006;152:909-13

Angioplasty, transluminal, percutaneous coronary

- Association between Thrombolytic In Myocardial Infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the Randomized Trial to Evaluate the Relative PROTECT against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30) (Gibson et al). 2006;152:756-61

- Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial (Marmor et al). 2006;152:876-81

- "Bolus-only" glycoprotein IIb/IIIa inhibitor use for elective percutaneous coronary intervention: maybe less is more? (Fischell). 2006;152:812-14 (Editorial)

- Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts (Mehta et al). 2006;152:801-6

- Distal protection in cardiovascular medicine: current status (Ali et al). 2006;152:207-16 (Curriculum cardiol.)

- Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TTAN)-TIMI 34 trial (Gibson et al). 2006;152:668-75

- Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to Assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitionN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) (Wiviott et al). 2006;152:627-35 (Trial design)

- Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) Trial (Ottervanger et al). 2006;152:636-40 (Trial design)

Angioplasty, transluminal, percutaneous coronary (continued)

Implementation of a continuous quality improvement program for percutaneous coronary intervention and cardiac surgery at a large community hospital (Brush et al). 2006;152:379-85

Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial (Amit et al). 2006;152:887.e9-887.c14

Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial (Rajagopal et al). 2006;152:149-54

A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention (Brophy et al). 2006;152:263-9

The predicament of offering elective percutaneous coronary intervention at sites without on-site cardiac surgery (Singh). 2006;152:810-11 (Editorial)

Predictors of long-term outcome after crush stenting of coronary bifurcation lesions: importance of the bifurcation angle (Dzavik et al). 2006;152:762-9

Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial (Exaire et al). 2006;152:157-63

Routine percutaneous coronary intervention in elderly patients with cardiogenic shock complicating acute myocardial infarction (Migliorini et al). 2006;152:903-8

Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States (Fang et al). 2006;152:1034-1040

Angioscopy

Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent (Oyabu et al). 2006;152:1167-73

Angiotensin-converting enzyme inhibitors

Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction (Borghetti et al). 2006;152:470-7

Improved outcomes in peripartum cardiomyopathy with contemporary (Amos et al). 2006;152:509-13

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation (Anand et al). 2006;152:217-22 (Curriculum cardiol.)

Angiotensin II type 1 receptor blockers

A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation (Radke et al). 2006;152:761.e1-761.e6

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation (Anand et al). 2006;152:217-22 (Curriculum cardiol.)

Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) trial: evolving the management of diastolic dysfunction in hypertension (Janardhanan et al). 2006;152:246-52 (Trial design)

What is the role of angiotensin-receptor blockade in cardiovascular protection? (Cohn). 2006;152:859.e1-859.e8 (Trial design)

Anorexigens; see Appetite depressants

Anti-arrhythmic agents

A history of heart failure predicts arrhythmia treatment efficacy: data from the antiarrhythmics versus implantable defibrillators (AVID) study (Brodsky et al). 2006;152:724-30

A perspective on antiarrhythmic drug therapy (Jolobe) (Letter); (Waldo) (Reply). 2006;152:e17, e19

Antibodies

Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization (Foo et al). 2006;152:290.e1-290.e7

Antibodies, monoclonal

Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview (Mahaffey et al). 2006;152:291-6

Reflections on early stopping of a clinical trial (Armstrong and Granger). 2006;152:407-9 (Editorial)

Anticoagulants

Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial (Wojnicz et al). 2006;152:713.e1-713.e7

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials (Flaker et al). 2006;152:967-73

Antigens, CD34

Reduced CD34+, renal anemia, and adverse outcomes (Andreotti et al). 2006;152:e21 (Letter)

Anxiety

Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality (Friedmann et al). 2006;152:940.e1-940.e8

Aorta

Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy (Bonapace et al). 2006;152:93.e1-93.e6

Is alcohol consumption associated with calcified atherosclerotic plaque in the coronary arteries and aorta? (Ellison et al). 2006;152:177-82

Aortic valve insufficiency

Aortic root dysfunction and its effect on left ventricular function in Ross procedure patients assessed with magnetic resonance imaging (Grotenhuis et al). 2006;152:975.e1-975.e8

Appetite depressants

Temporal trends and drug exposures in pulmonary hypertension: an American experience (Walker et al). 2006;152:521-6

Arginine

Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study (Schulze et al). 2006;152:493.e1-493.e8

Arrhythmia; see also Atrial fibrillation

Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: the Bi vs Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study (Gasparini et al). 2006;152:155.e1-155.e7

Arrhythmia; see also Atrial fibrillation (continued)

Comparison of left ventricular and biventricular pacing in patients with heart failure (Arya) (Letter); (Gasparini) (Reply). 2006;152:e55, e57

A history of heart failure predicts arrhythmia treatment efficacy: data from the antiarrhythmics versus implantable defibrillators (AVID) study (Brodsky et al.). 2006;152:724-30

Survival in octogenarians receiving implantable defibrillators (Koplan et al.). 2006;152:714-19

Arterial remodeling

Regression of coronary artery outward remodeling in patients with non-ST-segment acute coronary syndromes: a longitudinal study using noninvasive magnetic resonance imaging (Fernandes et al.). 2006;152:1122-31

Arteriosclerosis

Circulating endothelial progenitor cells predict coronary artery disease severity (Kunz et al.). 2006;152:190-5

Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS) (Russell et al.). 2006;152:867-75 (Trial design)

How to assess coronary artery remodeling by intravascular ultrasound (Schärdt and Bocksch). 2006;152:414-6 (Editorial)

Intravascular ultrasound assessment of fibrous cap remnants after coronary plaque rupture (Jensen et al.). 2006;152:327-32

Is alcohol consumption associated with calcified atherosclerotic plaque in the coronary arteries and aorta? (Ellison et al.). 2006;152:177-82

Arthritis, rheumatoid

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis (Cannon et al.). 2006;152:237-45 (Trial design)

Aspirin

Impact of organizational infrastructure on β-blocker and aspirin therapy for acute myocardial infarction (Ellerbeck et al.). 2006;152:579-84

Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes (Rieckmann et al.). 2006;152:922-7

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials (Flaker et al.). 2006;152:967-73

Asymmetric dimethylarginine; see Arginine**Atherosclerosis**

Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA: Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study (Nicholls et al.). 2006;152:67-74 (Trial design)

Atorvastatin

Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial (Cubeddu et al.). 2006;152:982.e1-982.e11

A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention (Brophy et al.). 2006;152:263-9

Atria, heart; see Heart atria**Atrial appendage**

Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation (Fountain et al.). 2006;152:720-3

WATCHMAN: an effective protection against stroke? (Stöllberger et al.) (Letter); (Fountain et al.) (Reply). 2006;152:e35, e37

Atrial fibrillation

ASympomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT) (Hohnloser et al.). 2006;152:442-7 (Trial design)

The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion (Gurevitz et al.). 2006;152:155.e9-155.e13

Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACIAL) study (Reynolds et al.). 2006;152:1096-102

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation (Anand et al.). 2006;152:217-22 (Curriculum cardiolo.)

A perspective on antiarrhythmic drug therapy (Jolobe) (Letter); (Waldo) (Reply). 2006;152:e17, e19

Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation (Fountain et al.). 2006;152:720-3

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: assessment of Reduction in Mortality and morbidity (CHARM) program (Ducharme et al.). 2006;152:86-92

Rate Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II (Van Gelder et al.). 2006;152:420-6 (Trial design)

Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the Study of Atrial Fibrillation Reduction (SAFARI) (Gold and Hoffmann). 2006;152:231-6 (Trial design)

Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy (Nilsson et al.). 2006;152:537.e1-537.e8

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials (Flaker et al.). 2006;152:967-73

Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure (Singh et al.). 2006;152:974.e7-974.e11

ST-segment abnormalities and premature complexes are predictors of new-onset atrial fibrillation: the Niigata Preventive Medicine Study (Watanabe et al.). 2006;152:731-5

Variation in pulmonary vein size during the cardiac cycle: implications for non-electrocardiogram-gated imaging (Hauser et al.). 2006;152:974.e1-974.e6

WATCHMAN: an effective protection against stroke? (Stöllberger et al.) (Letter); (Fountain et al.) (Reply). 2006;152:e35, e37

Atrial septal defects; see Heart septal defects, atrial Auscultation

The blood pressure measurement—revisited (Safar and Smulyan). 2006;152:417-9 (Editorial)

Autoantibodies

Stimulating autoantibodies directed against the cardiac β_1 -adrenergic receptor predict increased mortality in idiopathic cardiomyopathy (Störk et al.). 2006;152:697-704

Autonomic nervous system

Ethnic differences in heart rate variability: does ultralow-frequency heart rate variability really measure autonomic tone? (Thayer et al.). 2006;152:e27 (Letter)

B

B-type natriuretic peptide; see Natriuretic peptide, brain; Natriuretic peptide, brain

Benzazepines

Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EVAlUaTion of the I_f inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) study (Fox et al.). 2006;152:860-6 (Trial design)

Beta-1 adrenergic receptor; see Receptors, adrenergic, beta-1

Beta-blockers; see Adrenergic beta-agonists

Beta rays

Comparison between drug-eluting stents and beta-radiation for the treatment of diffuse in-stent restenosis: clinical and angiographic outcomes (Zavalloni et al.). 2006;152:908. e1-908.e7

Biological markers

Association between Thrombolysis In Myocardial Infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the Randomized Trial to Evaluate the Relative PROTECTION against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30) (Gibson et al.). 2006;152:756-61

Bivalirudin

Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial (Rajagopal et al.). 2006;152:149-54

Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial (Exaire et al.). 2006;152:157-63

Blood flow velocity

The prognostic value of the mitral diastolic filling velocity ratio for all-cause mortality and cardiovascular morbidity in African Americans: the atherosclerotic Risks in Communities (ARIC) study (Fox et al.). 2006;152:749-55

Blood glucose

A1c and mortality: an unexpected relationship in patients with advanced heart failure (Tayek). 2006;152:e5 (Letter)

Fasting blood glucose levels are related to exercise capacity in patients with coronary artery disease (Van de Veire et al.). 2006;152:486-92

Blood glucose (continued)

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials (Stettler et al.). 2006;152:27-38 (Curriculum cardiol.)

Reply (Tayek) (Letter); (Eshaghian) (Reply). 2006;152:e7

Blood pressure

B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures (Taylor et al.). 2006;152:1070-5

Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS) (Russell et al.). 2006;152:867-75 (Trial design)

Racial differences are seen in blood pressure response to fosinopril in hypertensive children (Menon et al.). 2006;152:394-9

Blood pressure determination

The blood pressure measurement—revisited (Safar and Smulyan). 2006;152:417-9 (Editorial)

Blood transfusion

Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery (Rogers et al.). 2006;152:1027-33

BNP; see Natriuretic peptide, brain

Bone marrow transplantation

Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function (Meluzin et al.). 2006;152:975.e9-975.e15

Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial—A prospective, multicenter, randomized trial (Hirsch et al.). 2006;152:434-41 (Trial design)

Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results (Beeres et al.). 2006;152:684.e11-684.e16

Brachial artery

The blood pressure measurement—revisited (Safar and Smulyan). 2006;152:417-9 (Editorial)

Brachytherapy

Comparison between drug-eluting stents and beta-radiation for the treatment of diffuse in-stent restenosis: clinical and angiographic outcomes (Zavalloni et al.). 2006;152:908.e1-908.e7

Bundle-branch block

Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: the Bi vs Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study (Gasparini et al.). 2006;152:155.e1-155.e7

Comparison of left ventricular and biventricular pacing in patients with heart failure (Arya) (Letter); (Gasparini) (Reply). 2006;152:e55, e57

Left bundle-branch block artifact on single photon emission computed tomography with technetium Tc 99m (Tc-99m) agents: mechanisms and a method to decrease false-positive interpretations (Higgins et al.). 2006;152:619-26 (Curriculum cardiol.)

Multislice computed tomography to rule out coronary artery disease in patients with acquired left bundle-branch block and low cardiac risk (Perrier et al.) (Letter); (Schuiff and Bax) (Reply). 2006;152:e23, e29

C**C-reactive protein**

C-reactive protein and risk of heart failure. The Rotterdam study (Kardys et al). 2006;152:514-20

Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort (Lakoski et al). 2006;152:593-8

Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease (Aguilar et al). 2006;152:298-304

Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure (Ng et al). 2006;152:94-101

Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction (Ohlmann et al). 2006;152:1160-6

Response of high-sensitivity C-reactive protein to exercise training in an at-risk population (Huffman et al). 2006;152:793-800

Uvulopalatopharyngoplasty decreases levels of C-reactive protein in patients with obstructive sleep apnea syndrome (Kinoshita et al). 2006;152:692.e1-692.e5

CABG; see Coronary artery bypass**Calcinoses**

The impact of cardiovascular risk factors on subclinical left main coronary artery disease: an intravascular ultrasound study (Kim et al). 2006;152:693.e7-693.e12

Is alcohol consumption associated with calcified atherosclerotic plaque in the coronary arteries and aorta? (Ellison et al). 2006;152:177-82

Candesartan

A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation (Radke et al). 2006;152:761.e1-761.e6

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: assessment of Reduction in Mortality and morbidity (CHARM) program (Ducharme et al). 2006;152:86-92

Captopril

Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction (Borghetti et al). 2006;152:470-7

Geographic variation in the treatment of acute myocardial infarction in the VALSartan In Acute myocardial infarction (VALIANT) trial (Reed et al). 2006;152:500-8

Cardiac catheterization; see Heart catheterization**Cardiac hypertrophy; see Cardiomegaly****Cardiac output, low**

The effect of altering heart rate on ventricular function in patients with heart failure treated with β -blockers (Thackray et al). 2006;152:713.e9-713.e13

Cardiac pacing, artificial

Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the Study of Atrial Fibrillation Reduction (SAFARI) (Gold and Hoffmann). 2006;152:231-6 (Trial design)

Cardiac surgical procedures

Contemporary performance of surgical ventricular restoration procedures: data from the Society of Thoracic Surgeons' National Cardiac Database (Hernandez et al). 2006;152:494-9

Implementation of a continuous quality improvement program for percutaneous coronary intervention and cardiac surgery at a large community hospital (Brush et al). 2006;152:379-85

Cardiac surgical procedures (continued)

Risk factors for deaths occurring within 30 days and 1 year after hospital discharge for cardiac surgery among pediatric patients (Chang et al). 2006;152:386-93

Serial radionuclide angiographic assessment of left ventricular ejection fraction and regional wall motion after mitral valve replacement in patients with rheumatic disease (Chowdhury et al). 2006;152:1200-6

Cardiogenic shock; see Shock, cardiogenic**Cardiomegaly**

Letter to the Editor (Faludi). 2006;152:e13 (Letter)
Response to Letter to the Editor (Faludi) (Letter); (Alter) (Reply). 2006;152:e15

Cardiomyopathies

Myocardial perfusion in apical ballooning syndrome correlate of myocardial injury (Elesber et al). 2006;152:469.e9-469.e13

Stimulating autoantibodies directed against the cardiac β_1 -adrenergic receptor predict increased mortality in idiopathic cardiomyopathy (Störk et al). 2006;152:697-704

Cardiomyopathy, dilated

Adjuvant therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial (Wojnicz et al). 2006;152:713.e1-713.e7

Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy (Bonapace et al). 2006;152:93.e1-93.e6

Immunoabsorption in dilated cardiomyopathy: 6-month results from a randomized study (Staudt et al). 2006;152:712.e1-712.e6

Improved outcomes in peripartum cardiomyopathy with contemporary (Amos et al). 2006;152:509-13

Cardiovascular diseases

Effect of α_1 -adrenergic receptors in cardiac pathophysiology (Shannon and Chaudhry). 2006;152:842-50

Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS) (Russell et al). 2006;152:867-75 (Trial design)

Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort (Lakoski et al). 2006;152:593-8

Heparin-induced thrombocytopenia and cardiovascular diseases (Das et al). 2006;152:19-26 (Curriculum cardiol.)

The impact of cardiovascular risk factors on subclinical left main coronary artery disease: an intravascular ultrasound study (Kim et al). 2006;152:693.e7-693.e12

Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: the Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: a randomized, controlled trial (Strandberg et al). 2006;152:585-92

The prognostic value of the mitral diastolic filling velocity ratio for all-cause mortality and cardiovascular morbidity in African Americans: the atherosclerotic Risks in Communities (ARIC) study (Fox et al). 2006;152:749-55

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial (Boston et al). 2006;152:448.e1-448.e7 (Trial design)

Response of high-sensitivity C-reactive protein to exercise training in an at-risk population (Huffman et al). 2006;152:793-800

Response to letter to the editor by Dr. Mackin (Hennekens). 2006;152:e59 (Reply)

What is the role of angiotensin-receptor blockade in cardiovascular protection? (Cohn). 2006;152:859.e1-859.e8 (Trial design)

Cardiovascular diseases, diagnosis

Measurement of the thickness of the fibrous cap by optical coherence tomography (Kume et al). 2006;152:755.e1-755.e4

Cardioversion; see Electric countershock

Carotid artery disease

Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative (Hsia et al). 2006;152:170-6
Cynical hostility and carotid atherosclerosis in African American and white women: the Study of Women's Health Across the Nation (SWAN) Heart Study (Everson-Rose et al). 2006;152:982.e7-982.e13

Catheter ablation

Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy (Nilsson et al). 2006;152:537.e1-537.e8

Cerebrovascular accident

ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT) (Hohnloser et al). 2006;152:442-7 (Trial design)

Ischemic stroke after heart failure: a community-based study (Witt et al). 2006;152:102-9

Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke (Ding et al). 2006;152:1108-14

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials (Flaker et al). 2006;152:967-73

WATCHMAN: an effective protection against stroke? (Stöllberger et al) (Letter); (Fountain et al) (Reply). 2006;152:e35, e37

Chest pain; see Angina, unstable; Angina pectoris

Child

Design of a large cross-sectional study to facilitate future clinical trials in children with the Fontan palliation (Sleeper et al). 2006;152:427-33 (Trial design)

Racial differences are seen in blood pressure response to fosinopril in hypertensive children (Menon et al). 2006;152:394-9

Risk factors for deaths occurring within 30 days and 1 year after hospital discharge for cardiac surgery among pediatric patients (Chang et al). 2006;152:386-93

Chlamydia pneumoniae

Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease (Aguilar et al). 2006;152:298-304

Cholesterol

Evaluation of dyslipidemia in the emergency department: Impact of cholesterol testing on subsequent therapy (Blomkalns et al). 2006;152:1181-5

Quality of cholesterol screening and management with respect to the National Cholesterol Education's Third Adult Treatment Panel (ATPIII) guideline in primary care practices in North Carolina (Bertoni et al). 2006;152:785-92

Skin cholesterol adds to Framingham risk assessment (Sprecher and Pearce). 2006;152:694-6

Total cholesterol levels and mortality risk in nonischemic systolic heart failure (Afsarmanesh et al). 2006;152:1076-82

Chromogranins

Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction (Estensen et al). 2006;152:927.e1-927.e6

Cilostazol

Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial (Zhang et al). 2006;152:770-6

Clinical trials

Design of a large cross-sectional study to facilitate future clinical trials in children with the Fontan palliation (Sleeper et al). 2006;152:427-33 (Trial design)
Reflections on early stopping of a clinical trial (Armstrong and Granger). 2006;152:407-9 (Editorial)

Clopidogrel

Clopidogrel-statin interaction: a mountain or a mole hill? (Steinhubl and Akers). 2006;152:200-3 (Editorial)

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitionN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) (Wiviott et al). 2006;152:627-35 (Trial design)

A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention (Brophy et al). 2006;152:263-9

Collagen type III

Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy (Bonapace et al). 2006;152:93.e1-93.e6

Computed tomography; see Tomography, x-ray computed

Congenital heart disease; see Heart defects, congenital

Congestive heart failure; see Heart failure, congestive

Coronary angiography

Acute coronary syndromes in young patients with angiographically normal coronary arteries (Klein and Park). 2006;152:607-10 (Editorial)

A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation (Radke et al). 2006;152:761.e1-761.e6

Predictors of long-term outcome after crush stenting of coronary bifurcation lesions: importance of the bifurcation angle (Dzavik et al). 2006;152:762-9

Coronary arteries

Anomalous right coronary artery arising from the pulmonary artery: a report of 7 cases and a review of the literature (Williams et al). 2006;152:1004.e9-1004.e17

Coronary arteriosclerosis

The impact of cardiovascular risk factors on subclinical left main coronary artery disease: an intravascular ultrasound study (Kim et al). 2006;152:693.e7-693.e12

Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative (Patel et al). 2006;152:641-7
Subclinical coronary atherosclerosis: racial profiling is necessary! (Orakzai et al). 2006;152:819-27 (Curriculum cardiol.)

Coronary artery bypass

Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery (Rogers et al). 2006;152:1027-33

Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts (Mehta et al). 2006;152:801-6

Coronary artery bypass (continued)

- Clinical outcome in patients with intermediate or equivocal left main coronary artery disease after deferral of surgical revascularization on the basis of fractional flow reserve measurements (Lindstaedt et al). 2006;152:156.e1-156.e9
- Controlling the independent variables in the clinical study of prayer: the devil is in the details (Burks). 2006;152:e41 (Letter)
- Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview (Mahaffey et al). 2006;152:291-6
- The impact of age on outcomes after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: one-year results from the Stent or Surgery (SoS) trial (Zhang et al). 2006;152:1152-9
- Letter to the editor (Carron et al). 2006;152:e63 (Letter)
- Letter to the editor by Dr. Adam H. Skolnick (Skolnick). 2006;152:e39
- Public versus private institutional performance reporting: what is mandatory for quality improvement? (Guru et al). 2006;152:573-8
- Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes (Alserius et al). 2006;152:599-605
- A "STEP" in the right direction (Lilly). 2006;152:e31 (Letter)
- A step towards more ethical prayer studies (Hobbins). 2006;152:e33 (Letter)
- Trends in postoperative length of stay after bypass surgery (Cowper et al). 2006;152:1193-9

Coronary circulation

- Association between Thrombolysis In Myocardial Infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the Randomized Trial to Evaluate the Relative PROTECTion Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30) (Gibson et al). 2006;152:756-61
- Clinical outcome in patients with intermediate or equivocal left main coronary artery disease after deferral of surgical revascularization on the basis of fractional flow reserve measurements (Lindstaedt et al). 2006;152:156.e1-156.e9
- Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial (Amit et al). 2006;152:887.e9-887.e14
- Left bundle-branch block artifact on single photon emission computed tomography with technetium Tc 99m (Tc-99m) agents: mechanisms and a method to decrease false-positive interpretations (Higgins et al). 2006;152:619-26 (Curriculum cardiol.)

Coronary disease

- Acute coronary syndromes in young patients with angiographically normal coronary arteries (Klein and Park). 2006;152:607-10 (Editorial)
- Anemia as independent predictor of major events in elderly patients with chronic angina (Mazzarelli and Pfisterer). 2006;152:991-6
- Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma (Donahue et al). 2006;152:478-85
- Evaluation of dyslipidemia in the emergency department: Impact of cholesterol testing on subsequent therapy (Blomkalns et al). 2006;152:1181-5

Coronary disease (continued)

- Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (Janardhanan et al). 2006;152:183-9
- Fasting blood glucose levels are related to exercise capacity in patients with coronary artery disease (Van de Veire et al). 2006;152:486-92
- Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database (Horne et al). 2006;152:305-11
- Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: the role of inflammation on top of tissue Doppler-derived systolic and diastolic function (Van de Veire et al). 2006;152:297.e1-297.e7
- Nonemergent coronary angioplasty without on-site surgical backup: a randomized study evaluating outcomes in low-risk patients (Melberg et al). 2006;152:888-95
- The prevalence of unrecognized depression in patients with acute coronary syndrome (Amin et al). 2006;152:928-34
- Prospective evaluation of the oxygen uptake efficiency slope as a submaximal predictor of peak oxygen uptake in aged patients with ischemic heart disease (Van Laethem et al). 2006;152:297.e9-297.e15
- Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey (Ansell et al). 2006;152:976-81
- Response to letter to the editor by Dr. Mackin (Hennekens). 2006;152:e59 (Reply)
- Self-rated health among women with coronary disease: depression is as important as recent cardiovascular events (Ruo et al). 2006;152:921.e1-921.e7
- What information can an invasive cardiologist obtain from brain natriuretic peptide? (Grabowski and Filipiak). 2006;152:e11 (Letter)
- Coronary disease, diagnosis**
- Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study (Schulze et al). 2006;152:493.e1-493.e8
- Circulating endothelial progenitor cells predict coronary artery disease severity (Kunz et al). 2006;152:190-5
- Clinical outcome in patients with intermediate or equivocal left main coronary artery disease after deferral of surgical revascularization on the basis of fractional flow reserve measurements (Lindstaedt et al). 2006;152:156.e1-156.e9
- Lipoprotein-associated phospholipase A₂ independently predicts the angiographic diagnosis of coronary artery disease and coronary death (May et al). 2006;152:997-1003
- Multislice computed tomography to rule out coronary artery disease in pilots with acquired left bundle-branch block and low cardiac risk (Perrier et al) (Letter); (Schuiff and Bax) (Reply). 2006;152:e23, e29
- The *p22pbpox* C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study (Fan et al). 2006;152:538-42
- Predicting significant coronary artery disease in patients with left ventricular dysfunction (Whellan et al). 2006;152:340-7
- Risk stratification of patients with chronic kidney disease: results of screening strategies incorporating clinical risk scoring and dobutamine stress echocardiography (Rakhit et al). 2006;152:363-70

Coronary disease, diagnosis (continued)

Subclinical coronary atherosclerosis: racial profiling is necessary! (Orakzai et al). 2006;152:819-27 (Curriculum cardiol.)

The value of stress single photon emission computed tomography in patients without known coronary artery disease presenting with dyspnea (Balaravi et al). 2006;152:551-7

Coronary disease, drug therapy

Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials (Brener et al). 2006;152:1058-62

A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation (Radke et al). 2006;152:761.e1-761.e6

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRIAL to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) (Wiviott et al). 2006;152:627-35 (Trial design)

Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA: Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study (Nicholls et al). 2006;152:67-74 (Trial design)

Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EVAlUAtion of the I₁ inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) study (Fox et al). 2006;152:860-6 (Trial design)

Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study (Nunes et al). 2006;152:914.e1-914.e7

Coronary disease, prognosis

Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease (Aguilar et al). 2006;152:298-304

Coronary disease, therapy

Clinical evidence for a health benefit from cardiac rehabilitation: an update (Williams et al). 2006;152:835-41 (Curriculum cardiol.)

Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT) (Thuesen et al). 2006;152:1139-44

Drug-eluting stents in total coronary occlusions: another piece of the puzzle solved? (Dzavik). 2006;152:807-9 (Editorial)

Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease (Johnston et al). 2006;152:1051-7

Evidence-based cardiovascular therapies and achievement of therapeutic goals in diabetic patients with coronary heart disease attended in primary care (Mostaza-Prieto et al). 2006;152:1063-9

The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes (Mehta et al). 2006;152:648-660

Predictors of long-term outcome after crush stenting of coronary bifurcation lesions: importance of the bifurcation angle (Dzavik et al). 2006;152:762-9

Coronary disease, therapy (continued)

Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries (Valgimigli et al). 2006;152:896-902

Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial (Kebek et al). 2006;152:882-6

Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes (Yan et al). 2006;152:676-83

Coronary occlusion; see Coronary disease

Coronary restenosis; see also Stents

Comparison between drug-eluting stents and beta-radiation for the treatment of diffuse in-stent restenosis: clinical and angiographic outcomes (Zavalloni et al). 2006;152:908.e1-908.e7

The favorable clinical and angiographic outcomes of high-dose dexamethasone-eluting stent: randomized controlled prospective study (Han et al). 2006;152:887.e1-887.e7

Letter to the editor (Chan and Ionescu) (Letter); (Chen and Bhatt) (Reply). 2006;152:e51, e53

Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial (Zhang et al). 2006;152:770-6

Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial (Kebek et al). 2006;152:882-6

Coronary stenosis

Skin cholesterol adds to Framingham risk assessment (Sprecher and Pearce). 2006;152:694-6

Coronary vessel anomalies

Anomalous right coronary artery arising from the pulmonary artery: a report of 7 cases and a review of the literature (Williams et al). 2006;152:1004.e9-1004.e17

Coronary vessels

Comparison between stenting and balloon angioplasty in patients undergoing primary angioplasty of small coronary vessels (De Luca et al). 2006;152:915-20

How to assess coronary artery remodeling by intravascular ultrasound (Schartl and Bocksch). 2006;152:414-6 (Editorial)

The impact of cardiovascular risk factors on subclinical left main coronary artery disease: an intravascular ultrasound study (Kim et al). 2006;152:693.e7-693.e12

Is alcohol consumption associated with calcified atherosclerotic plaque in the coronary arteries and aorta? (Ellison et al). 2006;152:177-82

Measurement of the thickness of the fibrous cap by optical coherence tomography (Kume et al). 2006;152:755.e1-755.e4

Regression of coronary artery outward remodeling in patients with non-ST-segment acute coronary syndromes: a longitudinal study using noninvasive magnetic resonance imaging (Fernandes et al). 2006;152:1122-31

Static and serial assessments of coronary arterial remodeling are discordant: an intravascular ultrasound analysis from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial (Sipahi et al). 2006;152:544-50

Corrections

- Circulating endothelial progenitor cells predict coronary artery disease severity (Kunz et al). 2006;152:190-5.
2006;152:776
- Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma (Donahue et al). 2006;152:478-85. 2006;152:1021
- Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN-TIMI 36 trial (Morrow et al). 2006;152:399, 400.e1-400.e9
- Intrafamilial variability of noncompaction of the ventricular myocardium (Johnson et al). 2006;151:1012.e7-1012.e14.
2006;152:262
- Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program (Ducharme et al). 2006;152:84-92. 2006;152:354

Correspondence; see Letters to the Editor; Letters to the editor**Cost-benefit analysis**

- Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure (Ng et al). 2006;152:94-101

Cyclooxygenase 2 inhibitors

- The COX-2 inhibitors—An update (Furberg). 2006;152:197-9
(Editorial)

Cytochrome P-450 enzyme system

- Clopidogrel-statin interaction: a mountain or a mole hill? (Steinhubl and Akers). 2006;152:200-3 (Editorial)
- A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention (Brophy et al). 2006;152:263-9

Cytokines

- Are elevations of N-terminal probrain natriuretic peptide in endurance athletes after prolonged strenuous exercise due to systemic inflammatory cytokines? (McLachlan). 2006;152:e1
(Letter)
- Brain natriuretic peptide (BNP) and exercise-induced immune reaction: reply to the letter-to-the-editor of MacLachlan and Mossop (MacLachlan) (Letter); (Scharag and Kindermann) (Reply). 2006;152:e3
- Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial (Ellis et al). 2006;152:1050.e9-1050.e14

D**Death; see Mortality****Death, sudden, cardiac; see also Mortality**

- Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death (Boriani et al). 2006;152:527.e1-527.e11

- Home defibrillation: a feasibility study in myocardial infarction survivors at intermediate risk of sudden death (Sanna et al). 2006;152:685.e1-685.e7

- Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) Trial (Ottervanger et al). 2006;152:636-40 (Trial design)

Defibrillator, implantable

- Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure (Singh et al). 2006;152:974.e7-974.e11

Defibrillators, implantable

- Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death (Boriani et al). 2006;152:527.e1-527.e11

- Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation (Leong-Sit et al). 2006;152:1103-7

- A history of heart failure predicts arrhythmia treatment efficacy: data from the antiarrhythmics versus implantable defibrillators (AVID) study (Brodsky et al). 2006;152:724-30

- Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) Trial (Ottervanger et al). 2006;152:636-40 (Trial design)

- Survival in octogenarians receiving implantable defibrillators (Koplan et al). 2006;152:714-19

Delivery of health care

- Racial variations in quality of care and outcomes in an ambulatory heart failure cohort (Deswal et al). 2006;152:348-54

- Socioeconomic status, treatment, and outcomes among elderly patients hospitalized with heart failure: findings from the National Heart Failure Project (Rathore et al). 2006;152:371-8

Depression

- Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes (Rieckmann et al). 2006;152:922-7

- The prevalence of unrecognized depression in patients with acute coronary syndrome (Amin et al). 2006;152:928-34

- Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality (Friedmann et al). 2006;152:940.e1-940.e8

- Self-rated health among women with coronary disease: depression is as important as recent cardiovascular events (Ruo et al). 2006;152:921.e1-921.e7

Dexamethasone

- The favorable clinical and angiographic outcomes of high-dose dexamethasone-eluting stent: randomized controlled prospective study (Han et al). 2006;152:887.e1-887.e7

Dexfenfluramine

- Temporal trends and drug exposures in pulmonary hypertension: an American experience (Walker et al). 2006;152:521-6

Diabetes mellitus

- Assessment of and physician response to glycemic control in diabetic patients presenting with an acute coronary syndrome (Conaway et al). 2006;152:1021-6

- Evidence-based cardiovascular therapies and achievement of therapeutic goals in diabetic patients with coronary heart disease attended in primary care (Mostaza-Prieto et al). 2006;152:1063-9

- Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS) (Russell et al). 2006;152:867-75 (Trial design)

- Fasting blood glucose levels are related to exercise capacity in patients with coronary artery disease (Van de Veire et al). 2006;152:486-92

- Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus (Wang et al). 2006;152:1050.e1-1050.e8

Diabetes mellitus (continued)

Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes (Alserius et al). 2006;152:599-605

Diabetes mellitus, therapy

A1c and mortality: an unexpected relationship in patients with advanced heart failure (Tayek). 2006;152:e5 (Letter)

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials (Stettler et al). 2006;152:27-38 (Curriculum cardiol.)

Reply (Tayek) (Letter); (Eshaghian) (Reply). 2006;152:e7

Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes (Yan et al). 2006;152:676-83

Diagnostic imaging

Biomarker screening for cardiac dysfunction: the more the merrier? (Tang). 2006;152:1-3 (Editorial)

Evaluation of diagnostic imaging technologies and therapeutics devices: better information for better decisions: proceedings of a multidisciplinary workshop (Calif). 2006;152:50-8 (Meetings)

Diagnostic techniques, cardiovascular

Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department (Peacock et al). 2006;152:253-62

Dialysis

The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients (Charytan et al). 2006;152:558-64

Diclofenac

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis (Cannon et al). 2006;152:237-45 (Trial design)

Dietary supplements

Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial (Cubeddu et al). 2006;152:982.e1-982.e5

Dobutamine

Risk stratification of patients with chronic kidney disease: results of screening strategies incorporating clinical risk scoring and dobutamine stress echocardiography (Rakhit et al). 2006;152:363-70

Dose-response relationship, drug

Clopidogrel-statin interaction: a mountain or a mole hill? (Steinhubl and Akers). 2006;152:200-3 (Editorial)

Racial differences are seen in blood pressure response to fosinopril in hypertensive children (Menon et al). 2006;152:394-9

Double outlet right ventricle

Borderline left ventricles in prenatally diagnosed atrioventricular septal defect or double outlet right ventricle: echocardiographic predictors of biventricular repair (Pitkänen et al). 2006;152:163.e1-163.e7

Drug delivery systems

Patterns and outcomes of drug-eluting coronary stent use in clinical practice (Rao et al). 2006;152:321-6

Drug evaluation

Rationale, design, and organization of the *PeriOperative ISchemic Evaluation* (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery (Devereaux et al). 2006;152:223-30 (Trial design)

Drug interactions

Clopidogrel-statin interaction: a mountain or a mole hill?

(Steinhubl and Akers). 2006;152:200-3 (Editorial)

A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention (Brophy et al). 2006;152:263-9

Drug therapy

Chronic inotropic therapy in end-stage heart failure (Hauptman et al). 2006;152:1095.e1-1095.e8

Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial (Cubeddu et al). 2006;152:982.e1-982.e5

Evidence-based cardiovascular therapies and achievement of therapeutic goals in diabetic patients with coronary heart disease attended in primary care (Mostaza-Prieto et al). 2006;152:1063-9

What is the role of angiotensin-receptor blockade in cardiovascular protection? (Cohn). 2006;152:859.e1-859.e8 (Trial design)

Drug therapy, combination

Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial infarction (VALIANT) trial (Reed et al). 2006;152:500-8

Dyslipidemia; see Hyperlipidemia

Dyspnea

Influence of history of heart failure on diagnostic performance and utility of B-type natriuretic peptide testing for acute dyspnea in the emergency department (Chung et al). 2006;152:949-55

The value of stress single photon emission computed tomography in patients without known coronary artery disease presenting with dyspnea (Balaravi et al). 2006;152:551-7

E

Echocardiography

Antecedent left ventricular mass and infarct size in ST-elevation myocardial infarction (Jakovishvili et al).

2006;152:285-90

Borderline left ventricles in prenatally diagnosed atrioventricular septal defect or double outlet right ventricle: echocardiographic predictors of biventricular repair (Pitkänen et al). 2006;152:163.e1-163.e7

Echocardiographic insights into atrial and ventricular mechanisms of functional tricuspid regurgitation (Fukuda et al). 2006;152:1207-13

Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation (Leong-Sit et al). 2006;152:1103-7

Persistence of iatrogenic atrial septal defect after pulmonary vein isolation—an underestimated risk? (Hammerstingl et al). 2006;152:362.e1-362.e5

Echocardiography, Doppler

Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: the role of inflammation on top of tissue Doppler-derived systolic and diastolic function (Van de Veire et al). 2006;152:297.e1-297.e7

Echocardiography, stress

Risk stratification of patients with chronic kidney disease: results of screening strategies incorporating clinical risk scoring and dobutamine stress echocardiography (Rakhit et al). 2006;152:363-70

Echocardiography, transesophageal

Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological evaluation (Srichai et al). 2006;152:75-84

Echocardiography, transthoracic

Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological evaluation (Srichai et al). 2006;152:75-84

Editorials

Acute coronary syndromes in young patients with angiographically normal coronary arteries (Klein and Park). 2006;152:607-10

Biomarker screening for cardiac dysfunction: the more the merrier? (Tang). 2006;152:1-3

The blood pressure measurement—revisited (Safar and Smulyan). 2006;152:417-9

"Bolus-only" glycoprotein IIb/IIIa inhibitor use for elective percutaneous coronary intervention: maybe less is more? (Fischell). 2006;152:812-14

Clopidogrel-statin interaction: a mountain or a mole hill? (Steinhubl and Akers). 2006;152:200-3

Continued improvements in quality improvement research (Peterson and Roe). 2006;152:1005-6

The COX-2 inhibitors—An update (Furberg). 2006;152:197-9

Drug-eluting stents in total coronary occlusions: another piece of the puzzle solved? (Dzavik). 2006;152:807-9

Failure of β-blockers in the reduction of perioperative events: where did we go wrong? (McCullough). 2006;152:815-18

How to assess coronary artery remodeling by intravascular ultrasound (Schartl and Bocksch). 2006;152:414-6

In transition: from family history into the post-genomic era (Schunkert and Mayer). 2006;152:204-6

Potential for improving sensitivity for detection of old myocardial infarction using the Q wave equivalent criteria in the Selvester QRS scoring system (Wagner). 2006;152:611-12

The predicament of offering elective percutaneous coronary intervention at sites without on-site cardiac surgery (Singh). 2006;152:810-11

Reflections on early stopping of a clinical trial (Armstrong and Granger). 2006;152:407-9

Reporting for provider performance: should we punish the bad, or try to make them all good? (Ferguson). 2006;152:410-3

Ejection fraction; see Stroke volume**Elderly; see Aged****Electric countershock**

The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion (Gurevitz et al). 2006;152:155.e9-155.e13

Home defibrillation: a feasibility study in myocardial infarction survivors at intermediate risk of sudden death (Sanna et al). 2006;152:685.e1-685.e7

Electrocardiography

The 12-lead electrocardiogram as a predictive tool of mortality after acute myocardial infarction: current status in an era of revascularization and reperfusion (Petrina et al). 2006;152:11-8 (Curriculum cardiol.)

Broken bodies, broken hearts? Limitations of the trauma system as a model for regionalizing care for ST-elevation myocardial infarction in the United States (Nallamothu et al). 2006;152:613-18 (Curriculum cardiol.)

Electrocardiography (continued)

Lack of sensitivity of the electrocardiogram for detection of old myocardial infarction: a cardiac magnetic resonance imaging study (Asch et al). 2006;152:742-8

Low voltage on the electrocardiogram is a marker of disease severity and a risk factor for adverse outcomes in patients with heart failure due to systolic dysfunction (Kamath et al). 2006;152:355-61

Potential for improving sensitivity for detection of old myocardial infarction using the Q wave equivalent criteria in the Selvester QRS scoring system (Wagner). 2006;152:611-12 (Editorial)

Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative (Patel et al). 2006;152:641-7

The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience (Goodman et al). 2006;152:277-84

ST-segment abnormalities and premature complexes are predictors of new-onset atrial fibrillation: the Niigata Preventive Medicine Study (Watanabe et al). 2006;152:731-5

ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification (Yan et al). 2006;152:270-6

Variation in pulmonary vein size during the cardiac cycle: implications for non-electrocardiogram-gated imaging (Hauser et al). 2006;152:974.e1-974.e6

Electrocardiography, ambulatory

A perspective on antiarrhythmic drug therapy (Jolobe) (Letter); (Waldo) (Reply). 2006;152:e17, e19

Embolism; see Thromboembolism

WATCHMAN: an effective protection against stroke? (Stöllberger et al) (Letter); (Fountain et al) (Reply). 2006;152:e35, e37

Embolization, therapeutic

Distal protection in cardiovascular medicine: current status (Ali et al). 2006;152:207-16 (Curriculum cardiol.)

Emergency medical services

Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center (Welsh et al). 2006;152:1007-14

The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes (Mehta et al). 2006;152:648-660

Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department (Peacock et al). 2006;152:253-62

Emergency service, hospital

Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integregrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial (Gibson et al). 2006;152:668-75

Enalapril

Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials (Brener et al). 2006;152:1058-62

Endothelium, vascular

Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent (Oyabu et al). 2006;152:1167-73

Enoxaparin

Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial (Wojnicz et al). 2006;152:713.e1-713.e7

Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS (Simnaeve et al). 2006;152:684.e1-684.e9

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (White et al). 2006;152:1041-9

Eptifibatide

Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial (Gibson et al). 2006;152:668-75

Equipment design

Distal protection in cardiovascular medicine: current status (Ali et al). 2006;152:207-16 (Curriculum cardiol.)

Equipment failure analysis

Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation (Leong-Sit et al). 2006;152:1103-7

Erythropoietin

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia (Palazzuoli et al). 2006;152:1095.e9-1095.e15

Estradiol

Estradiol increases platelet aggregation in PI^{A1/A1} individuals (Boudoulas et al). 2006;152:136-9

Estrogens, conjugated (USP)

Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative (Hsia et al). 2006;152:170-6

Ethics, clinical

A step towards more ethical prayer studies (Hobbs). 2006;152:e33 (Letter)

Ethnic groups

Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) (Cohen et al). 2006;152:110-7

Cynical hostility and carotid atherosclerosis in African American and white women: the Study of Women's Health Across the Nation (SWAN) Heart Study (Everson-Rose et al). 2006;152:982.e7-982.e13

Ethnic differences in heart rate variability: does ultralow-frequency heart rate variability really measure autonomic tone? (Thayer et al). 2006;152:e27 (Letter)

The *p22pbax* C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in high-risk Finnish Caucasian population. The Finnish Cardiovascular Study (Fan et al). 2006;152:538-42

Ethnic groups (continued)

The prognostic value of the mitral diastolic filling velocity ratio for all-cause mortality and cardiovascular morbidity in African Americans: the atherosclerotic Risks in Communities (ARIC) study (Fox et al). 2006;152:749-55

Racial differences are seen in blood pressure response to fosinopril in hypertensive children (Menon et al). 2006;152:394-9

Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy (Yood et al). 2006;152:777-84

Racial variations in quality of care and outcomes in an ambulatory heart failure cohort (Deswal et al). 2006;152:348-54

Subclinical coronary atherosclerosis: racial profiling is necessary! (Orakzai et al). 2006;152:819-27 (Curriculum cardiol.)

Etoricoxib: see Pyridines; Sulfones

Evidence-based medicine

Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes (Yan et al). 2006;152:676-83

Exercise

Are elevations of N-terminal probrain natriuretic peptide in endurance athletes after prolonged strenuous exercise due to systemic inflammatory cytokines? (McLachlan). 2006;152:e1 (Letter)

Brain natriuretic peptide (BNP) and exercise-induced immune reaction: reply to the letter-to-the-editor of MacLachlan and Mossop (MacLachlan) (Letter); (Scharhag and Kindermann) (Reply). 2006;152:e3

Clinical evidence for a health benefit from cardiac rehabilitation: an update (Williams et al). 2006;152:835-41 (Curriculum cardiol.)

Response of high-sensitivity C-reactive protein to exercise training in an at-risk population (Huffman et al). 2006;152:793-800

Exercise test

Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: the role of inflammation on top of tissue Doppler-derived systolic and diastolic function (Van de Veire et al). 2006;152:297.e1-297.e7

Exercise tolerance

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia (Palazzuoli et al). 2006;152:1095.e9-1095.e15

Fasting blood glucose levels are related to exercise capacity in patients with coronary artery disease (Van de Veire et al). 2006;152:486-92

The impact of the *AMPD1* gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: a study in 686 consecutive patients (Groote et al). 2006;152:736-41

Extracellular matrix

Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy (Bonapace et al). 2006;152:93.e1-93.e6

F

Faith healing

Controlling the independent variables in the clinical study of prayer: the devil is in the details (Burks). 2006;152:e41 (Letter)
Letter to the editor (Carron et al). 2006;152:e63 (Letter)

Faith healing (continued)

- Letter to the editor by Dr. Adam H. Skolnick (Skolnick). 2006;152:e39
 A "STEP" in the right direction (Lilly). 2006;152:e31 (Letter)
 A step towards more ethical prayer studies (Hobbins). 2006;152:e33 (Letter)

Fatty alcohols

- Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial (Cubeddu et al.). 2006;152:982.e1-982.e5

FDA; see Food and Drug Administration**Fenfluramine**

- Temporal trends and drug exposures in pulmonary hypertension: an American experience (Walker et al.). 2006;152:521-6

Fibrinolysis

- Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center (Weish et al.). 2006;152:1007-14

Fibrinolytic agents

- Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS (Sinnaeve et al.). 2006;152:684.e1-684.e9
 Association between Thrombolysis In Myocardial Infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the Randomized Trial to Evaluate the Relative PROTECTION against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30) (Gibson et al.). 2006;152:756-61

Fibrinolytic therapy; see Thrombolytic therapy**Folic acid**

- Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial (Bostom et al.). 2006;152:448.e1-448.e7 (Trial design)

Fontan procedure

- Design of a large cross-sectional study to facilitate future clinical trials in children with the Fontan palliation (Sleeper et al.). 2006;152:427-33 (Trial design)

Food and Drug Administration

- The COX-2 inhibitors—An update (Furberg). 2006;152:197-9 (Editorial)

Fosinopril

- Racial differences are seen in blood pressure response to fosinopril in hypertensive children (Menon et al.). 2006;152:394-9

G**Gelatinase B**

- Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure (Tanus-Santos). 2006;152:e9 (Letter)

Genetic predisposition to disease

- Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database (Horne et al.). 2006;152:305-11

In transition: from family history into the post-genomic era (Schunkert and Mayer). 2006;152:204-6 (Editorial)

Genetics

- Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes (Mank-Seymour et al.). 2006;152:1115-21

Genetics (continued)

- Family screening in noncompaction (Stöllberger et al.). 2006;152:e61 (Letter)

The impact of the *AMPD1* gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: a study in 686 consecutive patients (Groote et al.). 2006;152:736-41

Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke (Ding et al.). 2006;152:1108-14

Genotype

- Evaluation of *AMPD1* C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients (Collins et al.). 2006;152:312-20

Glomerular filtration rate

- Survival in octogenarians receiving implantable defibrillators (Koplan et al.). 2006;152:714-19

Glucose, plasma; see Blood glucose**Glycoprotein IIb/IIIa inhibitors**; see Platelet aggregation inhibitors**Graft occlusion, vascular**

- Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts (Mehta et al.). 2006;152:801-6

Granulocyte colony stimulating factor

- Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial (Ellis et al.). 2006;152:1050.e9-1050.e14

Guideline adherence

- The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes (Mehta et al.). 2006;152:648-660

- Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study (Carlhed et al.). 2006;152:1174-80

H**Health care costs**

- Chronic inotropic therapy in end-stage heart failure (Hauptman et al.). 2006;152:1095.e1-1095.e8

- Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial (Zhang et al.). 2006;152:770-6

Health care quality, access, and evaluation

- Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design (Jollis et al.). 2006;152:851-8, 851.e1-851.e11 (Trial design)

Health care surveys

- The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes (Mehta et al.). 2006;152:648-660

Health resources

- Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial (Zhang et al.). 2006;152:770-6

Heart, artificial

- Current status of the total artificial heart (Gray and Selzman). 2006;152:4-10 (Curriculum cardiol.)

Heart-assist devices

A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock (Burkhoff et al). 2006;152:469.e1-469.e8

Heart atria

ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT) (Hohnloser et al). 2006;152:442-7 (Trial design)

Echocardiographic insights into atrial and ventricular mechanisms of functional tricuspid regurgitation (Fukuda et al). 2006;152:1207-13

Heart auscultation

Effect of teaching and type of stethoscope on cardiac auscultatory performance (Iversen et al). 2006;152:85.e1-85.e7

Heart catheterization

B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures (Taylor et al). 2006;152:1070-5

Predicting significant coronary artery disease in patients with left ventricular dysfunction (Whellan et al). 2006;152:340-7

Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization (Foo et al). 2006;152:290.e1-290.e7

Heart conduction system

Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy (Nilsson et al). 2006;152:537.e1-537.e8

Heart defects, congenital

Design of a large cross-sectional study to facilitate future clinical trials in children with the Fontan palliation (Sleeper et al). 2006;152:427-33 (Trial design)

Heart diseases, diagnosis

ST-segment abnormalities and premature complexes are predictors of new-onset atrial fibrillation: the Niigata Preventive Medicine Study (Watanabe et al). 2006;152:731-5

Heart failure, congestive

A1c and mortality: an unexpected relationship in patients with advanced heart failure (Tayek). 2006;152:e5 (Letter)

Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy (Bonapace et al). 2006;152:93.e1-93.e6

Biomarker screening for cardiac dysfunction: the more the merrier? (Tang). 2006;152:1-3 (Editorial)

Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death (Boriani et al). 2006;152:527.e1-527.e11

Current status of the total artificial heart (Gray and Selzman). 2006;152:4-10 (Curriculum cardiol.)

Effect of α_1 -adrenergic receptors in cardiac pathophysiology (Shannon and Chaudhry). 2006;152:842-50

The effect of altering heart rate on ventricular function in patients with heart failure treated with β -blockers (Thackray et al). 2006;152:713.e9-713.e13

Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients (Collins et al). 2006;152:312-20

Force- and relaxation-frequency relations in patients with diastolic heart failure (Yamanaka et al). 2006;152:966.e1-966.e7

Heart failure, congestive (continued)

Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial infarction (VALIANT) trial (Reed et al). 2006;152:500-8

Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients (Archbold et al). 2006;152:1090-4

A history of heart failure predicts arrhythmia treatment efficacy: data from the antiarrhythmics versus implantable defibrillators (AVID) study (Brodsky et al). 2006;152:724-30

Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database (Horne et al). 2006;152:305-11

The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: a study in 686 consecutive patients (Groote et al). 2006;152:736-41

Low voltage on the electrocardiogram is a marker of disease severity and a risk factor for adverse outcomes in patients with heart failure due to systolic dysfunction (Kamath et al). 2006;152:355-61

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure (Tanus-Santos). 2006;152:e9 (Letter)

Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis (Ahmed et al). 2006;152:956-66

Patterns of use and potential impact of early β -blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events (Emery et al). 2006;152:1015-21

Predicting significant coronary artery disease in patients with left ventricular dysfunction (Whellan et al). 2006;152:340-7

Racial variations in quality of care and outcomes in an ambulatory heart failure cohort (Deswal et al). 2006;152:348-54

Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality (Friedmann et al). 2006;152:940.e1-940.e8

Reply (Tayek) (Letter); (Eshaghian) (Reply). 2006;152:e7

Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure (Singh et al). 2006;152:974.e7-974.e11

Socioeconomic status, treatment, and outcomes among elderly patients hospitalized with heart failure: findings from the National Heart Failure Project (Rathore et al). 2006;152:371-8

There is still hope for multifaceted intervention in heart failure (Ghali) (Letter); (LaPointe and Kramer) (Reply). 2006;152:e43, e45

Total cholesterol levels and mortality risk in nonischemic systolic heart failure (Afsarmanesh et al). 2006;152:1076-82

Heart failure, congestive, diagnosis

C-reactive protein and risk of heart failure. The Rotterdam study (Kardys et al). 2006;152:514-20

Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (Janardhanan et al). 2006;152:183-9

Influence of history of heart failure on diagnostic performance and utility of B-type natriuretic peptide testing for acute dyspnea in the emergency department (Chung et al). 2006;152:949-55

Ischemic stroke after heart failure: a community-based study (Witt et al). 2006;152:102-9

Heart failure, congestive, drug therapy

Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial (Wojnicz et al). 2006;152:713.e1-713.e7

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: assessment of Reduction in Mortality and morbidity (CHARM) program (Ducharme et al). 2006;152:86-92

Short and long-term mortality with nesiritide (Arora et al). 2006;152:1083-9

Statin use in heart failure: a cause for concern? (Raina et al). 2006;152:39-49 (Curriculum cardiol.)

Heart failure, congestive, prognosis

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia (Palazzuoli et al). 2006;152:1095.e9-1095.e15

Heart failure, congestive, therapy

Are registry hospitals different? A comparison of patients admitted to hospitals of a commercial heart failure registry with those from national and community cohorts (Heidenreich and Fonarow). 2006;152:935-9

Chronic inotropic therapy in end-stage heart failure (Hauptman et al). 2006;152:1095.e1-1095.e8

Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results (Wu). 2006;152:828-34 (Curriculum cardiol.)

Heart function tests

Biomarker screening for cardiac dysfunction: the more the merrier? (Tang). 2006;152:1-3 (Editorial)

Heart rate

The effect of altering heart rate on ventricular function in patients with heart failure treated with β -blockers (Thackray et al). 2006;152:713.e9-713.e13

Ethnic differences in heart rate variability: does ultralow-frequency heart rate variability really measure autonomic tone? (Thayer et al). 2006;152:e27 (Letter)

Force- and relaxation-frequency relations in patients with diastolic heart failure (Yamanaka et al). 2006;152:966.e1-966.e7

Letter to the Editor (Faludi). 2006;152:e13 (Letter)

RAtE Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II (Van Gelder et al). 2006;152:420-6 (Trial design)

Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I_i inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) study (Fox et al). 2006;152:860-6 (Trial design)

Response to Letter to the Editor (Faludi) (Letter); (Alter) (Reply). 2006;152:e15

Weight loss improves heart rate recovery in overweight and obese men with features of the metabolic syndrome (Brinkworth et al). 2006;152:693.e1-693.e6

Heart septal defects, atrial

Persistence of iatrogenic atrial septal defect after pulmonary vein isolation—an underestimated risk? (Hammerstingl et al). 2006;152:362.e1-362.e5

Heart septal defects, ventricular

Borderline left ventricles in prenatally diagnosed atrioventricular septal defect or double outlet right ventricle: echocardiographic predictors of biventricular repair (Pitkänen et al). 2006;152:163.e1-163.e7

Heart ventricles

Borderline left ventricles in prenatally diagnosed atrioventricular septal defect or double outlet right ventricle: echocardiographic predictors of biventricular repair (Pitkänen et al). 2006;152:163.e1-163.e7

Contemporary performance of surgical ventricular restoration procedures: data from the Society of Thoracic Surgeons' National Cardiac Database (Hernandez et al). 2006;152:494-9

Echocardiographic insights into atrial and ventricular mechanisms of functional tricuspid regurgitation (Fukuda et al). 2006;152:1207-13

Family screening in noncompaction (Stöllberger et al). 2006;152:e61 (Letter)

Hemodynamics

Immunoabsorption in dilated cardiomyopathy: 6-month results from a randomized study (Staudt et al). 2006;152:712.e1-712.e6

A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock (Burkhoff et al). 2006;152:469.e1-469.e8

Hemoglobin

Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients (Archbold et al). 2006;152:1090-4

Hemoglobin A_{1c}, glycosylated

A1c and mortality: an unexpected relationship in patients with advanced heart failure (Tayek). 2006;152:e5 (Letter)

Assessment of and physician response to glycemic control in diabetic patients presenting with an acute coronary syndrome (Conaway et al). 2006;152:1021-6

Reply (Tayek) (Letter); (Eshaghian) (Reply). 2006;152:e7

Hemorrhage

Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial (Marmor et al). 2006;152:876-81

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (White et al). 2006;152:1041-9

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials (Flaker et al). 2006;152:967-73

Heparin

Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS (Sinnaeve et al). 2006;152:684.e1-684.e9

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (White et al). 2006;152:1041-9

Heparin (continued)

- Heparin-induced thrombocytopenia and cardiovascular diseases (Das et al). 2006;152:19-26 (Curriculum cardiol.)
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial (Rajagopal et al). 2006;152:149-54
Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization (Foo et al). 2006;152:290.e1-290.e7

Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial (Exaire et al). 2006;152:157-63

Home nursing

Home defibrillation: a feasibility study in myocardial infarction survivors at intermediate risk of sudden death (Sanna et al). 2006;152:685.e1-685.e7

Homocysteine

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial (Boston et al). 2006;152:448.e1-448.e7 (Trial design)

Hormone replacement therapy

Estradiol increases platelet aggregation in PI^{A1/A1} individuals (Boudoulas et al). 2006;152:136-9

Hospitalization

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia (Palazzuoli et al). 2006;152:1095.e9-1095.e15

Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—a report from the SHould we revascularize Occluded Coronaries for cardiogenic shock? (SHOCK) trial and registry (Jeger et al). 2006;152:686-92

Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis (Ahmed et al). 2006;152:956-66

Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EVAluaTion of the I_r inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) study (Fox et al). 2006;152:860-6 (Trial design)

Trends in postoperative length of stay after bypass surgery (Cowper et al). 2006;152:1193-9

Hospitals

Are registry hospitals different? A comparison of patients admitted to hospitals of a commercial heart failure registry with those from national and community cohorts (Heidenreich and Fonarow). 2006;152:935-9

Nonemergent coronary angioplasty without on-site surgical backup: a randomized study evaluating outcomes in low-risk patients (Melberg et al). 2006;152:888-95

Hospitals, community

Implementation of a continuous quality improvement program for percutaneous coronary intervention and cardiac surgery at a large community hospital (Brush et al). 2006;152:379-85

Hospitals, community (continued)

The predicament of offering elective percutaneous coronary intervention at sites without on-site cardiac surgery (Singh). 2006;152:810-11 (Editorial)

Hospitals, military

Nonemergent percutaneous coronary interventions in a veterans affairs medical center without onsite cardiac surgery (Roussanov et al). 2006;152:909-13

Hostility

Cynical hostility and carotid atherosclerosis in African American and white women: the Study of Women's Health Across the Nation (SWAN) Heart Study (Everson-Rose et al). 2006;152:982.e7-982.e13

Hydroxymethylglutaryl-CoA reductase inhibitors

Clopidogrel-statin interaction: a mountain or a mole hill? (Steinhubl and Akers). 2006;152:200-3 (Editorial)

Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data (Lachaine et al). 2006;152:164-9

Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy (Yood et al). 2006;152:777-84

Statin use in heart failure: a cause for concern? (Raina et al). 2006;152:39-49 (Curriculum cardiol.)

Hyperkalemia

Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials (de Denus et al). 2006;152:705-12

Hyperlipidemia

Evaluation of dyslipidemia in the emergency department: Impact of cholesterol testing on subsequent therapy (Blomkalns et al). 2006;152:1181-5

Quality of cholesterol screening and management with respect to the National Cholesterol Education's Third Adult Treatment Panel (ATPIII) guideline in primary care practices in North Carolina (Bertoni et al). 2006;152:785-92

Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy (Yood et al). 2006;152:777-84

Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey (Ansell et al). 2006;152:976-81

Hypertension

Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database (Horne et al). 2006;152:305-11

Racial differences are seen in blood pressure response to fosinopril in hypertensive children (Menon et al). 2006;152:394-9

Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) trial: evolving the management of diastolic dysfunction in hypertension (Janardhanan et al). 2006;152:246-52 (Trial design)

Hypertension, pulmonary

Temporal trends and drug exposures in pulmonary hypertension: an American experience (Walker et al). 2006;152:521-6

Iatrogenic disease

Persistence of iatrogenic atrial septal defect after pulmonary vein isolation—an underestimated risk? (Hammerstingl et al). 2006;152:362.e1-362.e5

Immunosorbent techniques

Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study (Staudt et al). 2006;152:712.e1-712.e6

Infection

Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery (Rogers et al). 2006;152:1027-33

Inflammation

Brain natriuretic peptide (BNP) and exercise-induced immune reaction: reply to the letter-to-the-editor of MacLachlan and Mossop (MacLachlan) (Letter); (Scharhag and Kindermann) (Reply). 2006;152:e3

Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: the role of inflammation on top of tissue Doppler-derived systolic and diastolic function (Van de Veire et al). 2006;152:297.e1-297.e7

Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial (Mertens et al). 2006;152:125.e1-125.e8

Insurance, health

National evaluation of adherence to β -blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance (Kramer et al). 2006;152:454.e1-454.e8

Insurance benefits

National evaluation of adherence to β -blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance (Kramer et al). 2006;152:454.e1-454.e8

Intra-aortic balloon pumping

Elective versus provisional intraaortic balloon pumping in unprotected left main stenting (Briguori et al). 2006;152:565-72

A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock (Burkhoff et al). 2006;152:469.e1-469.e8

Intraoperative complications

Elective versus provisional intraaortic balloon pumping in unprotected left main stenting (Briguori et al). 2006;152:565-72

**Intravascular ultrasound; see Ultrasonography, interventional
Ischemic heart disease; see Myocardial ischemia****K****Kidney diseases**

Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease (Johnston et al). 2006;152:1051-7

Reduced CD34 $^{+}$, renal anemia, and adverse outcomes (Andreotti et al). 2006;152:e21 (Letter)

Risk stratification of patients with chronic kidney disease: results of screening strategies incorporating clinical risk scoring anddobutamine stress echocardiography (Rakhit et al). 2006;152:363-70

Kidney function tests

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia (Palazzuoli et al). 2006;152:1095.e9-1095.e15

Kidney transplantation

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial (Boston et al). 2006;152:448.e1-448.e7 (Trial design)

L**Left ventricular dysfunction; see Ventricular dysfunction, left****Letters to the Editor**

A1c and mortality: an unexpected relationship in patients with advanced heart failure (Tayek). 2006;152:e5

Are elevations of N-terminal probrain natriuretic peptide in endurance athletes after prolonged strenuous exercise due to systemic inflammatory cytokines? (McLachlan). 2006;152:e1

Brain natriuretic peptide (BNP) and exercise-induced immune reaction: reply to the letter-to-the-editor of MacLachlan and Mossop (MacLachlan) (Letter); (Scharhag and Kindermann) (Reply). 2006;152:e3

Comparison of left ventricular and biventricular pacing in patients with heart failure (Arya) (Letter); (Gasparini) (Reply). 2006;152:e55, e57

Controlling the independent variables in the clinical study of prayer: the devil is in the details (Burks). 2006;152:e41

Ethnic differences in heart rate variability: does ultralow-frequency heart rate variability really measure autonomic tone? (Thayer et al). 2006;152:e27

Family screening in noncompaction (Stöllberger et al). 2006;152:e61

Intercessory prayer (Dorn). 2006;152:e25

Letter to the Editor (Faludi). 2006;152:e13

Letter to the editor (Carron et al). 2006;152:e63; Chan and Ionescu) (Letter); (Chen and Bhatt) (Reply). 2006;152:e51, e53

Letter to the editor (Hakeem and Bhatti) (Letter); (Holmes Jr and Gersh) (Reply). 2006;152:e47, e49

Letter to the editor by Dr. Adam H. Skolnick (Skolnick). 2006;152:e39

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure (Tanus-Santos). 2006;152:e9

Multislice computed tomography to rule out coronary artery disease in pilots with acquired left bundle-branch block and low cardiac risk (Perrier et al) (Letter); (Schuiff and Bax) (Reply). 2006;152:e23, e29

A perspective on antiarrhythmic drug therapy (Jolobe) (Letter); (Waldo) (Reply). 2006;152:e17, e19

Reduced CD34 $^{+}$, renal anemia, and adverse outcomes (Andreotti et al). 2006;152:e21

Reply (Tayek) (Letter); (Eshaghian) (Reply). 2006;152:e7

Response to Letter to the Editor (Faludi) (Letter); (Alter) (Reply). 2006;152:e15

Response to letter to the editor by Dr. Mackin (Hennekens). 2006;152:e59 (Reply)

A "STEP" in the right direction (Lilly). 2006;152:e31 (Letter)

A step towards more ethical prayer studies (Hobbs). 2006;152:e33

There is still hope for multifaceted intervention in heart failure (Ghali) (Letter); (LaPointe and Kramer) (Reply). 2006;152:e43, e45

WATCHMAN: an effective protection against stroke? (Stöllberger et al) (Letter); (Fountain et al) (Reply). 2006;152:e35, e37

What information can an invasive cardiologist obtain from brain natriuretic peptide? (Grabowski and Filipiak). 2006;152:e11

Life style

Clinical evidence for a health benefit from cardiac rehabilitation: an update (Williams et al). 2006;152:835-41 (Curriculum cardiol.)

The Extensive Lifestyle Management Intervention (ELMI) after cardiac rehabilitation: a 4-year randomized controlled trial (Lear et al). 2006;152:333-9

Lipoproteins

Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial (Cubeddu et al). 2006;152:982.e1-982.e5

Lipoprotein-associated phospholipase A₂ independently predicts the angiographic diagnosis of coronary artery disease and coronary death (May et al). 2006;152:997-1003

Total cholesterol levels and mortality risk in nonischemic systolic heart failure (Afsarmanesh et al). 2006;152:1076-82

Lipoproteins, LDL cholesterol

Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS) (Russell et al). 2006;152:867-75 (Trial design)

Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy (Yood et al). 2006;152:777-84

Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey (Ansell et al). 2006;152:976-81

Long QT syndrome

Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes (Mank-Seymour et al). 2006;152:1115-21

M

Magnetic resonance imaging

Aortic root dysfunction and its effect on left ventricular function in Ross procedure patients assessed with magnetic resonance imaging (Grotenhuis et al). 2006;152:975.e1-975.e8

Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological evaluation (Srichai et al). 2006;152:75-84

Lack of sensitivity of the electrocardiogram for detection of old myocardial infarction: a cardiac magnetic resonance imaging study (Asch et al). 2006;152:742-8

Letter to the Editor (Faludi). 2006;152:e13 (Letter)

Regression of coronary artery outward remodeling in patients with non-ST-segment acute coronary syndromes: a longitudinal study using noninvasive magnetic resonance imaging (Fernandes et al). 2006;152:1122-31

Response to Letter to the Editor (Faludi) (Letter); (Alter) (Reply). 2006;152:e15

Mandatory reporting

Public versus private institutional performance reporting: what is mandatory for quality improvement? (Guru et al). 2006;152:573-8

Mass screening

Quality of cholesterol screening and management with respect to the National Cholesterol Education's Third Adult Treatment Panel (ATPIII) guideline in primary care practices in North Carolina (Bertoni et al). 2006;152:785-92

Matrix metalloproteinase-9; see Gelatinase B

Metabolic syndrome X

Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease (Aguilar et al). 2006;152:298-304

Weight loss improves heart rate recovery in overweight and obese men with features of the metabolic syndrome (Brinkworth et al). 2006;152:693.e1-693.e6

Metoprolol

The effects of perioperative β -blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial (Yang et al). 2006;152:983-90

Rationale, design, and organization of the *PeriOperative Ischemic Evaluation* (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery (Devereaux et al). 2006;152:223-30 (Trial design)

Military personnel

Multislice computed tomography to rule out coronary artery disease in pilots with acquired left bundle-branch block and low cardiac risk (Perrier et al) (Letter). (Schuiff and Bax) (Reply). 2006;152:e23, e29

Mitral regurgitation; see Mitral valve insufficiency

Mitral valve

Prognostic implication of valvular lesion and left ventricular size in asymptomatic patients with chronic organic mitral regurgitation and normal left ventricular performance (Krauss et al). 2006;152:1004.e1-1004.e8

The prognostic value of the mitral diastolic filling velocity ratio for all-cause mortality and cardiovascular morbidity in African Americans: the atherosclerotic Risks in Communities (ARIC) study (Fox et al). 2006;152:749-55

Serial radionuclide angiographic assessment of left ventricular ejection fraction and regional wall motion after mitral valve replacement in patients with rheumatic disease (Chowdhury et al). 2006;152:1200-6

Mitral valve insufficiency

Prognostic implication of valvular lesion and left ventricular size in asymptomatic patients with chronic organic mitral regurgitation and normal left ventricular performance (Krauss et al). 2006;152:1004.e1-1004.e8

Models, organizational

Broken bodies, broken hearts? Limitations of the trauma system as a model for regionalizing care for ST-elevation myocardial infarction in the United States (Nallamothu et al). 2006;152:613-18 (Curriculum cardiol.)

Impact of organizational infrastructure on β -blocker and aspirin therapy for acute myocardial infarction (Ellerbeck et al). 2006;152:579-84

Monocytes

Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results (Beeres et al). 2006;152:684.e11-684.e16

Mortality; see also Death, sudden, cardiac

A1c and mortality: an unexpected relationship in patients with advanced heart failure (Tayek). 2006;152:e5 (Letter)

Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery (Rogers et al). 2006;152:1027-33

Chronic inotropic therapy in end-stage heart failure (Hauptman et al). 2006;152:1095.e1-1095.e8

Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts (Mehta et al). 2006;152:801-6

Mortality; see also Death, sudden, cardiac (continued)

Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease (Johnston et al). 2006;152:1051-7

Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview (Mahaffey et al). 2006;152:291-6

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNergy) trial (White et al). 2006;152:1041-9

Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients (Collins et al). 2006;152:312-20

Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients (Archbold et al). 2006;152:1090-4

Lipoprotein-associated phospholipase A₂ independently predicts the angiographic diagnosis of coronary artery disease and coronary death (May et al). 2006;152:997-1003

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure (Tanus-Santos). 2006;152:e1 (Letter)

Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis (Ahmed et al). 2006;152:956-66

Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study (Jaffe et al). 2006;152:126-35

Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry (Zahn et al). 2006;152:1145-51

Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction (Ohlmann et al). 2006;152:1160-6

The prognostic value of the mitral diastolic filling velocity ratio for all-cause mortality and cardiovascular morbidity in African Americans: the atherosclerotic Risks in Communities (ARIC) study (Fox et al). 2006;152:749-55

Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality Evaluation of the I_f inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) study (Fox et al). 2006;152:860-6 (Trial design)

Reduced CD34⁺, renal anemia, and adverse outcomes (Andreotti et al). 2006;152:e21 (Letter)

Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality (Friedmann et al). 2006;152:940.e1-940.e8

Reply (Tayek) (Letter); (Eshaghian) (Reply). 2006;152:e7

Response to letter to the editor by Dr. Mackin (Hennickens). 2006;152:e59 (Reply)

Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes (Alserius et al). 2006;152:599-605

Short and long-term mortality with nesiritide (Arora et al). 2006;152:1083-9

Mortality; see also Death, sudden, cardiac (continued)

Stimulating autoantibodies directed against the cardiac β_1 -adrenergic receptor predict increased mortality in idiopathic cardiomyopathy (Störk et al). 2006;152:697-704

Total cholesterol levels and mortality risk in nonischemic systolic heart failure (Afsarmanesh et al). 2006;152:1076-82

Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States (Fang et al). 2006;152:1034-1040

MRI; see Magnetic Resonance Imaging; Magnetic resonance imaging**Muscle relaxation**

Force- and relaxation-frequency relations in patients with diastolic heart failure (Yamanaka et al). 2006;152:966.e1-966.e7

Myocardial contraction

Force- and relaxation-frequency relations in patients with diastolic heart failure (Yamanaka et al). 2006;152:966.e1-966.e7

Myocardial infarction

The 12-lead electrocardiogram as a predictive tool of mortality after acute myocardial infarction: current status in an era of revascularization and reperfusion (Petrina et al). 2006;152:11-8 (Curriculum cardiol.)

Acute coronary syndromes in young patients with angiographically normal coronary arteries (Klein and Park). 2006;152:607-10 (Editorial)

Antecedent left ventricular mass and infarct size in ST-elevation myocardial infarction (Iakobishvili et al). 2006;152:285-90

Assessment of and physician response to glycemic control in diabetic patients presenting with an acute coronary syndrome (Conaway et al). 2006;152:1021-6

Broken bodies, broken hearts? Limitations of the trauma system as a model for regionalizing care for ST-elevation myocardial infarction in the United States (Nallamothu et al). 2006;152:613-18 (Curriculum cardiol.)

Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease (Johnston et al). 2006;152:1051-7

Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients (Collins et al). 2006;152:312-20

Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients (Archbold et al). 2006;152:1090-4

Home defibrillation: a feasibility study in myocardial infarction survivors at intermediate risk of sudden death (Sanna et al). 2006;152:685.e1-685.e7

Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database (Horne et al). 2006;152:305-11

In transition: from family history into the post-genomic era (Schunkert and Mayer). 2006;152:204-6 (Editorial)

Letter to the editor (Chan and Ionescu) (Letter); (Chen and Bhatt) (Reply). 2006;152:e51, e53

Myocardial perfusion in apical ballooning syndrome correlate of myocardial injury (Elesber et al). 2006;152:469.e9-469.e13

Persistent depressive symptoms lower aspirin adherence afteracute coronary syndromes (Rieckmann et al). 2006;152:922-7

Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke (Ding et al). 2006;152:1108-14

Myocardial infarction (continued)

- Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study (Jaffe et al). 2006;152:126-35
- Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry (Zahn et al). 2006;152:1145-51
- Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative (Patel et al). 2006;152:641-7
- The prevalence of unrecognized depression in patients with acute coronary syndrome (Amin et al). 2006;152:928-34
- Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction (Estensen et al). 2006;152:927.e1-927.e6
- Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks (Rokos et al). 2006;152:661-7
- Regression of coronary artery outward remodeling in patients with non-ST-segment acute coronary syndromes: a longitudinal study using noninvasive magnetic resonance imaging (Fernandes et al). 2006;152:1122-31
- Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes (Alserius et al). 2006;152:599-605
- Sex and classic risk factors after myocardial infarction: a community study (Gerber et al). 2006;152:461-8
- Thrombospondin-4 1186G>C (A387P) is a sex-dependent risk factor for myocardial infarction: a large replication study with increased sample size from the same population (Cui et al). 2006;152:543.e1-543.e5
- Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States (Fang et al). 2006;152:1034-1040
- The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients (Charytan et al). 2006;152:558-64
- Myocardial infarction, diagnosis**
- Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (Janardhanan et al). 2006;152:183-9
- The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction (Kavak et al). 2006;152:118-25
- Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—a report from the SHould we revascularize Occluded Coronaries for cardiogenic shock? (SHOCK) trial and registry (Jeger et al). 2006;152:686-92
- Lack of sensitivity of the electrocardiogram for detection of old myocardial infarction: a cardiac magnetic resonance imaging study (Asch et al). 2006;152:742-8
- Potential for improving sensitivity for detection of old myocardial infarction using the Q wave equivalent criteria in the Selvester QRS scoring system (Wagner). 2006;152:611-12 (Editorial)
- Myocardial infarction, drug therapy**
- Age, outcomes, and treatment effects of fibrinolytic and antiplatelet combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS (Sinnaeve et al). 2006;152:684.e1-684.e9

Myocardial infarction, drug therapy (continued)

- Association between Thrombolysis In Myocardial Infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the Randomized Trial to Evaluate the Relative PROTECTION against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30) (Gibson et al). 2006;152:756-61
- Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview (Mahaffey et al). 2006;152:291-6
- Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevation acute anterior myocardial infarction (Borghetti et al). 2006;152:470-7
- Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (White et al). 2006;152:1041-9
- Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRIal to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) (Wiviott et al). 2006;152:627-35 (Trial design)
- Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial (Reed et al). 2006;152:500-8
- Impact of organizational infrastructure on β-blocker and aspirin therapy for acute myocardial infarction (Ellerbeck et al). 2006;152:579-84
- Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial (Amit et al). 2006;152:887.e9-887.e14
- National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance (Kramer et al). 2006;152:454.e1-454.e8
- Patterns of use and potential impact of early β-blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events (Emery et al). 2006;152:1015-21
- Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial (Mertens et al). 2006;152:125.e1-125.e8
- Myocardial infarction, prognosis**
- Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction (Ohlmann et al). 2006;152:1160-6
- The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience (Goodman et al). 2006;152:277-84
- ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification (Yan et al). 2006;152:270-6

Myocardial infarction, therapy

Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms (Parodi et al). 2006;152:1132-8

Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function (Meluzin et al). 2006;152:975.e9-975.e15

Comparison between stenting and balloon angioplasty in patients undergoing primary angioplasty of small coronary vessels (De Luca et al). 2006;152:915-20

Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial (Gibson et al). 2006;152:668-75

Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center (Welsh et al). 2006;152:1007-14

Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial (Ellis et al). 2006;152:1050.e9-1050.e14

Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) Trial (Ottervanger et al). 2006;152:636-40 (Trial design)

Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study (Carlhed et al). 2006;152:1174-80

Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial—A prospective, multicenter, randomized trial (Hirsch et al). 2006;152:434-41 (Trial design)

Letter to the editor (Hakeem and Bhatti) (Letter); (Holmes Jr and Gersh) (Reply). 2006;152:e47, e49

Nonemergent percutaneous coronary interventions in a veterans affairs medical center without onsite cardiac surgery (Roussanov et al). 2006;152:909-13

Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design (Jollis et al). 2006;152:851-8, 851.e1-851.e11 (Trial design)

Routine percutaneous coronary intervention in elderly patients with cardiogenic shock complicating acute myocardial infarction (Migliorini et al). 2006;152:903-8

Myocardial ischemia

Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death (Boriani et al). 2006;152:527.e1-527.e11

The Extensive Lifestyle Management Intervention (ELMI) after cardiac rehabilitation: a 4-year randomized controlled trial (Lear et al). 2006;152:333-9

Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department (Peacock et al). 2006;152:253-62

Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results (Beeres et al). 2006;152:684.e11-684.e16

Myocardial ischemia, drug therapy

The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative (Diercks et al). 2006;152:140-8

Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial (Rajagopal et al). 2006;152:149-54

Myocardial ischemia, therapy

Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) (Cohen et al). 2006;152:110-7

Myocardial reperfusion

Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms (Parodi et al). 2006;152:1132-8

Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial (Amit et al). 2006;152:887.e9-887.e14

Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design (Jollis et al). 2006;152:851-8, 851.e1-851.e11 (Trial design)

Myocardial revascularization

Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease (Johnston et al). 2006;152:1051-7

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (White et al). 2006;152:1041-9

The impact of age on outcomes after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: one-year results from the Stent or Surgery (SoS) trial (Zhang et al). 2006;152:1152-9

Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—a report from the SHould we revascularize Occluded Coronaries for cardiogenic shock? (SHOCK) trial and registry (Jeger et al). 2006;152:686-92

Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction (Ohlmann et al). 2006;152:1160-6

Routine percutaneous coronary intervention in elderly patients with cardiogenic shock complicating acute myocardial infarction (Migliorini et al). 2006;152:903-8

Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States (Fang et al). 2006;152:1034-1040

Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes (Yan et al). 2006;152:676-83

The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients (Charytan et al). 2006;152:558-64

N

- N-terminal prohormone brain natriuretic peptide; see Peptide fragments**
N-terminal prohormone natriuretic peptide; see Natriuretic peptide, brain; Peptide fragments
NADPH oxidase

The *p22phox* C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study (Fan et al). 2006;152:538-42

Natriuretic peptide, brain

Are elevations of N-terminal probrain natriuretic peptide in endurance athletes after prolonged strenuous exercise due to systemic inflammatory cytokines? (McLachlan). 2006;152:e1 (Letter)

B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures (Taylor et al). 2006;152:1070-5

Brain natriuretic peptide (BNP) and exercise-induced immune reaction: reply to the letter-to-the-editor of McLachlan and Mossop (McLachlan) (Letter); (Scharhag and Kindermann) (Reply). 2006;152:e3

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia (Palazzuoli et al). 2006;152:1095.e9-1095.e15

Influence of history of heart failure on diagnostic performance and utility of B-type natriuretic peptide testing for acute dyspnea in the emergency department (Chung et al). 2006;152:949-55

Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: the role of inflammation on top of tissue Doppler-derived systolic and diastolic function (Van de Veire et al). 2006;152:297.e1-297.e7

Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure (Ng et al). 2006;152:94-101

Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results (Wu). 2006;152:828-34 (Curriculum cardiol)

What information can an invasive cardiologist obtain from brain natriuretic peptide? (Grabowski and Filipiak). 2006;152:e11 (Letter)

Nesiritide

Short and long-term mortality with nesiritide (Arora et al). 2006;152:1083-9

Nitroprusside

Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial (Amit et al). 2006;152:887.e9-887.e14

NT-proBNP; see Natriuretic peptide, brain; Peptide fragments

O

Obesity

B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures (Taylor et al). 2006;152:1070-5

Obesity (continued)

The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative (Diercks et al). 2006;152:140-8

Weight loss improves heart rate recovery in overweight and obese men with features of the metabolic syndrome (Brinkworth et al). 2006;152:693.e1-693.e6

Oscillometry

The blood pressure measurement—revisited (Safar and Smulyan). 2006;152:417-9 (Editorial)

Osteoarthritis

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis (Cannon et al). 2006;152:237-45 (Trial design)

Otorhinolaryngologic surgical procedures

Uvulopalatopharyngoplasty decreases levels of C-reactive protein in patients with obstructive sleep apnea syndrome (Kinoshita et al). 2006;152:692.e1-692.e5

Outcome and process assessment (health care)

Contemporary performance of surgical ventricular restoration procedures: data from the Society of Thoracic Surgeons' National Cardiac Database (Hernandez et al). 2006;152:494-9

Outpatient care; see Ambulatory care

Overweight; see Obesity

Oxygen consumption

Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: the role of inflammation on top of tissue Doppler-derived systolic and diastolic function (Van de Veire et al). 2006;152:297.e1-297.e7

Prospective evaluation of the oxygen uptake efficiency slope as a submaximal predictor of peak oxygen uptake in aged patients with ischemic heart disease (Van Laethem et al). 2006;152:297.e9-297.e15

P

P-selectin

Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial (Mertens et al). 2006;152:125.e1-125.e8

Pacemaker, artificial

Asymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT) (Hohnloser et al). 2006;152:442-7 (Trial design)

Pactimibe

Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA: Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study (Nicholls et al). 2006;152:67-74 (Trial design)

Patient care

Are registry hospitals different? A comparison of patients admitted to hospitals of a commercial heart failure registry with those from national and community cohorts (Heidenreich and Fonarow). 2006;152:935-9

Patient care (continued)

Assessment of and physician response to glycemic control in diabetic patients presenting with an acute coronary syndrome (Conaway et al). 2006;152:1021-6

Patient compliance

National evaluation of adherence to β -blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance (Kramer et al). 2006;152:454.e1-454.e8

Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data (Lachaine et al). 2006;152:164-9

Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes (Rieckmann et al). 2006;152:922-7

Patient discharge

Risk factors for deaths occurring within 30 days and 1 year after hospital discharge for cardiac surgery among pediatric patients (Chang et al). 2006;152:386-93

Patient selection

The predicament of offering elective percutaneous coronary intervention at sites without on-site cardiac surgery (Singh). 2006;152:810-11 (Editorial)

Patient transfer

Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—a report from the SHould we revascularize Occluded Coronaries for cardiogenic shock? (SHOCK) trial and registry (Jeger et al). 2006;152:686-92

Pediatric patients; see Child**Pedigree**

Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database (Horne et al). 2006;152:305-11

Peptide fragments

B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures (Taylor et al). 2006;152:1070-5

Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide (Abhayaratna et al). 2006;152:941-8

Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results (Wu). 2006;152: 828-34 (Curriculum cardiol.)

Percutaneous coronary intervention; see Angioplasty; Angioplasty, Myocardial revascularization, Stents; Angioplasty, transluminal, percutaneous coronary; Myocardial revascularization; Stents**Periodicals**

Reporting for provider performance: should we punish the bad, or try to make them all good? (Ferguson). 2006;152:410-3 (Editorial)

Perioperative care

The effects of perioperative β -blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial (Yang et al). 2006;152:983-90

Failure of β -blockers in the reduction of perioperative events: where did we go wrong? (McCullough). 2006;152:815-18 (Editorial)

Peripartum cardiomyopathy; see Cardiomyopathy, dilated**Peripheral blood stem cell transplantation**

Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial—A prospective, multicenter, randomized trial (Hirsch et al). 2006;152:434-41 (Trial design)

Peroxidase

Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure (Ng et al). 2006;152:94-101

PET; see Positron-emission tomography**Pexelizumab; see Antibodies, monoclonal****Phospholipases A**

Lipoprotein-associated phospholipase A₂ independently predicts the angiographic diagnosis of coronary artery disease and coronary death (May et al). 2006;152:997-1003

Physician-patient relations

Evidence-based cardiovascular therapies and achievement of therapeutic goals in diabetic patients with coronary heart disease attended in primary care (Mostaza-Prieto et al). 2006;152:1063-9

Pioglitazone

Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus (Wang et al). 2006;152: 1050.e1-1050.e8

Piperazines

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitionN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) (Wiviott et al). 2006;152:627-35 (Trial design)

Plasma

Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma (Donaheue et al). 2006;152:478-85

Plasminogen activator inhibitor 1

Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke (Ding et al). 2006;152:1108-14

Platelet aggregation

Estradiol increases platelet aggregation in PI^{A1/A1} individuals (Boudoulas et al). 2006;152:136-9

Platelet aggregation inhibitors

Association between Thrombolysis In Myocardial Infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the Randomized Trial to Evaluate the Relative PROTECTION against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30) (Gibson et al). 2006;152:756-61

Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial (Marmur et al). 2006;152:876-81

"Bolus-only" glycoprotein IIb/IIIa inhibitor use for elective percutaneous coronary intervention: maybe less is more? (Fischell). 2006;152:812-14 (Editorial)

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (White et al). 2006;152:1041-9

Platelet aggregation inhibitors (continued)

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitionN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) (Wiviott et al). 2006;152:627-35 (Trial design)

Platelet factor 4

Heparin-induced thrombocytopenia and cardiovascular diseases (Das et al). 2006;152:19-26 (Curriculum cardiol.)
Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization (Foo et al). 2006;152:290.e1-290.e7

Platelet glycoprotein GPIIb-IIIa complex

Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial (Exaire et al). 2006;152:157-63

Policosanol; see Fatty alcohols

Polymorphism, genetic

The *p22phox* C242T gene polymorphism is associated with a reduced risk of angiographically verified coronary artery disease in a high-risk Finnish Caucasian population. The Finnish Cardiovascular Study (Fan et al). 2006;152:538-42

Positron-emission tomography

Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial (Mertens et al). 2006;152:125.e1-125.e8

Postmenopause

Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative (Hsia et al). 2006;152:170-6

Prasugrel; see Piperazines; Thiopenes

Prescriptions, drug

National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance (Kramer et al). 2006;152:454.e1-454.e8

Primary health care

Evidence-based cardiovascular therapies and achievement of therapeutic goals in diabetic patients with coronary heart disease attended in primary care (Mostaza-Prieto et al). 2006;152:1063-9

Quality of cholesterol screening and management with respect to the National Cholesterol Education's Third Adult Treatment Panel (ATPIII) guideline in primary care practices in North Carolina (Bertoni et al). 2006;152:785-92

Probucol

Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study (Nunes et al). 2006;152:914.e1-914.e7

Program development

Broken bodies, broken hearts? Limitations of the trauma system as a model for regionalizing care for ST-elevation myocardial infarction in the United States (Nallamothu et al). 2006;152:613-18 (Curriculum cardiol.)

Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks (Rokos et al). 2006;152:661-7

Prostheses and implants

Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation (Fountain et al). 2006;152:720-3

Protective clothing

A randomized controlled trial of women's early use of a novel undergarment following sternotomy: the Women's Recovery from Sternotomy Trial (WREST) (King et al). 2006;152:1186-92

Proteins

Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma (Donahe et al). 2006;152:478-85

Proteomics

Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma (Donahe et al). 2006;152:478-85

Psychosocial deprivation

Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study (Jaffe et al). 2006;152:126-35

PTCA; see Angioplasty, transluminal, percutaneous coronary Pulmonary artery

Anomalous right coronary artery arising from the pulmonary artery: a report of 7 cases and a review of the literature (Williams et al). 2006;152:1004.e9-1004.e17

Pulmonary veins

Persistence of iatrogenic atrial septal defect after pulmonary vein isolation—an underestimated risk? (Hammerstingl et al). 2006;152:362.e1-362.e5

Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy (Nilsson et al). 2006;152:537.e1-537.e8

Variation in pulmonary vein size during the cardiac cycle: implications for non-electrocardiogram-gated imaging (Hauser et al). 2006;152:974.e1-974.e6

Pyridines

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis (Cannon et al). 2006;152:237-45 (Trial design)

Q

Quality assurance, health care

Continued improvements in quality improvement research (Peterson and Roe). 2006;152:1005-6 (Editorial)

Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study (Carlhed et al). 2006;152:1174-80

Public versus private institutional performance reporting: what is mandatory for quality improvement? (Guru et al). 2006;152:573-8

Reporting for provider performance: should we punish the bad, or try to make them all good? (Ferguson). 2006;152:410-3 (Editorial)

Quality of health care; see Health care quality, access, and evaluation

Implementation of a continuous quality improvement program for percutaneous coronary intervention and cardiac surgery at a large community hospital (Brush et al). 2006;152:379-85

Racial variations in quality of care and outcomes in an ambulatory heart failure cohort (Deswal et al). 2006;152:348-54

Quality of life

Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study (Reynolds et al). 2006;152:1096-1102

Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial (Cooper et al). 2006;152:59-66 (Trial design)

R**Race; see Ethnic groups****Radionuclide angiography**

Serial radionuclide angiographic assessment of left ventricular ejection fraction and regional wall motion after mitral valve replacement in patients with rheumatic disease (Chowdhury et al). 2006;152:1200-6

Radionuclide imaging

Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms (Parodi et al). 2006;152:1132-8

Rapamycin

Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries (Valgimigli et al). 2006;152:896-902

Receptors, adrenergic, alpha-1

Effect of α_1 -adrenergic receptors in cardiac pathophysiology (Shannon and Chaudhry). 2006;152:842-50

Receptors, adrenergic, beta-1

Stimulating autoantibodies directed against the cardiac β_1 -adrenergic receptor predict increased mortality in idiopathic cardiomyopathy (Störk et al). 2006;152:697-704

Regional medical programs

Broken bodies, broken hearts? Limitations of the trauma system as a model for regionalizing care for ST-elevation myocardial infarction in the United States (Nallamothu et al). 2006;152:613-18 (Curriculum cardiol.)

Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks (Rokos et al). 2006;152:661-7

Rehabilitation

Clinical evidence for a health benefit from cardiac rehabilitation: an update (Williams et al). 2006;152:835-41 (Curriculum cardiol.)

The Extensive Lifestyle Management Intervention (ELMI) after cardiac rehabilitation: a 4-year randomized controlled trial (Lear et al). 2006;152:333-9

Religion and medicine

Intercessory prayer (Dorm). 2006;152:e25 (Letter)

Renal artery obstruction

Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial (Cooper et al). 2006;152:59-66 (Trial design)

Renin-angiotensin system

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation (Anand et al). 2006;152:217-22 (Curriculum cardiol.)

Renin-angiotensin system (continued)

What is the role of angiotensin-receptor blockade in cardiovascular protection? (Cohn). 2006;152:859.e1-859.e8 (Trial design)

Research support

Reflections on early stopping of a clinical trial (Armstrong and Granger). 2006;152:407-9 (Editorial)

Restenosis, coronary; see Coronary restenosis; Stents**Revascularization, myocardial; see Myocardial revascularization****Rheumatic heart disease**

Serial radionuclide angiographic assessment of left ventricular ejection fraction and regional wall motion after mitral valve replacement in patients with rheumatic disease (Chowdhury et al). 2006;152:1200-6

Rheumatoid arthritis; see Arthritis, rheumatoid**Risk assessment**

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis (Cannon et al). 2006;152:237-45 (Trial design)

Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials (de Denus et al). 2006;152:705-12

Response to letter to the editor by Dr. Mackin (Hennekens). 2006;152:e59 (Reply)

Risk stratification of patients with chronic kidney disease: results of screening strategies incorporating clinical risk scoring and dobutamine stress echocardiography (Rakhit et al). 2006;152:363-70

Skin cholesterol adds to Framingham risk assessment (Sprecher and Pearce). 2006;152:694-6

ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification (Yan et al). 2006;152:270-6

Risk factors

The Extensive Lifestyle Management Intervention (ELMI) after cardiac rehabilitation: a 4-year randomized controlled trial (Lear et al). 2006;152:333-9

Low voltage on the electrocardiogram is a marker of disease severity and a risk factor for adverse outcomes in patients with heart failure due to systolic dysfunction (Kamath et al). 2006;152:355-61

Persistence of iatrogenic atrial septal defect after pulmonary vein isolation—an underestimated risk? (Hammerstingl et al). 2006;152:362.e1-362.e5

Risk factors for deaths occurring within 30 days and 1 year after hospital discharge for cardiac surgery among pediatric patients (Chang et al). 2006;152:386-93

Rupture

Intravascular ultrasound assessment of fibrous cap remnants after coronary plaque rupture (Jensen et al). 2006;152:327-32

S**Saphenous vein**

Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts (Mchta et al). 2006;152:801-6

Schizophrenia

Response to letter to the editor by Dr. Mackin (Hennekens). 2006;152:e59 (Reply)

Sensitivity and specificity

Lack of sensitivity of the electrocardiogram for detection of old myocardial infarction: a cardiac magnetic resonance imaging study (Asch et al). 2006;152:742-8

Potential for improving sensitivity for detection of old myocardial infarction using the Q wave equivalent criteria in the Selvester QRS scoring system (Wagner). 2006;152:611-12 (Editorial)

Severity of illness index

Low voltage on the electrocardiogram is a marker of disease severity and a risk factor for adverse outcomes in patients with heart failure due to systolic dysfunction (Kamath et al). 2006;152:355-61

Sex factors; see also Women

C-reactive protein and risk of heart failure. The Rotterdam study (Kardys et al). 2006;152:514-20

The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion (Gurevitz et al). 2006;152:155.e9-155.e13

Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort (Lakoski et al). 2006;152:593-8

Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study (Reynolds et al). 2006;152:1096-1102

Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative (Patel et al). 2006;152:641-7

Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey (Ansell et al). 2006;152:976-81

Sex and classic risk factors after myocardial infarction: a community study (Gerber et al). 2006;152:461-8

Thrombospondin-4 1186G>C (A38TP) is a sex-dependent risk factor for myocardial infarction: a large replication study with increased sample size from the same population (Cui et al). 2006;152:543.e1-543.e5

Shock, cardiogenic

Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—a report from the SHould we revascularize Occluded Coronaries for cardiogenic shock? (SHOCK) trial and registry (Jeger et al). 2006;152:686-92

A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock (Burkhoff et al). 2006;152:469.e1-469.e8

Routine percutaneous coronary intervention in elderly patients with cardiogenic shock complicating acute myocardial infarction (Migliorini et al). 2006;152:903-8

Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States (Fang et al). 2006;152:1034-1040

Sirolimus

Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent (Oyabu et al). 2006;152:1167-73

Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT) (Thuesen et al). 2006;152:1139-44

Sirolimus (continued)

Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry (Zahn et al). 2006;152:1145-51

Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCAND-STENT) trial (Kelbæk et al). 2006;152:882-6

Skin

Skin cholesterol adds to Framingham risk assessment (Sprecher and Pearce). 2006;152:694-6

Sleep apnea, obstructive

Uvulopalatopharyngoplasty decreases levels of C-reactive protein in patients with obstructive sleep apnea syndrome (Kinoshita et al). 2006;152:692.e1-692.e5

Social class

Ethnic differences in heart rate variability: does ultralow-frequency heart rate variability really measure autonomic tone? (Thayer et al). 2006;152:e27 (Letter)

Socioeconomic status, treatment, and outcomes among elderly patients hospitalized with heart failure: findings from the National Heart Failure Project (Rathore et al). 2006;152:371-8

Social isolation

Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality (Friedmann et al). 2006;152:940.e1-940.e8

SPECT; see Tomography, emission-computed, single-photon

Statins; see Hydroxymethylglutaryl-CoA reductase inhibitors

Stem cells

Circulating endothelial progenitor cells predict coronary artery disease severity (Kunz et al). 2006;152:190-5

Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial (Ellis et al). 2006;152:1050.e9-1050.e14

Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus (Wang et al). 2006;152:1050.e1-1050.e8

Stents

Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent (Oyabu et al). 2006;152:1167-73

Comparison between drug-eluting stents and beta-radiation for the treatment of diffuse in-stent restenosis: clinical and angiographic outcomes (Zavalloni et al). 2006;152:908.e1-908.e7

Comparison between stenting and balloon angioplasty in patients undergoing primary angioplasty of small coronary vessels (De Luca et al). 2006;152:915-20

Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT) (Thuesen et al). 2006;152:1139-44

A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation (Radke et al). 2006;152:761.e1-761.e6

Drug-eluting stents in total coronary occlusions: another piece of the puzzle solved? (Dzavik). 2006;152:807-9 (Editorial)

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (White et al). 2006;152:1041-9

Stents (continued)

- Elective versus provisional intraaortic balloon pumping in unprotected left main stenting (Briguori et al). 2006;152:565-72
- The favorable clinical and angiographic outcomes of high-dose dexamethasone-eluting stent: randomized controlled prospective study (Han et al). 2006;152:887.e1-887.e7
- The impact of age on outcomes after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: one-year results from the Stent or Surgery (SoS) trial (Zhang et al). 2006;152:1152-9
- Letter to the editor (Chan and Ionescu) (Letter); (Chen and Bhatt) (Reply). 2006;152:e51, e53; Hakeem and Bhatti) (Letter); (Holmes Jr and Gersh) (Reply). 2006;152:e47, e49
- Patterns and outcomes of drug-eluting coronary stent use in clinical practice (Rao et al). 2006;152:321-6
- A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention (Brophy et al). 2006;152:263-9
- Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry (Zahn et al). 2006;152:1145-51
- Predictors of long-term outcome after crush stenting of coronary bifurcation lesions: importance of the bifurcation angle (Dzavik et al). 2006;152:762-9
- Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial (Zhang et al). 2006;152:770-6
- Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study (Nunes et al). 2006;152:914.e1-914.e7
- Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era: Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries (Valgimigli et al). 2006;152:896-902
- Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCAND-STENT) trial (Keldkamp et al). 2006;152:882-6
- Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial (Cooper et al). 2006;152:59-66 (Trial design)
- Sternum**
- A randomized controlled trial of women's early use of a novel undergarment following sternotomy: the Women's Recovery from Sternotomy Trial (WREST) (King et al). 2006;152:1186-92
- Stethoscopes**
- Effect of teaching and type of stethoscope on cardiac auscultatory performance (Iversen et al). 2006;152:85.e1-85.e7
- Stress echocardiography; see Echocardiography, stress**
- Stress test; see Echocardiography, stress; Exercise test**
- Stroke; see Cerebrovascular accident**
- Stroke volume**
- Force- and relaxation-frequency relations in patients with diastolic heart failure (Yamanaka et al). 2006;152:966.e1-966.e7
- A history of heart failure predicts arrhythmia treatment efficacy: data from the antiarrhythmics versus implantable defibrillators (AVID) study (Brodsky et al). 2006;152:724-30

Stroke volume (continued)

- Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction (Ohlmann et al). 2006;152:1160-6
- Serial radionuclide angiographic assessment of left ventricular ejection fraction and regional wall motion after mitral valve replacement in patients with rheumatic disease (Chowdhury et al). 2006;152:1200-6
- Survival in octogenarians receiving implantable defibrillators (Koplan et al). 2006;152:714-19
- Sudden cardiac death; see Death, sudden, cardiac**
- Sulfones**
- Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis (Cannon et al). 2006;152:237-45 (Trial design)
- Sulfonylurea compounds**
- A1c and mortality: an unexpected relationship in patients with advanced heart failure (Tayek). 2006;152:e5 (Letter)
- Reply (Tayek) (Letter); (Eshaghian) (Reply). 2006;152:e7
- Surgical procedures, elective**
- Elective versus provisional intraaortic balloon pumping in unprotected left main stenting (Briguori et al). 2006;152:565-72
- Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery (Devereaux et al). 2006;152:223-30 (Trial design)
- Surgical procedures, operative**
- A randomized controlled trial of women's early use of a novel undergarment following sternotomy: the Women's Recovery from Sternotomy Trial (WREST) (King et al). 2006;152:1186-92

T

Tachycardia, ventricular

Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death (Boriani et al). 2006;152:527.e1-527.e11

Taxus

Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era: Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries (Valgimigli et al). 2006;152:896-902

Teaching

Effect of teaching and type of stethoscope on cardiac auscultatory performance (Iversen et al). 2006;152:85.e1-85.e7

Technetium

Left bundle-branch block artifact on single photon emission computed tomography with technetium Tc 99m (Tc-99m) agents: mechanisms and a method to decrease false-positive interpretations (Higgins et al). 2006;152:619-26 (Curriculum cardiol.)

Tenecteplase

Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS (Sinnaeve et al). 2006;152:684.e1-684.e9

Thiopenes

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to Assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) (Wiviott et al). 2006;152:627-35 (Trial design)

Thrombocytopenia

Heparin-induced thrombocytopenia and cardiovascular diseases (Das et al). 2006;152:19-26 (Curriculum cardioi.)
Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization (Foo et al). 2006;152:290.e1-290.e7

Thromboembolism

Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological evaluation (Srichai et al). 2006;152:75-84

Thrombolytic therapy

Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS (Sinnaeve et al). 2006;152:684.e1-684.e9

Association between Thrombolytic In Myocardial Infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the Randomized Trial to Evaluate the Relative PROTECT against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Antiplatelet and Antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30) (Gibson et al). 2006;152:756-61

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to Assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) (Wiviott et al). 2006;152:627-35 (Trial design)

Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock—a report from the SHould we revascularize Occluded Coronaries for cardiogenic shock? (SHOCK) trial and registry (Jeger et al). 2006;152:686-92

Letter to the editor (Hakeem and Bhatti) (Letter); (Holmes Jr and Gersh) (Reply). 2006;152:e47, e49

Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial (Mertens et al). 2006;152:125.e1-125.e8

Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes (Yan et al). 2006;152:676-83

Thrombosis

Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials (Brener et al). 2006;152:1058-62

Thrombospondin-4; see Thrombospondins

Thrombospondins

Thrombospondin-4 1186G>C (A387P) is a sex-dependent risk factor for myocardial infarction: a large replication study with increased sample size from the same population (Cui et al). 2006;152:543.e1-543.e5

Tissue Doppler imaging; see Echocardiography, Doppler

Tissue inhibitor of metalloproteinase-1

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure (Tanus-Santos). 2006;152:e9 (Letter)

Tomography, emission-computed, single-photon

Left bundle-branch block artifact on single photon emission computed tomography with technetium Tc 99m (Tc-99m) agents: mechanisms and a method to decrease false-positive interpretations (Higgins et al). 2006;152:619-26 (Curriculum cardioi.)

The value of stress single photon emission computed tomography in patients without known coronary artery disease presenting with dyspnea (Balaravi et al). 2006;152:551-7

Tomography, optical coherence

Measurement of the thickness of the fibrous cap by optical coherence tomography (Kume et al). 2006;152:755.e1-755.e4

Tomography, x-ray computed

Multislice computed tomography to rule out coronary artery disease in pilots with acquired left bundle-branch block and low cardiac risk (Perrier et al) (Letter); (Schuiff and Bax) (Reply). 2006;152:e23, e29

Torsades de pointes

Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes (Mank-Seymour et al). 2006;152:1115-21

Transplantation, autologous

Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function (Meluzin et al). 2006;152:975.e9-975.e15

Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results (Beeres et al). 2006;152:684.e11-684.e16

Trauma centers

Broken bodies, broken hearts? Limitations of the trauma system as a model for regionalizing care for ST-elevation myocardial infarction in the United States (Nallamothu et al). 2006;152:613-18 (Curriculum cardioi.)

Tricuspid valve

Echocardiographic insights into atrial and ventricular mechanisms of functional tricuspid regurgitation (Fukuda et al). 2006;152:1207-13

Tricuspid valve insufficiency

Echocardiographic insights into atrial and ventricular mechanisms of functional tricuspid regurgitation (Fukuda et al). 2006;152:1207-13

Tropponin

The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction (Kavsak et al). 2006;152:118-25

Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction (Ohlmann et al). 2006;152:1160-6

U

Ultrasonography

Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA: Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study (Nicholls et al). 2006;152:67-74 (Trial design)

Ultrasoundography, interventional

Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials (Brener et al). 2006;152:1058-62

A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation (Radke et al). 2006;152:761.e1-761.e6

How to assess coronary artery remodeling by intravascular ultrasound (Schartl and Bocksch). 2006;152:414-6 (Editorial)

The impact of cardiovascular risk factors on subclinical left main coronary artery disease: an intravascular ultrasound study (Kim et al). 2006;152:693.e7-693.e12

Intravascular ultrasound assessment of fibrous cap remnants after coronary plaque rupture (Jensen et al). 2006;152:327-32

Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study (Nunes et al).

2006;152:914.e1-914.e7

Static and serial assessments of coronary arterial remodeling are discordant: an intravascular ultrasound analysis from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial (Sipahi et al). 2006;152:544-50

V**Valsartan**

Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial infarction (VALIANT) trial (Reed et al). 2006;152:500-8

Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) trial: evolving the management of diastolic dysfunction in hypertension (Janardhanan et al). 2006;152:246-52 (Trial design)

Vascular diseases

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials (Stettler et al). 2006;152:27-38 (Curriculum cardiol.)

Vascular surgical procedures

The effects of perioperative β -blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial (Yang et al). 2006;152:983-90

Ventricular arrhythmias; see Arrhythmia**Ventricular dysfunction**

Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide (Abhayaratna et al). 2006;152:941-8

Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) trial: evolving the management of diastolic dysfunction in hypertension (Janardhanan et al). 2006;152:246-52 (Trial design)

Ventricular dysfunction, left

Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (Janardhanan et al). 2006;152:183-9

Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial infarction (VALIANT) trial (Reed et al). 2006;152:500-8

The impact of the *AMPD1* gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: a study in 686 consecutive patients (Groote et al). 2006;152:736-41

Ventricular dysfunction, left (continued)

Low voltage on the electrocardiogram is a marker of disease severity and a risk factor for adverse outcomes in patients with heart failure due to systolic dysfunction (Kamath et al). 2006;152:355-61

Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure (Ng et al). 2006;152:94-101

Myocardial perfusion in apical ballooning syndrome correlate of myocardial injury (Elesber et al). 2006;152:469.e9-469.e13

Predicting significant coronary artery disease in patients with left ventricular dysfunction (Whellan et al). 2006;152:340-7

Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials (de Denu et al). 2006;152:705-12

Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality Evaluation of the I_f inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) study (Fox et al). 2006;152:860-6 (Trial design)

Ventricular function

Comparison of 1-year effects of left ventricular and biventricular pacing in patients with heart failure who have ventricular arrhythmias and left bundle-branch block: the Bi vs Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias (BELIEVE) multicenter prospective randomized pilot study (Gasparini et al). 2006;152:155.e1-155.e7

Comparison of left ventricular and biventricular pacing in patients with heart failure (Arya) (Letter); (Gasparini) (Reply). 2006;152:e55, e57

Echocardiographic insights into atrial and ventricular mechanisms of functional tricuspid regurgitation (Fukuda et al). 2006;152:1207-13

The effect of altering heart rate on ventricular function in patients with heart failure treated with β -blockers (Thackray et al). 2006;152:713.e9-713.e13

Prognostic implication of valvular lesion and left ventricular size in asymptomatic patients with chronic organic mitral regurgitation and normal left ventricular performance (Krauss et al). 2006;152:1004.e1-1004.e8

Serial radionuclide angiographic assessment of left ventricular ejection fraction and regional wall motion after mitral valve replacement in patients with rheumatic disease (Chowdhury et al). 2006;152:1200-6

Ventricular function, left

Aortic root dysfunction and its effect on left ventricular function in Ross procedure patients assessed with magnetic resonance imaging (Grotenhuis et al). 2006;152:975.e1-975.e8

Force- and relaxation-frequency relations in patients with diastolic heart failure (Yamanaka et al). 2006;152:966.e1-966.e7

Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial (Ellis et al). 2006;152:1050.e9-1050.e14

Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients (Archbold et al). 2006;152:1090-4

Immunoabsorption in dilated cardiomyopathy: 6-month results from a randomized study (Staudt et al). 2006;152:712.e1-712.e6

Ventricular function, left (continued)

Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial—A prospective, multicenter, randomized trial (Hirsch et al). 2006;152:434-41 (Trial design)

Maximum oxygen uptake at peak exercise in elderly patients with coronary artery disease and preserved left ventricular function: the role of inflammation on top of tissue Doppler-derived systolic and diastolic function (Van de Veire et al). 2006;152:297.e1-297.e7

Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results (Beeres et al). 2006;152:684.e1-684.e16

Ventricular remodeling

Antecedent left ventricular mass and infarct size in ST-elevation myocardial infarction (Iakobishvili et al). 2006;152:285-90

Letter to the Editor (Faludi). 2006;152:e13 (Letter)

Response to Letter to the Editor (Faludi) (Letter); (Alter) (Reply). 2006;152:e15

Vitamins

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial (Bostom et al). 2006;152:448.e1-448.e7 (Trial design)

W

WATCHMAN Left Atrial Appendage

Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation (Fountain et al). 2006;152:720-3

WATCHMAN Left Atrial Appendage System

WATCHMAN: an effective protection against stroke? (Stöllberger et al) (Letter); (Fountain et al) (Reply). 2006;152:e35, e37

Weight loss

Weight loss improves heart rate recovery in overweight and obese men with features of the metabolic syndrome (Brinkworth et al). 2006;152:693.e1-693.e6

Women; see also Sex factors

Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery (Rogers et al). 2006;152:1027-33

Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative (Hsia et al). 2006;152:170-6 Cynical hostility and carotid atherosclerosis in African American and white women: the Study of Women's Health Across the Nation (SWAN) Heart Study (Everson-Rose et al). 2006;152:982.e7-982.e13

Estradiol increases platelet aggregation in PI^{A1/A1} individuals (Boudoulas et al). 2006;152:136-9

A randomized controlled trial of women's early use of a novel undergarment following sternotomy: the Women's Recovery from Sternotomy Trial (WREST) (King et al). 2006;152:1186-92

Self-rated health among women with coronary disease: depression is as important as recent cardiovascular events (Ruo et al). 2006;152:921.e1-921.e7

Z

Zofenopril; see Captopril